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Abstract
Direct-to-consumer advertising (DTCA) of prescription medications and healthcare facilities has
generated much debate over the potential benefits and adverse consequences for the public at large,
patients, clinician-patient relationships, and the overall healthcare system. This dissertation is aimed at
contributing to this debate through studying the impact of DTCA in the context of cancer treatment. Study
1 assessed the reliability and validity of three candidate measures of patient-reported exposure to cancerrelated DTCA across seven criteria. The study found that all three measures performed well in terms of
convergent, nomological, discriminant, and face validity. Findings from this study offer support for
utilizing these survey measures in future studies targeting cancer patients. Next, Study 2 examined the
prevalence and correlates of cancer-related DTCA exposure in a sample of patients in Pennsylvania
diagnosed with breast, prostate, or colorectal cancers. On average, patients reported modest exposure to
such DTCA (median exposure was once per week). Significant correlates of exposure included cancer
type, age, stage of disease, and ethnicity. Study 3 investigated the relationships between DTCA exposure
and subsequent information seeking behaviors. The analyses detected a significant association between
DTCA exposure and cancer patients' subsequent information engagement with their clinicians at one-year
follow-up. Exposure to DTCA was marginally significant in predicting information seeking from nonclinician (lay media and interpersonal) sources. Based on the Integrative Model of Behavioral Prediction, a
focused analysis showed a significant indirect path between DTCA exposure and subsequent information
seeking from non-clinician sources, mediated through attitudes and intention to seek from these sources.
Study 4 was guided by the Structural Influence Model of Communication to explore disparities in health
information seeking behaviors arising from DTCA exposure. The study found that the associations
between DTCA exposure and active information seeking behaviors were not moderated by patients' age,
educational level, race/ethnicity, or cancer type. To conclude, these studies would likely inform the
ongoing debate and future research regarding the impact of cancer-related DTCA exposure on
communication outcomes and disparities.
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ABSTRACT
CANCER-RELATED DIRECT-TO-CONSUMER ADVERTISING – A STUDY OF ITS
ANTECEDENTS, INFLUENCE ON PATIENT INFORMATION SEEKING
BEHAVIORS, AND CONTINGENT EFFECTS
Andy Soon Leong Tan
Robert C Hornik
Direct-to-consumer advertising (DTCA) of prescription medications and
healthcare facilities has generated much debate over the potential benefits and adverse
consequences for the public at large, patients, clinician-patient relationships, and the
overall healthcare system. This dissertation is aimed at contributing to this debate through
studying the impact of DTCA in the context of cancer treatment. Study 1 assessed the
reliability and validity of three candidate measures of patient-reported exposure to
cancer-related DTCA across seven criteria. The study found that all three measures
performed well in terms of convergent, nomological, discriminant, and face validity.
Findings from this study offer support for utilizing these survey measures in future
studies targeting cancer patients. Next, Study 2 examined the prevalence and correlates of
cancer-related DTCA exposure in a sample of patients in Pennsylvania diagnosed with
breast, prostate, or colorectal cancers. On average, patients reported modest exposure to
such DTCA (median exposure was once per week). Significant correlates of exposure
included cancer type, age, stage of disease, and ethnicity. Study 3 investigated the
relationships between DTCA exposure and subsequent information seeking behaviors.
vi

The analyses detected a significant association between DTCA exposure and cancer
patients’ subsequent information engagement with their clinicians at one-year follow-up.
Exposure to DTCA was marginally significant in predicting information seeking from
non-clinician (lay media and interpersonal) sources. Based on the Integrative Model of
Behavioral Prediction, a focused analysis showed a significant indirect path between
DTCA exposure and subsequent information seeking from non-clinician sources,
mediated through attitudes and intention to seek from these sources. Study 4 was guided
by the Structural Influence Model of Communication to explore disparities in health
information seeking behaviors arising from DTCA exposure. The study found that the
associations between DTCA exposure and active information seeking behaviors were not
moderated by patients’ age, educational level, race/ethnicity, or cancer type. To conclude,
these studies would likely inform the ongoing debate and future research regarding the
impact of cancer-related DTCA exposure on communication outcomes and disparities.
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Chapter 1 BACKGROUND AND LITERATURE REVIEW
Introduction
The practice of direct-to-consumer advertising (DTCA) for prescription
medications and healthcare services is controversial in the United States and subject to
much debate involving stakeholders ranging from consumer interest groups, medical
professionals, the pharmaceutical industry, and regulatory agencies (Bonaccorso &
Sturchio, 2002; Fox & Ward, 2008; Frosch, Grande, Tarn, & Kravitz, 2010; Hoen, 1998;
Hollon, 1999, 2005; Holmer, 1999, 2002; E. T. Rosenthal, 2010b). On one side there are
arguments that DTCA potentially provides educational information for consumers that
leads to patient empowerment, increases patient adherence to treatment, and subsequently
improves patient outcomes (Calfee, 2002). Conversely, critics counter that possible
adverse effects of DTCA include patients being misled with inaccurate information
intended to sell a product, alteration of patient-physician relationships, inappropriate use
of prescription drugs, side-effects from over-treatment, and ballooning healthcare costs
(Lipsky & Taylor, 1997). Thus far, purported benefits and adverse consequences of
DTCA voiced by both sides of the debate are not convincingly borne out in research over
the past two decades, underlining the need for more inquiry on the implications of
DTCA, if any, on physician or patient behaviors and on health outcomes.
Extending from the broader debate of the overall benefits and risks of DTCA in
general, more recent research is being conducted to examine the impact of specific kinds
1

of DTCA that targets patients who are diagnosed with certain severe medical conditions.
Studies that focus on DTCA for treatments of cardiovascular disease and cancer—disease
conditions requiring complex care—are two such examples of research on specific kinds
of DTCA. In the case of such “subspecialty DTCA”, the specialized nature of treatments,
complicated technical information, higher risks of adverse outcomes, and higher costs
justify greater skepticism about claims of educational benefits of such advertising for
patients and calls for heightened scrutiny of its impact on patient perceptions, decisionmaking processes, and health outcomes (Abel, Burstein, Hevelone, & Weeks, 2009).
This dissertation research addresses knowledge gaps associated with one specific
form of “subspecialty DTCA”, that is cancer-related DTCA. For the purpose of this
present research, cancer-related DTCA is defined as “promotional efforts by a
pharmaceutical company, healthcare provider, or medical facility to present information
about medications, medical devices, or medical services for patients diagnosed with
cancer in the lay media environment” (adapted from Wilkes, Bell, & Kravitz, 2000). In
the following sections, I outline the purpose of each study in this research, rationale for
engaging in research specifically on cancer-related DTCA, historical and regulatory
background of DTCA, and relevant literature on DTCA research underpinning this
dissertation project. More detailed literature reviews relevant for the research objectives
of each of the four individual studies are included in the introduction sections of the
respective studies.

2

Purpose
The overall purpose of this dissertation project is to study the antecedents of
patients’ exposure to DTCA, assess the influence of DTCA on patient information
seeking behaviors, and examine communication disparities associated with DTCA in the
specific context of cancer treatment. This research includes four distinct but inter-related
studies. Laying the groundwork for this research is Study 1, which assessed the reliability
and validity of a set of self-reported survey measures to elicit patients’ frequency of
exposure to DTCA. Findings from this study provide important validity information on
the use of measures employed in existing surveys when compared with alternative
approaches of measuring exposure to DTCA. These validation results further provide
support for justifying the use of self-reported measures of DTCA exposure in examining
the research questions in the remaining studies.
Next, Study 2 is an analysis of survey data from a population-based sample of
cancer patients to provide information on the correlates of patients’ DTCA exposure.
This study assessed whether there is differential exposure of DTCA across different
patient characteristics and the potential for communication disparities. Briefly, this study
compared the frequency of exposure to DTCA between patients across different cancer
diagnoses (breast, prostate, or colorectal cancer), race/ethnicity, levels of educational
attainment, and age groups. Disparities in exposure to DTCA based on individual
characteristics may have important implications for reinforcing existing health disparities
in cancer outcomes among socially advantaged and disadvantaged groups.
3

Study 3 investigated the associations between DTCA exposure and cancer
patients’ subsequent information seeking behaviors. This study offers empirical evidence
to inform the ongoing debate about the spillover informational benefit of DTCA on
broader patient information engagement about managing their illness. The study further
identifies potential psychosocial mechanisms that may account for DTCA motivating
health information seeking behaviors.
Guided by the Structural Influence Model of Communication, Study 4 built on
Studies 2 and 3 to analyze whether the lagged associations between DTCA exposure and
health information seeking behaviors are contingent upon various patient characteristics.
This study aims to contribute to the literature in communication inequalities associated
with public health information in the context of cancer care by assessing whether age,
educational level, race/ethnicity, and cancer type moderate the above associations.
Presence of communication disparities may have implications for widened disparities in
cancer outcomes among certain patient groups.
Rationale
There are several reasons for focusing on cancer treatment advertising in this
dissertation research. From an epidemiological standpoint, cancer is the second leading
cause of mortality in the U.S., accounting for an estimated 573,855 deaths in 2010, or
more than 1,500 people a day (Murphy, Xu, & Kochanek, 2012). Cancer survivors
number approximately 11.7 million Americans (last estimated in 2007) and close to 1.6
4

million new cancer cases are expected to be diagnosed each year (American Cancer
Society, 2011). Given the sizable proportion of the population for whom cancer-related
DTCA would be salient, efforts to better understand potential impacts of cancer treatment
advertising on cancer patients are justifiable.
As noted earlier, in terms of weighing the risks versus educational benefits of
subspecialty DTCA, cancer treatment is often specialized in nature, requires multidisciplinary care, potentially involves serious adverse effects, and is associated with high
costs. Such complex information about cancer treatment is arguably less amenable to
convey using direct advertising to patients when compared to DTCA that are targeted for
less life-threatening symptoms or conditions where the stakes are not as high (Abel et al.,
2009). In other words, direct educational benefits posited by DTCA advocates appear less
compelling in the case of cancer treatment, especially given the complexity and urgency
associated with the disease trajectory of many forms of cancer. It is equally important to
consider that there may be risks of cancer-related DTCA in encouraging inappropriate
treatments or over-utilization of healthcare among certain cancer patients with advanced
stage illnesses when curative treatment options may be limited. Research on the
informational impact of cancer-related DTCA is important to provide empirical evidence
to help evaluate the risks and benefits of such DTCA on cancer outcomes.
Another reason for focusing on DTCA in cancer care is related to mounting
recognition that cancer patients are actively engaging and navigating through the rapidly
evolving and potentially confusing public health information environment (Viswanath,
5

2005). DTCA contributes to this relentless profusion of health information on cancer
treatment available to healthy individuals, those who are at-risk (e.g., individuals with
strong family history of cancer), or newly diagnosed cancer patients alike. Literature on
cancer communication suggests cancer patients have a wide variety of information needs
and engage with various information sources to meet these needs (Rutten, Arora, Bakos,
Aziz, & Rowland, 2005; Rutten, Squiers, & Hesse, 2006). One qualitative study indicated
cancer patients frequently report cross-source use of information, moving from traditional
media sources (e.g., broadcast television or print newspapers and magazines)—where
DTCA are usually presented—to other sources including their physicians or other health
professionals, lay interpersonal contacts, and the internet (Nagler, Romantan, et al.,
2010). A survey among cancer patients in Pennsylvania found about one in five patients
(19%) bring information from traditional media sources (i.e., television, radio,
newspapers, or magazines) to discuss with their treating doctors (Lewis, Gray, Freres, &
Hornik, 2009). Some of this information from media sources may conceivably include
treatment ads although the study did not specify the type of information that patients
bring to discuss with their physicians. In this dissertation research, one objective is to add
to the growing literature on cancer communication by examining how DTCA contributes
to this dynamic process of patients’ active information engagement across varied sources
for managing their illness.
A further motivation for focusing on cancer-related DTCA is the concern over the
impact of DTCA on patient-provider relationships. To address this concern, Abel and
6

colleagues (2009) examined the extent to which cancer patients from one cancer center
receiving active treatment discuss cancer-related DTCA with their clinicians. Mirroring
the above research by Nagler et al. (2010) and Lewis et al. ( 2009) on cross-source
information seeking, Abel and colleagues (2009) also reported that under one in five
patients (17%) who were aware of DTCA for cancer-related prescription medications had
been prompted by an ad to talk to their cancer doctor or nurse about a prescription drug in
the past year. This suggests that DTCA may not be a prominent factor in influencing
patient-provider discussions about cancer treatment options among cancer patients
receiving active treatment. The study was limited by the convenience study sample of
patients within a single cancer center and the emphasis on interactions about drug
information rather than discussions about treatment more broadly. One objective in this
dissertation research is to address the above gaps in understanding the role of DTCA in
relation to the patient-provider interactions surrounding cancer-related treatment
information.
Historical and Regulatory Background
An exhaustive review of how DTCA became prevalent, development of
regulations for DTCA, and evolution of stakeholder perspectives about DTCA is beyond
the scope of this project and is more amply described elsewhere (Donohue, 2006;
Palumbo & Mullins, 2002; Pines, 1999; Terzian, 1999; J. H. Young, 1961). However, a
brief account of the growth and regulation of DTCA is necessary to provide a historical
context for this dissertation project.
7

The advent of promoting medicinal treatments in the U.S. can be traced to 1708
when Nicholas Boone, an apothecary in Boston, first paid a fee to place a newspaper ad
for a patent medicine (J. H. Young, 1961, 1967). Leading up to the 20th-century, patent
medicine ads accounted for a substantial proportion of newspaper publishers’ advertising
revenues (J. H. Young, 1961, 1967). During this period, it was the norm for patients to
engage with self-treatment using such advertised products and regulations of patent
medicines were not yet in place to ensure public safety. This was also an era when
physicians had not yet achieved the role as professional gatekeepers of potentially
harmful medicinal substances as they have today (Donohue, 2006).
Norms of direct consumer access to medicinal products gradually shifted toward
more restricted access due to increased regulation of the drug industry beginning in the
turn of the 20th-century. In 1906, President Theodore Roosevelt signed into law the Pure
Food and Drugs Act to ensure the quality and purity of drugs through the requirement of
stricter regulation on labeling contents of medicinal products. While the law prohibited
misleading information about ingredients of a drug as stated on labels, it did not limit
false therapeutic claims from appearing on such labels that could misinform consumers of
drug benefits (Donohue, 2006). Subsequent passage of the Food, Drug, and Cosmetic Act
(FDCA) in 1938 improved drug safety by requiring manufacturers to obtain U.S. Food
and Drug Administration (FDA) approval of drugs prior to marketing and sale. The 1938
FDCA included additional stringent requirements for drug labeling and provision of
consumer instructions on the packaging. Legislative amendments to the FDCA between
8

1938 and 1969 gradually reduced the direct availability of many over-the-counter (OTC)
medications to consumers. Over time, these legislations increasingly limited patients’
access to many drugs through physician prescription only, raised the requirements for
proving safety and effectiveness of drugs, and introduced various advertising regulations
for drug manufacturing companies (Donohue, 2006). These regulations progressively
restricted consumer self-treatment while boosting the role of physicians as gatekeepers to
substances that are potentially harmful if used without appropriate medical supervision.
The paradigm shift in increased regulatory oversight of medicines and evolving
importance of physicians to gain access to medications dramatically reduced direct
advertising to consumers by drug manufacturers. As a result, in the ensuing decades,
prescription medication promotional spending remained largely directed at physicians.
The predominance of marketing to physicians rather than directly to consumers is still the
case today. Some examples of physician-directed promotions currently in practice
include paid advertising in medical journals, detailing by sales representatives, and direct
mailing to physicians (Harris, 1964; Rehder, 1965).
By the 1980s, a small number of ads for drugs and vaccines began appearing in
print publications, radio, and television (Donohue, 2006; Kolata, 1983). Following public
concerns surrounding the risks of misleading drug ads, FDA requested a two-year
voluntary moratorium on DTCA in 1983, during which the first consumer survey was
conducted to assess public perceptions and behaviors regarding DTCA. This moratorium
was lifted in 1985 and FDA announced that standards for ads directed at physicians
9

would be applied to DTCA (Terzian, 1999). The FDA guidance in 1997 spelt out ways
that drug manufacturers could advertise their products on broadcast media. Subsequent
amendments to this guidance in 2007 gave FDA the authority to review television ads for
drugs prior to dissemination (Food and Drug Administration, 2007, p.939). However, in
practice, the FDA review process has not kept pace with the rapid growth in the volume
of DTCA. Repeated audits by the General Accounting Office revealed that the FDA did
not have sufficient resources to effectively monitor and prevent drug companies from
disseminating DTCA that contained misleading information (United States General
Accounting Office, 2002, 2006, 2008). Although the guidelines are in place with various
restrictions, the floodgates have been opened, permitting drug manufacturers to promote
prescription medications directly to consumers and resulting in a rapid increase in the
placement of DTCA on broadcast media.
While the focus has been on DTCA of prescription drugs historically, recent
developments in promoting medical treatments encompass direct advertising of other
forms of health-related products and services. Examples of these advertising include
hospitals or doctors offering medical services in specialized clinics or medical centers or
ads for innovative types of medical devices. In contrast to regulatory safeguards for
prescription drugs DTCA, this recent trend of healthcare providers or medical facilities
advertising treatment services directly to consumers is not under similar federal oversight
(E. T. Rosenthal, 2010a, 2010b). One study on the frequency and content of promotional
ads by reputable academic medical centers reported the majority of such ads include
10

emotional appeals and highlight the prestige of institutions in targeting prospective
patients. These ads often do not undergo any review by the respective institutional review
boards (Larson, Schwartz, Woloshin, & Welch, 2005). The authors proposed that in the
interests of patient protection and consistency with FDA guidelines that regulate
advertising for the purpose of recruiting research participants, there is a need for more
oversight on such promotional activities conducted by healthcare institutions.
Promotional Spending on DTCA
Overall industry promotional spending on prescription drugs through DTCA
increased dramatically, quadrupling from $985 million in 1996 to $4.2 billion in 2005
(Donohue, Cevasco, & Rosenthal, 2007). Recent data indicate that DTCA spending
reached a peak of $5.9 billion in 2006 and stabilized at $4.4 billion by 2010 (Kornfield,
Donohue, Berndt, & Alexander, 2013). Despite these large sums, DTCA spending to date
represents only a small proportion of total promotional expenditures by pharmaceutical
manufacturers; DTCA accounted for about 19% of overall promotional expenses in 2010
(Kornfield et al., 2013). DTCA spending also accounts for a minor cost to manufacturers
as a percentage of sales, ranging from 1.4% to 2.0% between 2001 and 2010 (Donohue et
al., 2007; Kornfield et al., 2013). This is largely because the absolute value of the
pharmaceuticals market has grown phenomenally. In contrast, promotional spending
directed at physicians and free samples are still the dominant forms of drug advertising.
In 2010, manufacturers spent $23.3 billion on promotion to providers, constituting the
majority of the overall industry promotional spending based on reported expenditure
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trends and accounting for 7.6% of drug sales (Kornfield et al., 2013). This was almost
five times the amount spent on DTCA in the same year.
Nevertheless, the volume of prescription drug DTCA available in the public
sphere and resultant exposure to consumers are sizeable. This is illustrated in a study by
Brownfield and colleagues (2004) who reported that 428 prescription medication ads
appeared over the period of one sampled week on three major television networks in
Atlanta, Georgia. These ads occupied 311 minutes of airtime, translating to over 16 hours
of exposure to such ads per year for an average television viewer. The authors contrasted
this amount of exposure to DTCA of prescription medications with an average American
spending approximately 15 minutes each year with her primary care physician.
Promotional spending by healthcare providers and facilities is smaller in
comparison to prescription drug promotional spending but this is still substantial and
growing steadily. Between 2001 and 2005, promotional spending by hospitals, clinics,
and medical centers nearly doubled from $493 million to $810 million (American
Medical Association, 2006). A more recent report indicated American hospitals increased
their ad spending from $596 million in the first six months of 2010 to $717 million in the
same period in 2011, representing a year-on-year increase of 20% (Newman, 2011).
There is limited data on promotional spending trends aggregated by disease
condition or on the expenditures for subspecialty advertising such as cancer-related
DTCA. At present, there is no published source of information on overall promotional
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spending for cancer-related treatment specifically. One recent study obtained data on
advertising spending for three select brands of aromatase inhibitors (i.e., anastrozole,
letrozole, and exemestane for reducing breast cancer recurrence risk in postmenopausal
women) between 2005 and 2007 and reported that monthly expenditures of DTCA on
these brands varied considerably between about $120,000 to over $22 million (Abel et
al., 2013). However, there is some evidence that cancer-related DTCA constitutes only a
minor component of the overall promotional spending on DTCA for prescription
medications. Studies reporting the top twenty pharmaceutical drugs in terms of ad
spending did not find cancer-related medications featuring among these highly advertised
drugs (Donohue et al., 2007; M. B. Rosenthal, Berndt, Donohue, Frank, & Epstein,
2002). Based on content analyses of ads in consumer print magazines, cancer-related
DTCA for prescription drugs occurs less frequently than DTCA related to other health
conditions including allergies, oral contraceptives, HIV and AIDS, and dermatological
conditions (Bell, Wilkes, & Kravitz, 2000; Welch Cline & Young, 2004; Wilkes et al.,
2000; Woloshin, Schwartz, Tremmel, & Welch, 2001). One reason may be oncologyrelated medications ads tended to appear more frequently in magazines targeted for
cancer patients (e.g., CURE, Coping with Cancer, and MAMM: Women, Cancer &
Community) rather than in general interest magazines (Abel, Lee, & Weeks, 2007).
Similarly, systematic data sources on promotional spending by healthcare
providers and medical facilities for cancer treatment services are absent. Cancer centers
are seen as reluctant in revealing their advertising activities to attract patients (E. T.
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Rosenthal, 2010a, 2010b). A few studies provide some indication of the extent of
promotion by healthcare providers for cancer treatment. In one recent analysis of 400
U.S. hospital websites, Jin et al. (2011) reported 41% of these websites described robotic
surgery. Of these sites, 32% made claims of improved cancer control with robotic
surgery. In another content analysis of print ads in local newspapers by 17 nationally
acclaimed academic medical centers, researchers showed cancer treatment services were
advertised less frequently compared to other health conditions or healthcare services
(Larson et al., 2005). The study found that 10 of 122 unique print ads from these medical
centers promoted cancer treatment services. The study excluded print ads meant for
patient recruitment into clinical trials or public announcements of community events
unrelated to promoting hospital services. These findings suggest more research may be
warranted to document the prevalence and promotional spending of cancer-related DTCA
among medical centers.
Consumer Awareness and Opinions of DTCA
Several consumer surveys over the past decade consistently found overall public
awareness of DTCA in general to be high (Aikin, Swasy, & Braman, 2004; Murray, Lo,
Pollack, Donelan, & Lee, 2004). One survey conducted by the FDA reported 81% of a
national sample of adults were aware of DTCA in 2002 (Aikin et al., 2004). Another
survey conducted among adults in Sacramento, California found that awareness of 10
drugs advertised at the time of the study ranged from 8% to 72%. On average,
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respondents reported being aware of four drug ads out of the 10 ads that were shown to
them (Bell, Kravitz, & Wilkes, 1999).
Public opinion about DTCA was mixed based on the FDA national survey. While
the majority of respondents agreed DTCA helped make them aware of new drugs (77%)
and provided enough information to decide whether to visit a physician (58%), a sizable
proportion agreed DTCA made the drug seem better than it was (58%) and made it seem
as though a doctor was not needed to make decisions about prescribing the drug (23%)
(Aikin et al., 2004).
Surveys have been conducted on awareness and opinions of specific cancerrelated DTCA of prescription medications among cancer patients. In one study among
cancer patients who were receiving active treatment for hematologic and breast cancers,
Abel et al. (2009) found 86% of respondents were aware of DTCA for at least one of 24
specific medications for cancer treatment or supportive care. The highest awareness
levels were for DTCA promoting supportive medications during chemotherapy including
Procrit (erythropoietin alfa) for improving red blood cell count and Neulasta
(pegfilgrastim) for boosting immune cells. Respondents who were aware of these DTCA
had mostly favorable opinions concerning such ads. The majority agreed or somewhat
agreed that DTCA made them aware of treatments they did not know (62%), provided
information in a balanced manner (65%), and provided information in language they
could understand (89%). In contrast, a small minority of these patients felt that DTCA
made them less confident in their provider’s judgment (11%), suggesting that it was
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unlikely that such ads were harmful to most patients’ relationships with their physicians.
The study was limited to assessing awareness of DTCA for cancer-related prescription
medications and the study population was confined to cancer patients diagnosed with
either breast or hematologic cancers and receiving treatment at a single institution.
Consumer and Physician Behaviors Associated With DTCA
There is evidence that DTCA is associated with certain consumer communication
behaviors including information seeking behaviors and prescription requests from their
physicians. In the 2002 FDA survey, 43% of respondents reported that DTCA prompted
them to look for more information about the advertised drug or health condition from
their healthcare provider, reference books, interpersonal contacts, and the internet (Aikin
et al., 2004). In another national survey, about half of the respondents (47%) who
indicated they had seen a drug ad that was personally relevant in the past year reported
talking about information in the ad during a visit with their doctor (Murray et al., 2004).
In addition, studies indicated physician prescription behaviors are altered when
consumers request certain advertised prescriptions. In the survey by Murray et al. (2004),
among respondents who discussed information from a drug ad with their physicians, 29%
reported they were prescribed the medication mentioned in the ad. In a randomized
controlled trial, Kravitz et al. (2005) found physicians were more likely to prescribe antidepressants when standardized patient actors made a general request for medications or a
brand-specific request than when no such requests were made. These associations were
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present when standardized patients actors portrayed major depression symptoms (for
which treatment is indicated) as well as when actors portrayed adjustment disorders with
depressed mood (for which treatment is not indicated). Based on these findings, the
authors concluded that patient requests have a profound impact on physician prescribing
patterns for these mental health conditions in opposing directions—potentially improving
care by reducing under treatment of major depression while worsening care by overuse of
antidepressants in adjustment disorders.
Currently, there is limited research that focuses on patient and physician behavior
with regards to cancer-related DTCA for medications, healthcare providers, or hospital
facilities. In the study by Abel et al. (2009) described earlier, only a small proportion of
cancer patients (17%) who were aware of DTCA reported they discussed an advertised
treatment with their physicians. Of these patients who discussed DTCA with their
physicians, about one in five (19%) reported receiving a prescription for the medication
while 62% were told by their physicians that they did not need the medication. The
proportion of patients who received the medication was comparatively lower than those
described above in the national survey by Murray et al. (2004) related to DTCA in
general and prescription behaviors. Further research is needed in this area to assess
whether cancer-related DTCA may be associated with patient communication behaviors
(e.g., information seeking about their condition, requests for prescriptions, or requests for
referrals to other hospitals) and physician behaviors.
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Summary
This chapter provided a brief introduction to the controversy surrounding the
practice of DTCA and the rationale for focusing the dissertation research on cancerrelated DTCA. Through a brief outline of historical regulatory events and a review of
selected literature on patient awareness, opinions, and behaviors associated with DTCA, I
identified several knowledge gaps in the research on cancer-related DTCA that this
dissertation aimed to address. The next chapter will outline relevant theoretical
frameworks that guided the design of this dissertation project.
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Chapter 2 THEORETICAL FRAMEWORK
There are many potential positive or adverse effects of DTCA on patient and
physician behaviors, healthcare utilization and outcomes. The subject of this research is
an important one among these possible effects—whether DTCA motivates patients to
engage in additional health information seeking from their healthcare providers or from
other sources. In this dissertation, the studies are guided by theoretical concepts relevant
to DTCA effects on health information seeking behavior. These concepts are derived
from psychosocial theories of predicting behavior including the Integrative Model of
Behavioral Prediction and Social Cognitive Theory, the framework of patient-centered
communication in cancer care, and the Structural Influence Model of Communication.
These key theoretical concepts are briefly outlined below and integrated into the
subsequent chapters describing each study in this dissertation research.
Integrative Model of Behavioral Prediction
The Integrative Model (IM) offers a theoretical framework to situate the present
research in studying the relationships between cancer-related DTCA exposure and patient
communication behaviors. Broadly, the IM specifies a causal pathway between one’s
intention to perform a behavior and the actual engagement in the behavior. The IM
further theorizes that behavioral intention is influenced by individuals’ underlying
attitudes toward the specific behavior, perceived normative pressure (PNP) to perform the
behavior, and perceived behavioral control (PBC) associated with enacting the behavior.
Intention is operationalized as an individual’s self-reported likelihood of performing a
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behavior in a future timeframe. Intention is further defined in terms of specific time,
action, context, and target to be compatible with the behavior of interest. Attitude toward
the behavior is defined as “degree to which a person has a favorable or unfavorable
evaluation or appraisal of the behavior in question” (Ajzen, 1991, p.188) (i.e., whether
performing the behavior would be good or bad for oneself, beneficial or harmful, wise or
foolish). PNP is a person’s “perceived social pressure to perform or not to perform the
behavior” (Ajzen, 1991, p.188) or whether important others think one should or should
not perform the behavior and whether others who are similar are also performing the
behavior. PBC refers to “people’s perception of the ease or difficulty of performing the
behavior of interest” (Ajzen, 1991, p183), that is whether someone believes that he or she
would have the ability to perform the behavior and that it would be under his or her
control to engage in the behavior.
Applying the above IM constructs to the dissertation research, Study 3 explores
the theoretical pathways between exposure to DTCA and patients’ active cancer-related
health information seeking, mediated through individuals’ attitudes, PNP, and PBC
associated with actively seeking information behaviors. DTCA exposure is hypothesized
to influence these IM constructs in a few ways. For instance, spokespersons featured in
DTCA may serve as models to actively engage with their physicians to talk about their
health condition. These portrayals of patient-doctor discussions convey positive outcome
expectations about the information seeking that are associated with positive attitudes
toward the behavior. They may also influence perceived descriptive norms that other
patients are likely to consult their doctor for information. DTCA may improve behavioral
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control through observing spokespersons enacting discussions effectively and
information aimed at empowering patients’ ability to discuss with their doctor about their
condition. For instance, in an ad for Detrol LA (indicated for overactive bladder
symptoms), a spokesperson promoted a website that provided tips on how patients can
get the discussion started with their physician about their symptoms.
At present, there is a lack of empirical evidence that is directly relevant for this
dissertation research regarding the psychosocial mediators of DTCA effects on general
health information seeking; prior studies focused on specific drug inquiry as the
behavioral outcome (Deshpande, Menon, Perri III, & Zinkhan, 2004; Herzenstein, Misra,
& Posavac, 2004; Liu, Doucette, Farris, & Nayakankuppam, 2005; Welch Cline &
Young, 2004; H. N. Young, Lipowski, & Welch Cline, 2005; H. N. Young & Welch
Cline, 2005). Despite this, seeking information about an advertised treatment may be
considered as a subset of general health information seeking. Therefore, findings from
studies that examined pathways of DTCA effects on drug inquiry behaviors may still
inform the generation of hypotheses pertaining to similar theoretical mechanisms of
DTCA effects on general health information seeking. In one study utilizing the Theory of
Planned Behavior and Self-Efficacy Theory, Liu and colleagues (2005) found that
attitudes and subjective norms toward seeking drug information from physicians and
pharmacists predicted intentions to seek from these sources among a sample of patients
with osteoarthritis who were recently exposed to DTCA for osteoarthritis prescription
medications. In contrast, only attitudes toward seeking drug information from the internet
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predicted intention to seek from the internet. Perceived difficulty was not predictive of
intentions to seek from all three sources.
Social Cognitive Theory
Social Cognitive Theory (SCT) provides another theoretical framework to
understand the psychosocial determinants of health behaviors (Bandura, 1986). SCT
posits that core determinants of behavior include: 1) knowledge of the risks and benefits
of health behaviors, 2) perceived self-efficacy of one’s control over performance of
health behaviors, 3) outcome expectancies or beliefs about the likelihood and value of
enacting certain behaviors, 4) health goals, 5) perceived facilitators, and 6) social and
structural impediments to behavior change (Bandura, 2004). Other key concepts from
SCT are reciprocal determinism (defined as a triadic model in which behavior, personal
factors, and environmental factors interact as determinants of one another) and
observational learning of new behaviors through exposure in the media or peer modeling
(McAlister, Perry, & Parcel, 2008). Of these theoretical constructs in SCT, three key
concepts that are relevant for Study 3 in this dissertation research are observational
learning, outcome expectancies, and self-efficacy.
Observational learning or vicarious learning is a central concept of SCT (Bandura,
1986) which refers to the process of “learning to perform new behaviors by exposure to
interpersonal or media displays of them, particularly through peer modeling” (McAlister
et al., 2008). According to Bandura, there are four key processes underlying
observational learning: 1) attention to the modeled behavior, 2) retention of an observed
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behavior, 3) production of the behavior, and 4) motivation to imitate the modeled
behavior (Bandura, 1986). For DTCA to influence observational learning of the desired
behavior (e.g., interacting with physicians, requesting the treatment, or finding out more
information about an advertised treatment), ads must first attract patients’ attention,
ensure retention of information from the ad, guide patients to produce the desired
behavior through peer modeling, and motivate them to enact the behavior by generating
positive outcome expectancies.
Outcome expectancies are defined as “beliefs about the likelihood of various
outcomes that might result from the behaviors that a person might choose to perform, and
the perceived value of those outcomes” (McAlister et al., 2008). The concept of outcome
expectancy is not unique to SCT and corresponds closely to similar constructs described
in other influential behavioral theories including the IM in the earlier section (Fishbein &
Ajzen, 2010) and the Health Belief Model (Champion & Skinner, 2008). The underlying
premise of the importance of outcome expectancies in predicting behavior is the notion
that consumers act rationally to maximize benefits and minimize costs. Therefore,
consumers would be more likely to undertake a specific behavior if they believe doing so
would provide more rewards or have least amount of costs. Relating this to DTCA,
beliefs about positive outcomes associated with discussing an advertised treatment with
physicians or with receiving the treatment may motivate patients to discuss information
from an ad or request for the advertised treatment.
Self-efficacy is another central concept of SCT widely incorporated in behavioral
change communication and interventions. The concept refers to “people’s judgments of
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their capabilities to organize and execute courses of action required to attain designated
types of performances” (Bandura, 1986) and is found to be a predictor of health
behaviors directly or indirectly across different domains (Gwaltney, Metrik, Kahler, &
Shiffman, 2009; Holden, 1991; Strecher, McEvoy DeVellis, Becker, & Rosenstock,
1986). Consistent with the concept of self-efficacy and its impact on health behaviors,
advocates claim DTCA plays a role in encouraging patient autonomy and participation in
medical decision making through raising awareness about therapeutic choices, promoting
information seeking, and reaching autonomous decision choices (Calfee, 2002; Holmer,
1999; Zachry III & Ginsburg, 2001). It should be noted that self-efficacy as described in
SCT corresponds closely to perceived behavioral control, which is a core construct in the
IM.
In the context of research on DTCA, the above SCT concepts offer meaningful
theoretical mechanisms for expecting and explaining effects of advertising on cancer
patients’ cognitions and behaviors. For instance, in a series of content analyses
employing SCT concepts to examine the visual and textual elements of DTCA in print
magazines, researchers found DTCA contains various characteristics frequently
associating positive outcome expectancies with the use of advertised drugs (Welch Cline
& Young, 2004; H. N. Young & Welch Cline, 2005). These behavioral motivators
included portraying rewards in terms of identity, relational, or instrumental benefits
associated with using an advertised drug. Survey research among young female
consumers suggested positive outcome expectancies of discussing about an advertised
drug with their physicians were associated with increased intention to communicate with
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physicians about the drug (H. N. Young et al., 2005). Through the perspective of
observational learning, one of the studies examined the role of models in DTCA and
reported the majority of DTCA depicted models who possessed positive characteristics
(e.g., being healthy, active, and friendly) (Welch Cline & Young, 2004). The authors
concluded portraying models whom consumers could identify with and desired to
emulate might facilitate consumers’ observational learning to modify interactions with
their physicians and to discuss about an advertised drug.
Framework for Patient-Centered Communication in Cancer Care
Cancer patients have a wide variety of information needs related to their condition
and frequently seek information from various sources to meet their needs (Hesse, Arora,
Burke Beckjord, & Finney Rutten, 2008; Nagler, Gray, et al., 2010; Rutten et al., 2005;
Squiers, Finney Rutten, Treiman, Bright, & Hesse, 2005). Studies consistently find that
most cancer patients turn to their clinicians when they are looking for cancer information
(Hesse et al., 2008; Lewis et al., 2009; Rutten et al., 2005). Accordingly, effective
patient-clinician communication constitutes an important element of information
acquisition by cancer patients and plays a critical role in influencing patient health
outcomes (Epstein & Street Jr., 2007; Street Jr., Makoul, Arora, & Epstein, 2009).
The framework for patient-centered communication offers a model for
understanding the pathways through which patient-clinician communication may lead to
better health outcomes (Street Jr. et al., 2009). First, core communication functions (e.g.,
information exchange, responding to emotions, making decisions, and enabling self25

management) may have direct influences on health outcomes including survival,
emotional well-being, or symptom control. In addition, communication may indirectly
influence health outcomes through proximal outcomes (e.g., patient knowledge and
understanding, satisfaction, and trust in clinicians) or intermediate outcomes such as
access to care, quality medical decisions, and self-care skills. Street and colleagues (2007,
2009) proposed seven pathways through which communication could contribute to
improved health: 1) facilitate access to needed care, 2) increase patient knowledge and
shared understanding, 3) enhance therapeutic alliances (among clinicians, patient, and
family), 4) enhance emotional self-management, 5) activate social support and advocacy
resources, 6) increase quality of medical decisions, and 7) enable patient agency (selfefficacy and empowerment). From the above concepts, I highlight the roles of patientclinician information exchange as they pertain to Study 3 in this dissertation research.
Patient-clinician information exchange is conceptualized as one of the core
functions of patient-clinician communication that could affect patient outcomes (Epstein
& Street Jr., 2007). Information exchange refers to the “reciprocal efforts of both
clinicians and patients to manage information and achieve, even negotiate, a shared
understanding of the medical and personal issues underlying the patient’s health
condition” (Street Jr. & Epstein, 2008). For effective information exchange to occur,
patients should actively engage with their physicians to elicit more and clearer
information. Physicians should concurrently use partnering and supportive forms of
communication tailored to the information needs, beliefs, and values of their patients
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(Street Jr., Gordon, Ward, Krupat, & Kravitz, 2005; Zandbelt, Smets, Oort, Godfried, &
de Haes, 2007).
To frame patient-clinician discussions about DTCA within the concept of
information exchange, one scenario would be an actively engaged patient bringing
information from a cancer treatment ad to discuss with his or her physician. In the course
of the discussion, the physician may respond with supportive information and explanation
about benefits and risks associated with the advertised treatment. This exchange of
information in turn leads to improved patient understanding and other outcomes. For
instance, Martinez et al. (Martinez, Schwartz, Freres, Fraze, & Hornik, 2009) found
patient-clinician information engagement about various cancer-related topics—which
included discussing information patients had gotten elsewhere—was found to predict
increased feelings of being informed and treatment decision satisfaction among cancer
survivors. This was corroborated by another study that found almost all cancer patients
(96%) who discussed an advertised cancer prescription drug with their physicians were
satisfied with the discussion even though most of them did not eventually receive a
prescription for the advertised medication (Abel et al., 2009). The findings suggest
information exchange about DTCA, in this case initiated by patients, may contribute to
intermediate outcomes of patient satisfaction about treatment decisions or about their
interactions with clinicians.
Patient knowledge and shared understanding are viewed as intermediate outcomes
that could contribute to improved patient health. In order to make informed treatment
decisions, patients need to have an understanding of their disease condition as well as
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effectiveness, risks, and benefits associated with various treatment options (Braddock,
Edwards, Hasenberg, Laidley, & Levinson, 1999). Both clinicians and patients play
important roles in this process (Charles, Gafni, & Whelan, 1997). Apart from managing
the complexity and uncertainty of treatment-related information, clinicians need to
consider individual values, needs, and preferences of patients and communicate
effectively to come to a shared understanding of the above issues (Street Jr. et al., 2009).
Relating the concept of patient knowledge to research on DTCA, patients may obtain—
through discussion and information exchange with their treating doctors—a better
understanding of whether an advertised treatment is appropriate for their specific
condition and attendant risks and benefits involved with the treatment. From this process,
patients may experience increased satisfaction about the discussion or treatment decision
as described earlier (Abel et al., 2009; Martinez et al., 2009), improved ability to cope
with the illness (Hagerty, 2005; Roberts, Cox, Reintgen, Baile, & Gibertini, 1994), and
more commitment to the treatment plan (Zolnierek & Dimatteo, 2009), all of which may
contribute to improved treatment outcomes and patient health.
Alternatively, patient-centered communication may lead to improved patient
health outcomes through enhancing patient empowerment and agency. The concept of
agency is closely related to PBC described above in the IM and self-efficacy in SCT and
encompasses patient perceptions and skills across various domains. These skills include
the ability to engage actively with clinicians in medical encounters, participate in
treatment decision-making, and to perform self-care for everyday health-related activities
(O’Hair et al., 2003). Effective patient-clinician communication may facilitate patient
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involvement in the decision-making process and offer resources for patients to develop
specific skills for self-care (Van Dam, Van der Horst, Van den Borne, Ryckman, &
Crebolder, 2003). In terms of the role of DTCA in enhancing patient agency, evidence
supports the view that these ads may give patients the confidence to talk to their doctors
about their concerns, improve discussions with their physicians, and increase feelings of
being in control (Abel et al., 2009; Murray et al., 2004).
Structural Influence Model of Communication
The Structural Influence Model of Communication, described by Kontos &
Viswanath (2011), suggests disparities in health communication have important roles in
mediating relationships between social determinants (e.g., race, education, and income),
access to healthcare resources, and more distal health outcomes (e.g., health behaviors,
adherence, and treatment outcomes). The underlying assumption for this model is the
notion that “control of communication is power and that whoever has the capacity to
generate, access, use and distribute information enjoys social power and advantages that
accrue from it”. According to the model, communication inequalities that may lead to
health outcomes disparities include differences between social groups in terms of their: 1)
exposure, 2) attention, 3) external information seeking, and 4) processing of health
information. Most relevant to this dissertation research are inequalities in DTCA
exposure (Study 2) and external information seeking following DTCA (Study 4).
Applying concepts of Structural Influence Model of Communication to the impact
of cancer-related DTCA, Kontos & Viswanath (2011) suggested communication
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inequalities associated with DTCA may arise at three distinct but related levels: 1) certain
groups may be less likely to gain exposure to DTCA, 2) differential attention and
processing of DTCA may occur, and 3) some groups may not engage in additional
information seeking after viewing DTCA. If such inequalities exist, DTCA may have
differential effects between certain social groups. For example, on one hand, if some
groups were more likely to be exposed to DTCA or attend to such ads, they may be more
aware of treatment options available for their cancers than others. This may widen health
outcomes disparities between these groups. On the other hand, detrimental effects of
DTCA such as inappropriate use of treatments may affect one group more than others due
to communication inequalities at various levels. For instance, it may be that certain social
groups are more likely to look for additional information about an advertised treatment
and are therefore able to weigh benefits and risks of an advertised treatment better than
other groups. Therefore, research is necessary to assess whether certain groups have
higher exposure to DTCA than others (Study 2) and whether certain groups are more
likely to engage in additional information seeking following DTCA (Study 4).
Summary
Relevant theoretical concepts are adapted from psychosocial models of behavioral
change (IM and SCT), patient-centered communication, and the Structural Influence
Model of Communication in this dissertation research. Specifically, Study 2 drew on the
concepts of communication inequalities in exposure and attention to examine
determinants of cancer survivors’ reported exposures to DTCA. In addition, Study 3
assessed the impact of patients’ exposure to DTCA on active information seeking based
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on the concept of information exchange from patient-centered communication framework
and explored the theoretical pathways of this relationship through psychosocial constructs
from the IM. Finally, Study 4 explored communication inequalities associated with
DTCA by comparing its effects on information seeking behaviors across patients with
different characteristics.
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Chapter 3 MEASURING EXPOSURE TO DIRECT-TO-CONSUMER
ADVERTISING—A VALIDATION STUDY IN THE CONTEXT OF CANCERRELATED TREATMENT ADVERTISING (STUDY 1)
Abstract
Emerging research suggests that direct-to-consumer advertising (DTCA) may be
associated with patient and physician behaviors pertaining to treatment decision making.
However, systematic efforts to develop and validate measures of patient exposure to
DTCA are lacking. This study evaluated three candidate measures (I-III) of patientreported exposure to cancer-related DTCA. Using data from two population-based
surveys, this study assessed the performance of each measure based on seven criteria.
Results were consistent across both surveys; all three measures performed well in terms
of convergent, nomological, discriminant, and face validity with a few differences
between these measures. Measure I—the briefest of the three measures—posed the
lowest level of survey costs and respondent burden among the three measures and was
also deployed successfully for mailed and internet-based survey administration. Future
directions for application and research relevant for cancer-related DTCA as well as
DTCA for other illnesses are discussed.
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Introduction
The practice of direct-to-consumer advertising (DTCA) for prescription
medications and healthcare services is controversial in the United States and subject to
much debate (Bonaccorso & Sturchio, 2002; Fox & Ward, 2008; Frosch et al., 2010;
Hoen, 1998; Hollon, 1999, 2005; Holmer, 1999, 2002; E. T. Rosenthal, 2010b). Cancerrelated DTCA, a form of “subspecialty DTCA” which is targeted at patients with cancer,
is of further concern because of the limited options of highly effective interventions and
potentially higher risks associated with specialized treatments (Abel et al., 2007). To
better understand the extent of cancer patients’ perceptions of cancer-related DTCA—
which is defined as “promotional efforts by a pharmaceutical company, healthcare
provider, or medical facility to present information about medications, medical devices,
or medical services for patients diagnosed with cancer in the lay media environment”
(adapted from Wilkes, Bell, & Kravitz, 2000)—and the potential impact of exposure to
this advertising on various treatment-related behaviors or outcomes, it is essential to be
able to measure patients’ exposure to DTCA adequately.
Prior research that formally assessed the validity of exposure measures of cancerrelated DTCA or DTCA more generally is lacking. This research presents an approach to
validate candidate measures of patients’ exposure to DTCA. While the present study
pertains to the specific context of cancer treatment advertising, this approach would also
benefit research in DTCA associated with other illnesses because of the similarity in the
conceptual issues faced by measuring DTCA exposures. I first begin with a brief review
of the rationale for this study and conceptual issues related to measuring cancer-related
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DTCA exposure. Next, validation criteria and methods are outlined, followed by findings
from two population-based surveys. Finally, I discuss the implications of the findings and
recommendations for further research.
Rationale for study and conceptual issues of measuring cancer-related DTCA
exposure
The impetus for this present validation research stemmed from a need to assess
the reliability and validity of existing survey items of cancer-related DTCA exposure that
were to be used in the analyses reported in subsequent chapters. These exposure items
were part of a survey among a sample of cancer patients in Pennsylvania (to be described
shortly). Participants were asked, “Since your diagnosis, how often have you seen or
heard advertisements concerning each of the following?” for three categories of ads
including “treatment alternatives for your cancer”, “dealing with side effects of
treatment”, and “hospitals or doctors offering services for cancer”. Responses were
measured along a 5-point scale (1 = Never to 5 = Almost every day). Lower scores
represented lower frequencies of exposure to these types of ads (see Appendix A).
These three survey items are conceptually novel compared to exposure measures
of DTCA described in the literature and encompass a few measurement limitations. First,
the individual items focus on three broad categories of treatment ads that differ topically
from measures in previous literature. These prior studies on DTCA exposure
overwhelmingly focused on measuring exposure to prescription drug ads alone (Abel et
al., 2009; Aikin et al., 2004; Bell, Kravitz, et al., 1999; Deshpande et al., 2004; Frosch,
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May, Tietbohl, & Pagán, 2011; Martinez & Lewis, 2009; Murray et al., 2004; Sumpradit,
Fors, & McCormick, 2002; Weissman et al., 2003; Wilkes et al., 2000). Second, the
survey items in our study are brief and do not elaborate with examples or define the
individual categories of ads for the respondents. The concern with this brevity is the
inherent assumption that respondents could discriminate among the named categories and
report their exposure to ads according to those categories accurately. For instance, on its
face, the survey item on the category of “hospitals of doctors offering services for
cancer” could conceivably trigger recalling different types of ads in different respondents.
In comparison, Abel and colleagues (2009) provided a list of 24 cancer-related brand
name medications that appeared in print advertisements to prompt patients’ responses
about their awareness of ads for each of these medications. Third, the survey items in our
research asked respondents about the frequency of encountering cancer treatment ads.
This contrasts with measures from other studies that only asked about awareness (i.e.,
whether respondents had seen or heard prescription drug advertisements (yes/no)) (Aikin
et al., 2004). Furthermore, the three survey items in our study may be limited by the
absence of prompts to recall ad exposure from various sources, potentially leading to
under-reporting exposures. They differ from measures used by studies to assess
respondents’ exposure to prescription drug ads across a variety of sources including
television, radio, newspapers or magazines, or on the internet (Aikin et al., 2004;
Martinez & Lewis, 2009).
The above conceptual issues motivated a separate survey to assess if modifying
the existing cancer-related DTCA survey items to address these issues would improve the
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ability to measure DTCA exposure more accurately. For instance, the brief instructions in
the existing items for how respondents should think about their exposure to cancerrelated DTCA may appear to reduce the face validity of these items. On the other hand,
the brevity of these items might be simpler to understand and less confusing among
respondents. This concern drove the effort to compare various versions of these survey
items to assess whether brevity was in fact lowering the validity of the existing items and
to judge the relative usefulness in measuring exposure of different versions across several
criteria. In one modified version, survey items include longer verbal descriptions of each
of the ad categories and list media sources to prompt respondents about their recall of
cancer treatment ads from these sources. For instance, respondents were asked
“Sometimes hospitals or doctors advertise their services (radiation therapy,
chemotherapy, or comprehensive treatment) for treating patients with cancer. These
advertisements may appear in the mass media (e.g., television, radio, newspapers,
magazines, billboards, or the internet). Since your diagnosis, how often have you seen or
heard advertisements concerning hospitals or doctors offering services for cancer?”
(Appendix A). Despite these slightly more detailed descriptions, respondents may still
not understand the named categories uniformly or distinguish between the categories. In a
second set of alternative survey items, I incorporate longer descriptions of each ad
category, list various media sources, and further provide two exemplars of ads that are
representative of each category to illustrate what the ad categories mean for respondents
(Appendices A and B). This separate survey is designed to compare the performance of
these modified versions in terms of reliability and validity against the existing measure
using various criteria. Essentially, if the existing exposure measure is not substantially
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different from the modified versions, this would justify retaining the existing measures
for investigating the associations between cancer-related DTCA and communication
behaviors in the previously mentioned cancer patient survey.
Validation approach
The approach of this study is adapted from related validation frameworks for
assessing the performance of alternative measures of exposure to cancer information
(Romantan, Hornik, Price, Cappella, & Viswanath, 2008), scanned information exposure
(Kelly, Niederdeppe, & Hornik, 2009), and contradictory health messages (Nagler &
Hornik, 2012). This study examines how well each of the three candidate measures of
cancer-related DTCA exposure performs based on the following seven criteria that are
most relevant: 1) convergent validity, 2) nomological validity, 3) discriminant validity, 4)
test-retest reliability, 5) face validity, 6) survey costs, and 7) respondent burden. These
criteria are explicated further in Table 3.1. To assess the performance of the candidate
measures of exposure to cancer-related DTCA among cancer patients, this research relies
on two data sources—the Pennsylvania Cancer Patient Survey and an online survey of
cancer patients across the U.S. The methods and findings from these two data sources are
described separately, followed by an overall discussion.
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Table 3.1 Operationalization of Validation Criteria
Criteria

Definition

Convergent validity

1. Moderate to strong inter-item correlations (Pearson’s
correlation r ≥ 0.35),
2. Items load on a unidimensional construct, and
3. Internal consistency based on reliability measures
(Cronbach’s alpha≥0.70).

Nomological validity

1. Correlations between patients’ exposure to cancerrelated DTCA with variables that would be expected
to predict cancer-related DTCA exposure as well as
those that would be affected by exposure to cancerrelated DTCA:
a. General media usage,
b. Health media exposure,
c. Scanning of treatment information, and
d. Discussing with physicians about information
from lay media sources (where cancer-related
DTCA would be encountered).

Discriminant validity

1. Candidate measures of cancer-related DTCA exposure
would be more strongly associated with one another
than with the variables assessed for nomological
validity.

Test-retest reliability

1. Correlations between repeated measures of exposure
to cancer-related DTCA over time.

Face validity

1. Subjective assessment of the extent that candidate
measures accurately reflected the definition of cancerrelated DTCA.

Survey costs

1. Length of the measures in terms of word count and
2. Number of responses required.

Respondent cognitive
burden

1. Subjective assessment of the extent that measures
demanded more cognitive effort to comprehend the
instructions of the measures and report their exposure
to cancer-related DTCA.
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Study 1A—Pennsylvania Cancer Patient Survey
Method
Study Population
Between 2006 and 2008, as part of a larger study, annual surveys were conducted
among a probability sample of patients who were diagnosed with breast, prostate, or
colorectal cancers and were reported, as legally required, to the Pennsylvanian Cancer
Registry (PCR) in 2005. The data collection and survey instrument development
procedures are detailed elsewhere (Nagler, Gray, et al., 2010). Survey questionnaires
were designed following literature review, extended patient interviews, and expert
consultation. The University of Pennsylvania Institutional Review Board approved the
study. This present research focuses on the surveys in 2006 and 2007 (Rounds 1 and 2)
that collected data about cancer patients’ exposure to cancer-related DTCA. In Round 1,
2013 participants completed the survey (American Association for Public Opinion
Research response rate 4 was 64%) (AAPOR, 2006). Among 1758 respondents who
agreed to be re-contacted, 1293 (74%) completed the Round 2 survey.
Measures
Cancer-related DTCA exposure (Measure I)
As described earlier, three items asked respondents about their frequency of
seeing or hearing about advertisements concerning “treatment alternatives for your
cancer”, “dealing with side effects of treatment”, and “hospitals or doctors offering
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services for cancer”, measured on a 5-point scale (1 = Never to 5 = Almost every day)
(see Appendix A). The numerical scores assigned to responses to these three items were
treated as interval and averaged to form the measure of cancer-related DTCA exposure
(Measure I) (Round 1: M = 2.41, SD = 1.02; Round 2: M = 2.21, SD = 0.95).
Health media exposure
Participants’ exposure to health information from media sources is expected to be
positively associated with exposure to cancer-related DTCA. Participants reported how
frequently they had found out about health information in the preceding 30 days from
five media sources (i.e., newspapers or general magazines, medical magazines or
newsletters, health segments on television news, television programs other than news,
and the internet). Responses for these items ranges on a 4-point scale from ‘not at all’ to
‘two or more times per week’ and were summed into an index of health media exposure
(Round 1: M = 10.43, SD = 3.59; Round 2: M = 10.48, SD = 3.47).
Scanning about treatment information
Furthermore, encountering cancer treatment information during routine use of
media sources is expected to be positively associated with cancer-related DTCA
exposure. Respondents were asked “What information have you come across about your
cancer from media sources (television, radio, newspapers, magazines, Internet) when you
were not looking for it since your diagnosis?” and were able to select if they had come
across information about “what treatments were the best for my cancer”, “which doctors
of hospitals would be the best for me”, and “how to manage side effects of treatments”.
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These binary responses (yes or no) were summed into a 0-5 point index of treatmentrelated information scanning (Round 1: M = 1.05, SD = 1.03; Round 2: M = 0.56, SD =
0.86).
Discussion with treating doctors
Prior research suggests that exposure to prescription drug DTCA prompts patients
to discuss the advertised drug with their physicians (Aikin et al., 2004; Murray et al.,
2004). Cancer-related DTCA exposure is expected to be associated with discussion with
one’s physicians about cancer-related information. Four survey items asked if
respondents had discussed information they had gotten from media sources (i.e.,
television or radio; books, brochures, or pamphlets; newspapers or magazines; and
internet excluding personal emails) with their treating doctors since the cancer diagnosis.
These are media sources through which DTCA for cancer treatments tend to be noticed
by cancer patients (Abel et al., 2009). The items were summed into an index (range of 0 –
4) of discussion with treating doctors (Round 1: M = 0.78, SD = 1.07; Round 2: M = 0.59,
SD = 1.01).
Analyses
Analyses for assessing the performance of Measure I were conducted using the
Stata release 11 statistical package (StataCorp, 2009). To assess convergent validity,
correlation analyses between Measure I items, computation of the Cronbach’s alpha
statistic, and principal component analysis were performed. Nomological validity was
assessed with correlations between the DTCA exposure scale with health media
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exposure, scanning about treatment information, and discussion with physicians at
Rounds 1 and 2. Using the ‘CORRCI’ command in Stata, I examined discriminant
validity by comparing the correlation and its confidence intervals between DTCA
exposures in Rounds 1 and 2 against those between the DTCA exposures of each round
with the nomological criterion variables. Erring on the side of being conservative, these
correlations were deemed to be different if there is no overlap in the confidence intervals.
Test-retest reliability was assessed with the correlation between cancer-related DTCA
exposures in Rounds 1 and 2.
Results
At Round 1, half of the study sample was female (51%) and the average age was
63 years. Other participant characteristics are reported in Table 3.2. The distributions
(mean and standard deviation) of individual Measure I items in both rounds and the
resulting DTCA exposure scales are summarized in Table 3.3.
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Table 3.2 Participant Characteristics
Study 1A

Study 1B

N=2013

N=363

Characteristics

M

SD

Age

66

12

Gender – Female

%

M

SD

53

16

%

51

52

Some high school and below

16

2

High school

41

23

Some college or two-year degree

22

36

4-year college degree or higher

22

39

White

83

89

Black

13

6

Other

4

6

Colon cancer

34

10

Breast cancer

34

21

Prostate cancer

32

16

Other

0

43a

Education

Race/ ethnicity

Cancer type

Note. aExamples of other cancer diagnoses were skin cancers (12%), endometrial cancer
(4%), lymphoma (3%), and leukemia (3%).
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Table 3.3 Distributions of Items and Scales of Candidate Measures of cancer-related
DTCA Exposure
Study 1B

Study 1A

Individual Items
Treatment
alternatives
Dealing with
side-effects

Measure I

Measure I

Measure I

Measure II

Measure III

Round 1a

Round 2b

N=363

N=216

N=147

N=2013

N=1293

M

SD

M

SD

2.22

1.23

2.04

1.15

2.61 1.51

2.64 1.44

2.74 1.47

2.22

1.30

1.92

1.10

2.45 1.43

2.60 1.37

2.48 1.41

2.87

1.34

2.75

1.33

3.24 1.36

3.26 1.37

3.27 1.31

2.41

1.02

2.21

0.95

2.77 1.22

2.83 1.19

2.83 1.14

M

SD

M

SD

M

SD

Hospital or
doctors offering
services

Combined scale
Cancer-related
DTCA exposure

Note. Means are based on a five-point scale (1 = Never and 5 = Almost everyday).
a
The number of cases with missing values for the individual items ranged from 519 to
597; these were predominantly due to 369 cases who were randomized to receive a
shortened form of the questionnaire in Round 1 that excluded these cancer-related DTCA
items. The remainder was due to item non-response or multiple responses to an item.
b
The number of cases with missing values for the individual items ranged from 129 to
211 in Round 2; these were due to item non-response or multiple responses to an item.
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Convergent validity—In this study population, Measure I items are moderately
correlated with one another (inter-item Pearson’s r ranged from 0.420 to 0.477 in Round
1 and from 0.461 to 0.474 in Round 2) (Table 3.4). In addition, the three items
demonstrate reasonable internal consistency (Cronbach’s alpha=0.724 in Round 1 and
0.742 in Round 2). Principal component analyses show that the items load on a single
component with an eigenvalue greater than one in both Rounds 1 and 2, accounting for
64% and 66% of the total variances respectively.
Table 3.4 Inter-Item Pearson’s Correlations Between Measure I Items (Study 1A)
Round 1
1
1. Ads concerning treatment

2

Round 2
3

- 0.420

1

2

3

0.420

- 0.474 0.465

- 0.477

- 0.461

-

-

0.724

0.742

alternatives for cancer
2. Ads concerning dealing with side
effects of treatment
3. Ads concerning hospitals or
doctors offering services for cancer
Cronbach’s alpha

Note. All Ps <.0005.
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Nomological validity—The DTCA exposure scale derived using Measure I items
is correlated with health media exposure and information scanning about cancer
treatment from media sources in both Rounds 1 and 2. The DTCA exposure scale is also
correlated with discussion with physicians about information from lay media sources
across both Rounds 1 and 2 (Table 3.5).
Test-retest reliability—The correlation of DTCA exposure scales between the two
rounds is moderate (Pearson’s r = .492) (Table 3.5).
Discriminant validity—Based on the results in Table 3.5, the association between
DTCA scales in Rounds 1 and 2 is stronger than the correlations of each of these scales
with the nomological criterion variables (no overlap of the confidence intervals). This
supports the inference that the DTCA exposure scale may be a distinct measure
comparing with these variables.
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Table 3.5 Pearson’s Correlations Between Cancer-Related DTCA Exposure Scale
and Health Media Exposure, Scanning for Treatment Information, and Discussion
with Physicians (Study 1A)

DTCA exposure in Round 1 by DTCA exposure in
Round 2

DTCA exposure in Round 1 by Health media exposure
Round 1
DTCA exposure in Round 1 by Scanning for treatment
information in Round 1
DTCA exposure in Round 1 by Discuss lay media
information with treating doctor in Round 1

DTCA exposure in Round 2 by Health media exposure
Round 2
DTCA exposure in Round 2 by Scanning for treatment
information in Round 2
DTCA exposure in Round 2 by Discuss lay media
information with treating doctor in Round 2

Pearson’s r

95% CI

0.492

0.441 - 0.540

0.360

0.299 - 0.418

0.309

0.246 - 0.369

0.194

0.127 - 0.258

0.224

0.158 - 0.287

0.270

0.206 - 0.332

0.179

0.113 - 0.244

Note. All Ps <.0005
Face validity—As discussed earlier, one limitation associated with the brevity of
self-reported exposure items in the Pennsylvanian survey is patients may not be able to
distinguish ads with different types of content precisely according to the brief
descriptions in the items (i.e., alternative treatments for cancer, hospitals or doctors
offering services, or dealing with side-effects of treatment). In addition, the items did not
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prompt respondents to report coming across DTCA across various media. Therefore,
these items may not have accurately captured patients’ exposure to DTCA across a
variety of media sources (e.g., television, print magazines, billboards, or the internet).
Patients’ self-reported exposure to DTCA based on these items may consequently
underestimate their true exposure. However, the brevity of the items in Measure I could
be easier to understand and less prone to confusion among respondents. As I will describe
shortly in Study 1B, comparisons with more detailed versions of these items would be
valuable in assessing whether the brevity of Measure I affected the performance of this
measure in other criteria.
Survey costs and respondent burden—Measure I items consist of 52 words and
three distinct responses, suggesting that survey costs would be low to moderate. Although
brief, these items are judged to have modest cognitive burden because respondents have
to generate a summary estimate of their exposure to classes of DTCA, not just specific
ads (i.e., treatment alternatives, dealing with treatment side effects, and hospital or
doctors offering services) before giving their response.
To summarize, based on this study among a probability sample of Pennsylvanian
patients diagnosed with breast, colorectal, or prostate cancers, Measure I items can be
considered as reliable and valid means of assessing exposure to DTCA. These items
demonstrate reasonable convergent validity, nomological validity against selected
criterion measures, test-retest reliability between repeated measures over time, and
discriminant validity. In addition, Measure I items are likely to impose low to moderate
survey costs and cognitive burden for participants. However, the trade-off associated with
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the brevity of these items may be reduced face validity. Another limitation of Study 1A is
that the sample consisted of only Pennsylvanian patients diagnosed with three types of
cancers. This may limit the generalizability of the validity and reliability of Measure I,
although there are no a priori reasons to expect substantial differences in other patient
populations with different cancer types. To address these limitations, a second study
conducted among a sample of patients diagnosed with different cancers across the U.S.
compares Measure I with more detailed alternate measures (II and III).
Study 1B—Online Panel Cancer Patient Survey
Method
Study Population
The data for this study is from a self-administered web-based survey between
March and May 2012 among 363 adults who reported they had been diagnosed with
cancer; these participants were recruited from an existing national opt-in panel
maintained by Survey Sampling International (SSI) comprising persons who had a
history of cancer. The criteria for inclusion to the study were having any cancer diagnosis
within the past two years (from January 2010 onwards) and being aged 21 years or older.
The criterion to include only patients who were recently diagnosed was necessary as it is
assumed cancer-related DTCA would be more salient for these patients compared with
those who had been diagnosed and treated many years ago. Because prior experience of
online surveys indicated an under-representation of male participants, the study utilized
quota sampling to ensure approximately half of the study participants would be male. The
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University of Pennsylvania IRB approved this validation study as research that qualified
for exemption from IRB review.
Measures
Cancer-related DTCA Exposure (Measures I to III)
Measure I items are identical to those described in Study 1A. These items were
averaged into a scale of DTCA exposure (M = 2.77, SD = 1.22). All the participants in
this study were asked the Measure I items.
Measure II comprises three items that showed respondents descriptions of the
content of each category of DTCA (i.e., treatment alternatives, dealing with treatment
side-effects, and hospitals or doctors offering services) and two exemplars of DTCA
collated from television and print advertising sources. Participants were then asked to
recall how frequently they saw each type of ads (Appendices A and B). To illustrate,
respondents first read a description for ads about hospitals and doctors. Next, participants
viewed two examples representing this category of ads (e.g., one print ad and one video
ad showing hospitals and doctors providing cancer treatment services randomly chosen
from a pool of four print ads and four video ads respectively). They were then asked how
frequently they recalled encountering similar ads about hospitals and doctors offering
treatment services since their cancer diagnosis. The three items were averaged into an
alternate scale of DTCA exposure (M = 2.83, SD = 1.19). Approximately two-thirds of
the study population was randomly assigned to respond to Measure II items.

50

Measure III is identical to Measure II with the exception that the items do not
provide exemplars of ads (see Appendix A). The average of the three Measure III items
formed another alternative DTCA exposure scale (M = 2.83, SD = 1.14). One-third of the
study population was randomly assigned to answer Measure II items.
Nomological Criterion Variables
Items for health media exposure (M = 11.64, SD = 4.82), scanning for treatment
information (M = 0.93, SD = 1.07), and discussion with physicians (M = 0.77, SD = 1.03)
were included in the questionnaire. These measures are identical to those described in
Study 1A. In addition, respondents reported on their frequency of use of eight media
channels (i.e., newspaper, magazine, national and local news, television programs, radio,
email, and the internet) in the past 7 days (between 0 to 7 times). Responses to these
items were summed to create an index of general media use (M = 36.88, SD = 11.52).
Analyses
The validation analyses proceeded in a parallel manner to Study 1A. I first
assessed the performance of Measures I to III using the criteria laid out in the earlier
section on validation approach except for the test-retest reliability criterion because
repeat measures of DTCA exposure using these items were not collected in Study 1B.
In addition, I assessed the threat that respondents assigned to Measure II items
reported their exposure to specific exemplars that they viewed rather than their recall of a
general class of ads represented by the exemplars. To illustrate, if the mean recall for
having seen or heard ads about medications to deal with treatment side-effects varied
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significantly between participants who were shown an ad for Procrit (erythropoietin alfa)
compared to those who were shown an ad for Neulasta (pegfilgrastim), this could signal
respondents were not recalling their overall exposure to ads for dealing with treatment
side-effects. Instead, respondents may be recalling their exposure to the individual ads
that they viewed. To assess this possible threat, I performed one-way ANOVA tests to
compare the means of each of the Measure II items with the ad shown as the between
subjects factor.
Another concern was the potential threat of ordering effects in the way the
candidate measures were presented in the survey. I attempted to minimize this threat by
separating Measure I items from Measures II/III items with other survey questions (e.g.,
nomological criterion measures). I further assessed the potential of ordering effects by
randomly assigning half the participants to receive Measure I first while the remainder
received Measure II or III first. The above validation analyses were repeated to detect the
presence of any substantive differences in the findings due to the order of measures in the
questionnaire.
Results
Approximately 52% of the respondents were female and the mean age was 53
years. Other participant characteristics are summarized in Table 3.2. This study
population tended to be younger, have higher education levels, and was less ethnically
diverse compared to the Pennsylvanian sample of cancer patients in Study 1A.
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The distributions (mean and standard deviation) of individual items of Measures I
– III and the resulting DTCA exposure scales are summarized in Table 3.3. The means of
the corresponding exposure items do not differ appreciably between Measures I – III,
leading to a first conclusion that there is no substantial under-reporting of DTCA
exposure based on Measure I items compared with Measures II or III.
Convergent validity—In Study 1B, the items in all three candidate measures of
DTCA demonstrate moderate to strong inter-item correlations within the respective
measures (inter-item Pearson’s r = 0.427 to 0.693). Furthermore, the items in these three
measures are internally consistent (Cronbach’s alpha=0.743 to 0.814) (Table 3.6).
Principal component analysis extracted one single component with an eigenvalue greater
than one in all three measures (accounting for 73%, 71%, and 62% of the total variances
in Measures I, II, and III respectively). Additionally, topic-matching items from
Measures I and II tend to be more strongly correlated than with non-matching items; a
similar pattern is also observed for correlations between matching items from Measures I
and III (Table 3.7). The summed DTCA exposure scales derived from Measures I and II
are strongly correlated (Pearson’s r = 0.713; 95% CI = 0.641 to 0.773). The scales from
Measures I and III are also strongly correlated (Pearson’s r = 0.765; 95% CI = 0.689 to
0.825).
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Table 3.6 Inter-Item Pearson’s Correlations Within Alternative Measures of
Exposure to Cancer-Related DTCA (Study 1B)
Measure I
1
1. Treatment
alternatives

-

2. Dealing with sideeffects

2

3

1

0.693 0.589
-

-

2

Measure III
3

1

0.618 0.585
-

0.489

3. Hospital or doctors
offering services
Cronbach’s alpha

Measure II

-

0.578

2

3

0.556 0.487
-

0.427

-

-

-

0.813

0.814

0.743

Note. All Ps <.0005.
Table 3.7 Inter-Item Pearson’s Correlations Between Alternative Measures of
Exposure to Cancer-Related DTCA (Study 1B)
Measure I

Measure II
1

2

Measure III
3

1

2

3

1 Treatment alternatives

0.588 0.498 0.433

0.718 0.478 0.449

2 Dealing with side-effects

0.528 0.583 0.407

0.563 0.662 0.367

3 Hospital or doctors offering services

0.516 0.470 0.580

0.594 0.384 0.640

Note. All Ps <.0005. Matching items across measures (in bold) tend to be more strongly
correlated than non-matching items.
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Nomological validity—The analysis show that all three exposure scales using
Measure I-III items are significantly correlated with the nomological criterion variables
of general media use, health media exposure, treatment information scanning, and
discussion with physicians about cancer information from lay media sources (Pearson’s r
= 0.298 to 0.632) (Table 3.8).
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Table 3.8 Pearson’s Correlations Between Cancer-Related DTCA Exposure Measures and Nomological Criterion Measures
(Study 1B)
Measure I

Measure II

Measure III

Pearson’s r

95% CI

Pearson’s r

95% CI

Pearson’s r

95% CI

1. General media use

0.298

0.201 - 0.389

0.299

0.173 - 0.416

0.375

0.227 - 0.506

2. Health media exposure

0.632

0.566 - 0.690

0.564

0.465 - 0.649

0.627

0.517 - 0.716

3. Scanning for treatment
information

0.510

0.430 - 0.582

0.410

0.293 - 0.515

0.491

0.357 - 0.604

4. Discuss lay media information
with treating doctor

0.395

0.305 - 0.479

0.343

0.220 - 0.456

0.373

0.224 - 0.504

Note. All Ps <.0005.
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Discriminant validity—The correlations between Measures I and II DTCA
exposure scales and the correlations between Measures I and III exposure scales tend to
be stronger compared with the correlations between Measures I-III and the nomological
criterion variables. Comparing the confidence intervals of these correlations in Table 3.8,
I conclude that the DTCA exposure scales are distinct from general media use, treatment
information scanning, and discussion with physicians. However, the confidence intervals
of correlations within candidate DTCA exposure measures overlap with those of
correlations between these exposure measures and health media exposure.
Face validity—Compared with Measure I, Measure II and III comprise more
detailed items that prompt respondents to consider their exposure to DTCA across a
variety of media sources and descriptions about each category of ads. Measure II items
further provide exemplars of print and video ads. Accordingly, Measures II and III are
deemed to have higher face validity compared to Measure I.
Survey costs and respondent burden—As described above, Measure I items
consist of 52 words and three distinct responses. In contrast, Measure II items consist of
269 words while Measure III has 161 words, approximately three to five times as many
words as Measure I. Both Measure II and III are also judged to have higher levels of
cognitive burden on participants than Measure I because of the need to process and recall
multiple sources of DTCA exposure that would match the textual descriptions. In the case
of Measure II items, the cognitive burden would be the highest because participants
would need to generate memories of encountering ads similar to the ad exemplars of each
category of DTCA that they viewed.
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Based on the ANOVA tests, mean DTCA exposure as reported with Measure II
items do not differ significantly among ad exemplars of the three categories of DTCA
shown. The eta-squared values for these tests range from 0.002 to 0.015, which further
indicate the variance in DTCA exposure explained by the ad exemplars viewed is
minimal (Table 3.9). Finally, there is no evidence of systematic ordering effects;
comparing the above validation analyses between participants who answered Measure I
items first and those who received the Measure I items later, there are no substantive
differences. For example, the correlation between Measure 1 and II if Measure I appeared
first in the survey (r=0.70) is slightly weaker in comparison to that if Measure II appeared
first (r=0.81). Conversely, the correlation between Measures I and III when Measure I
appeared first (r=0.83) is slightly stronger than the correlation if Measure III appeared
first (r=0.75).
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Table 3.9 One-Way Between-Participants Analysis of Variance of Effect of Ads
Shown on Measure II Items in Study 1B
Category of ads and specific ads

M

Alternative treatment print ads
1. Altoona Regional Radiosurgery (A)
2. Altoona Regional Radiosurgery (B)
3. Las Vegas Cyberknife at Summerlin
4. St. Peter’s University Hospital Cyberknife
Alternative treatment video ads
1. Memorial Cancer Institute Cyberknife
2. Fox Chase Cancer Center Minimally Invasive
Surgery
3. Novalis TX at St Vincent’s Medical Center
4. Phoenix Cyberknife
Treatment side effects print ads
1. Zuplenz (A)
2. Aloxi
3. Zuplenz (B)
4. Zometa

2.50
2.70
2.69
2.69

1.414
1.488
1.342
1.514

2.65
2.64

1.507
1.471

2.53
2.72

1.424
1.374

2.46
2.78
2.63
2.56

Treatment side effects video ads
1. Neulasta
2. Procrit (A)
3. Procrit (B)
4. Procrit (C)

2.65
2.36
2.77
2.67

Doctor and hospital print ads
1. Sylvester Comprehensive Cancer Center (A)
2. Sylvester Comprehensive Cancer Center (B)
3. Sylvester Comprehensive Cancer Center (C)
4. Sylvester Comprehensive Cancer Center (D)

3.12
3.20
3.20
3.56

Doctor and hospital video ads
1. UNC Cancer Center
2. Carle Cancer Center
3. Hudson Valley Hospital Center
4. Terrebonne General Medical Center – Mary
Bird Perkins Cancer Center

3.16
3.33
3.29
3.28
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SD

F(3, 212)

P

0.249

0.862

Etasquared
0.004

0.148

0.931

0.002

0.463

0.708

0.007

0.873

0.456

0.012

1.066

0.364

0.015

0.150

0.930

0.002

1.410
1.388
1.369
1.350

1.388
1.266
1.417
1.438

1.508
1.265
1.379
1.270

1.347
1.476
1.390
1.294

To summarize Study 1B findings, this web-based survey among an opt-in sample
of patients across the U.S. diagnosed with a wide variety of cancers compares the
performance of three candidate measures of DTCA exposure. Measures I to III display
reasonable convergent validity and nomological validity. Discriminant validity is largely
supported; discrimination between scales derived from Measures I to III and three out of
four criterion variables are significant. Measures II and III are deemed to have higher
face validity compared to Measure I. However, Measure I is likely to incur the lowest
survey costs and respondent burden.
Discussion
This validation study assesses the performance of three alternative measures of
cancer-related DTCA exposure among cancer patients using a comprehensive set of
criteria across two distinct study populations. Study 1A involved repeated mailed
questionnaires among a probability sample of patients from Pennsylvania who were
diagnosed with breast, colorectal, or prostate cancers. In comparison, Study 1B involved
a cross-sectional web-based survey among patients who were diagnosed with a variety of
cancers across the U.S.
Due to the multiple validity criteria in this research, the findings of the
performance of candidate measures of cancer-related DTCA exposure based on Studies
1A and 1B are summarized for comparison in Table 3.10 (adapted from Nagler & Hornik
(2012) and Romantan et al. (2008)). Across the criteria of convergent, nomological, and
discriminant validity, Measures I-III performed equally well for the most part. All three
60

measures demonstrate adequate levels of convergent validity as evidenced by internal
consistency and unidimensionality measures. They are also associated with variables that
are likely to predict exposure to DTCA as well as behaviors that may arise from exposure
(i.e., discussion with physicians). Discrimination between these measures and other
associated measures (e.g., health media exposure and treatment information scanning) is
replicated in both Studies 1A and 1B. Measure 1 is further evaluated for test-retest
reliability. However, these three measures differ in terms of face validity, survey costs,
and respondent burden. Measure 1 had lower face validity compared with the detailed
versions of Measures II and III. However, the brevity of Measure I did not appear to
affect its performance in other validity criteria when compared to the more detailed
measures. Measures II and III are more costly and impose higher cognitive burden on
respondents. Strikingly, respondents were able to extrapolate their exposure to categories
of DTCA from viewing two exemplars of each ad category using Measure II items; their
responses did not suggest they were merely recalling exposure to specific exemplars that
they viewed. Weighing these findings across the criteria, Measure I would be appropriate
as the first option for eliciting DTCA exposure in either mailed or web-based survey
formats. If resources permit and face validity is a priority, Measure III may be an
alternative choice. The added advantage of face validity from Measure II (including print
and television ad exemplars) should be considered against the disadvantages of cost,
participant burden, and limitation to data collection methods requiring audiovisual
technologies.
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Table 3.10 Summary of Analyses Across Validity Criteria
Candidate
Exposure
Measures

Convergent
validity

Nomological
validity

Discriminant
validity

Test-retest
reliability

Face
validity

Survey
costs

Respondent
burden

Measure I

4

4

3

4

2

4

4

Measure II

4

4

3

n/a

4

1

1

Measure III

4

4

3

n/a

3

3

3

Note. 1 = worst performance; 4 = best performance
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The replication of validity testing for Measure I across these two studies and
exploration of alternative measures (II and III) in Study 1B provides increased confidence
in the performance Measure I to assess DTCA exposure among a diverse population of
cancer patients. The representative sample of cancer patients in Study 1A, although from
a single state, can be viewed as an improvement from studies that are limited to
convenience samples of cancer patients or those that involve patients from a single health
system. While the study population in Study 1B is not a representative sample of cancer
patients across the U.S., I argue that Study 1B complements the findings from Study 1A
through the inclusion of a more diverse population of cancer patients (i.e., broader
geographic locations and cancer diagnoses). Moreover, the web-based survey in Study
1B enables testing exposure measures that include audiovisual exemplars of DTCA; this
would be precluded by mailed questionnaires or phone interviews. This validation
approach involving a combination of study populations, survey designs, and modes of
data collection described here may serve as an illustrative example for future research
aimed at developing and validating self-reported measures of exposure to DTCA
associated with other illnesses.
This study is limited in terms of the narrow context of DTCA promoting cancerrelated treatments and health services. Despite an expanded operationalization of DTCA
exposure beyond prescription medications only for cancer treatment, it may be argued
that the validation findings here may not generalize to measures of exposure to DTCA for
other illnesses. Future investigations should consider adapting measures described in this
current study for measuring exposure to other disease-specific DTCA and to
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systematically validate these adapted measures. Although substantial modification may
be needed for Measure II because of the content-specific exemplars, Measures I and III
may be more easily adapted into survey items that measure exposure to DTCA of other
illnesses.
The study is also limited by the reliance on self-reported and closed-ended
measures of exposure to cancer-related DTCA. Recall biases are a threat to inferences
about whether self-reported DTCA exposure truly reflects participants’ past exposure or
more likely their memory of encoded exposure to such advertising in the media
(Southwell, Barmada, Hornik, & Maklan, 2002; Southwell & Langteau, 2011; Southwell,
2005). Consequently, population-level measures of exposures through media market
gross rating points of televised health campaign advertising or news reporting have been
increasingly implemented as predictors of behaviors instead of individual-level selfreported media exposure measures (Farrelly, Davis, Haviland, Messeri, & Healton, 2005;
Hwang & Southwell, 2009; Wakefield et al., 2008). Closed-ended survey questions that
specify a particular subject matter may also contain researchers’ biases and may miss the
content that is most meaningful for the study population compared to open-ended
questions that permit more in-depth assessment of exposures that are of most interest to
the target population (Clarke & Kline, 1974). Nevertheless, these alternatives to selfreported and closed-ended measures are not without their limitations. For instance,
media-market gross rating points represent environmental availability of media messages
and therefore reflect the opportunity to be exposed to media messages; individuals within
the media market may not necessarily be exposed at all (Slater, 2004). Responses to
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open-ended questions about exposure may reflect one’s knowledge about a health topic
rather than merely exposure (Salmon, 1986) and are often more costly and complex to
collect and analyze (Romantan et al., 2008) than closed-ended items.
Despite these limitations, this validation study offers novel insights into valid,
reliable, and field-tested measures of cancer-related DTCA exposure among cancer
patients that have the potential to be adapted for measuring exposure to DTCA of other
illnesses. The validation approach encompassing complementary study populations,
designs, modes of data collection, and comprehensive criteria may also serve as a model
for future research aimed at systematic comparisons of candidate measures of DTCA
exposure.
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Chapter 4 A STUDY OF THE FREQUENCY AND CORRELATES OF
EXPOSURE TO CANCER-RELATED DIRECT-TO-CONSUMER
ADVERTISING AMONG BREAST, PROSTATE, AND COLORECTAL CANCER
PATIENTS (STUDY 2)
Abstract
Cancer-related direct-to-consumer advertising (DTCA) is controversial because
cancer treatment is complex and entails more risks and costs than typical treatments that
are advertised for other conditions. Contributing to the growing research on DTCA, this
study describes the prevalence and correlates of cancer patients’ frequency of DTCA
exposure. A sample of 2013 patients diagnosed with breast, prostate, or colorectal
cancers and reported to the Pennsylvania Cancer Registry in 2005 responded to a mailed
questionnaire. Three survey items assessed patients’ frequency of encountering ads
concerning treatment alternatives for cancer, dealing with side effects of treatment, and
doctors or hospitals offering services for cancer following their diagnosis. These items
were summed to form the overall exposure DTCA measure. Descriptive and multivariate
analyses were performed. Overall exposure to DTCA in the sample was modest (median
was once per week). Breast cancer patients reported significantly higher overall
exposures to DTCA than prostate and colorectal cancer patients (all Ps<0.0005). Older
patients consistently reported lower overall exposure to DTCA across the three cancer
types. Other significant correlates included ethnicity (higher exposures among AfricanAmerican prostate cancer patients vs. white; lower exposures in Hispanic colorectal
cancer patients vs. white), and cancer stage (higher exposures in stage IV prostate cancer
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patients vs. stages 0-II). Disparities in exposure to DTCA are present based on age,
ethnicity and cancer stage and have important implications on clinical and regulatory
practice in cancer care.
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Introduction
Direct-to-consumer advertising (DTCA) of medical treatments remains highly
controversial and generates intense debate between proponents and critics of the value (or
detrimental effect) of such promotional efforts (Bonaccorso & Sturchio, 2002; Mintzes,
2002). Extending from this broader debate, DTCA for cancer-related products and
services has attracted an increasing level of scrutiny and attention from researchers and
practitioners involved in cancer care and survivorship. Special considerations about the
appropriateness of DTCA in oncology arise because of the highly specialized nature of
cancer diagnosis and treatment compared to other disease conditions, potential risks of
cancer-related medications or services, costs involved in cancer care, and possible
widening of communication disparities (Bloss, Darst, Topol, & Schork, 2011; Gollust,
Hull, & Wilfond, 2002; Kontos & Viswanath, 2011; Lippi, Favaloro, & Plebani, 2011;
Lovett, Liang, & Mackey, 2012; Lovett & Liang, 2011).
In a recent review, Gray and Abel classified the rapidly diversifying types of
consumer marketing in oncology into DTCA for cancer-related medications, cancer
facilities, imaging services, genetic tests, and cancer screening or surveillance tests (Gray
& Abel, 2012). This provides a useful overview of the spectrum of DTCA of products
and services for cancer screening, diagnosis, treatment, and follow-up surveillance. While
research is accumulating on specific forms of DTCA (e.g., prescription medications, high
technology imaging services, and genetic testing) (Abel et al., 2007; Finney Rutten,
Gollust, Naveed, & Moser, 2012; Illes et al., 2004), information about the extent of
DTCA promoting cancer facilities appears to be lacking in the literature. Furthermore,
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although several studies have described the content of DTCA for cancer-related products
and services (Abel et al., 2007; Illes et al., 2004; Lachance, Erby, Ford, Allen, &
Kaphingst, 2010; Larson et al., 2005; Lovett et al., 2012), less research has been
conducted on how frequently the public at large or cancer patients were exposed to such
DTCA (Abel et al., 2009; Finney Rutten et al., 2012).
This present study aims to contribute to the apparent gap in the literature by
describing cancer patients’ frequency of exposure to types of DTCA in oncology using
data from a population-based survey. In this article, cancer-related DTCA (DTCA) is
broadly defined as “promotional efforts by a pharmaceutical company, healthcare
provider, or medical facility to present information about treatments for patients
diagnosed with cancer in the lay media environment” (Wilkes et al., 2000). Recognizing
that different patients may have varying experiences, the study compares DTCA
exposures between patients diagnosed with breast, prostate, and colorectal cancer and
explores whether individual patient characteristics are correlated with advertising
exposures. The findings in this study would generate much needed evidence on the
frequency of exposures to DTCA among cancer patients, identify potential areas of
communication disparities, and inform clinical and regulatory practice.
Method
Study Population
This study relied on survey data from patients who were diagnosed with breast,
prostate, or colorectal cancers and whose names were sent to the Pennsylvanian Cancer
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Registry in 2005. Patients with these three cancer types were randomly selected to
participate in the survey in September 2006, approximately 9 to 21 months after their
initial diagnoses. After the initial data collection, an oversample among patients
diagnosed with colorectal cancer, those with Stage IV disease, and African American
patients was added to increase sample sizes for subgroup analyses. Overall, 679 breast
cancer patients, 650 prostate cancer patients, and 684 colorectal cancer patients
completed the survey. The American Association for Public Opinion Research response
rates (AAPOR RR#4) (The American Association for Public Opinion Research, 2006) for
breast, prostate, and colorectal cancer patients were 68%, 64%, and 61% respectively.
The survey questionnaire was designed following literature review, patient interviews,
and expert consultation. These questionnaires were mailed to participants based on
Dillman’s procedure for mail surveys (Dillman & Dillman, 2000). Further details of the
data collection and survey instrument development procedures are described fully
elsewhere (Nagler, Gray, et al., 2010). The university’s institutional review board
approved the study.
Measures
Exposure to DTCA was operationalized as patients’ self-reported frequency of
encountering three different types of ads since their cancer diagnosis: 1) treatment
alternatives for cancer, 2) drugs for dealing with side effects of treatment, and 3)
hospitals or doctors offering services for cancer. Responses for each survey item ranged
along a 5-level scale (never, less than every month, about twice a month, about once a
week, almost every day). To allow easier interpretation of these response options in the
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descriptive analyses, each response choice was recoded to represent the frequency of
encountering the aforementioned ads per week (i.e., 0, 0.2, 0.5, 1, and 7 respectively). An
overall exposure to DTCA was computed by adding participants’ responses to the three
survey items (ranging from 0 to 21). Of the 2013 participants, 369 were not asked these
questions on DTCA exposure because they randomly received a short version of the
questionnaire with fewer items as part of another study (Kelly, Fraze, & Hornik, 2010).
An additional 150 to 228 respondents for each of the three DTCA exposure items were
missing because of item non-response. Therefore, data on overall DTCA exposure was
available for 1505 or 75% of the initial sample.
Potential predictor variables of exposure to DTCA were participants’ age, sex,
ethnicity, education, marital status, and AJCC/UICC stage of cancer at diagnosis
(Greene, American Joint Committee on Cancer, & American Cancer Society, 2002)
(derived from cancer registry data). Of the 2013 participants, missing values for predictor
variables ranged from 3 to 132 cases due to item non-response or insufficient information
for cancer staging in the registry. All participants were included in the analyses described
below.
Analyses
Descriptive analyses were performed using SPSS version 20.0 (IBM Corp, 2011)
to describe the distributions of frequency of exposure to each category of ads and the
overall frequency of exposure to DTCA across the three cancer types. Initial analyses
showed that these variables were not normally distributed (skewness ranged from 2.05 to
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3.61; kurtosis ranged from 2.40 to 11.74; all univariate Shapiro-Wilk tests were
significant at p < 0.0005). Pairwise comparisons of exposure to each category of ads and
overall exposure to DTCA between cancer types were performed with the Kruskal-Wallis
tests corrected for Type I errors using the Bonferroni approach. Multivariate analyses
were performed using the Mplus software (Muthén & Muthén, 1998) to fit full
information maximum likelihood (FIML) models predicting the overall exposure to
DTCA within each cancer type. Research has demonstrated that the FIML technique is
superior to ad hoc methods for dealing with missing data in predictor variables (e.g.,
listwise deletion, pairwise deletion, mean imputation) and has the benefits of reducing
bias and sampling variability in multiple regression models (Enders & Bandalos, 2001;
Enders, 2001). Huber-White covariance adjustments were applied to the estimated
standard errors as these are robust to non-normality in the data. The models applied poststratification sample weights to adjust the final sample to represent the patient population
from the cancer registry in terms of race, age, gender, marital status, time of diagnosis,
and stage at diagnosis; adjust for survey non-response; and account for the oversampling
of certain subgroups of patients.
Results
Table 4.1 summarizes the characteristics of the overall sample and patients within
each cancer type. Overall, the average age of the sample was 66 years, half was female,
44% had some college education or higher, 83% were white, 67% were married, and 71%
had early stage cancer (stages 0 to II). Approximately equal numbers of patients from
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each of cancer type were represented in the sample. Additional details by cancer type are
available in Table 4.1.
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Table 4.1 Demographic Characteristics Of Study Participants By Cancer Type
All patients

Breast

Prostate

Colorectal

(n=2013)

(n=679)

(n=650)

(n=684)

% or M (SD) % or M (SD) % or M (SD) % or M (SD)
Age at diagnosis (years)a

66.1 (12.4)

60.8 (13.4)

66.9 (9.6)

66.6 (12.6)

Femalea

50.9

100.0

0.0

50.6

56.5

53.9

53.0

62.6

Some college and higher 43.5

46.1

47.0

37.4

Education levelb
High school and lower

Race
White

83.1

83.1

80.5

85.5

African-American

12.8

12.8

15.2

10.4

Hispanic and other

4.2

4.1

4.3

4.1

Not married

32.9

42.0

21.3

35.0

Married

67.1

58.0

78.7

65.0

Stage 0-II

71.0

77.9

77.2

58.0

Stage III

12.9

6.6

6.0

25.9

Stage IV

16.1

15.4

16.8

16.1

Marital statusb

Stage of diseasec

Note. a3 missing values.
b
34 missing values.
c
132 missing values.
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Figure 4.1 displays the distribution of overall exposure to DTCA in the study
sample. The summary statistics of exposure to each category of ads and overall exposure
to DTCA for the study sample and within each cancer type are presented in Table 4.2.
The overall reported exposure to DTCA in the sample was modest (M=2.6 times per
week, SD=4.3, median=once per week). However, a small proportion of the sample
(16.1%) reported having more substantial exposure to DTCA ads of seven times a week
or more. Based on the Kruskal-Wallis test (corrected for Type I errors using the
Bonferroni approach), the distribution of overall exposure to DTCA among breast cancer
patients was significantly different from those of prostate and colorectal cancer patients
(all ps<.0005). Several pairwise comparisons of the distributions of exposure to each
category of DTCA also showed significant differences across cancer types (all ps<.0005).
For ads about treatment alternatives, exposure among breast and prostate cancer patients
differed from colorectal cancer patients. The exposure to ads about dealing with side
effects was significantly different in all pairwise comparisons between these three cancer
types. In addition, the distribution of exposure to ads on hospitals or doctors for breast
cancer patients differed significantly when compared with those of prostate and
colorectal cancer patients.
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Figure 4.1 Distribution Of Overall Weekly Exposure To Cancer-Related Direct-ToConsumer Advertising (n=1505)
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Table 4.2 Distribution Of Weekly Exposure To Cancer-Related Direct-To-Consumer Advertising By Cancer Type
All patients
(n=1505)
M (SD)
Median

Breast
(n=511)
M (SD) Median

Prostate
(n=470)
M (SD) Median

Colorectal
(n=524)
M (SD)
Median

Treatment alternatives (0 to 7)

0.7 (1.6)

0.2

0.9 (2.0)

0.2

0.5 (1.2)

0.2

0.5 (1.4)

0.2

Dealing with side effects (0 to 7)

0.7 (1.7)

0.2

1.1 (2.1)

0.2

0.4 (1.2)

0.0

0.7 (1.6)

0.2

Hospitals or doctors (0 to 7)

1.3 (2.3)

0.5

1.9 (2.7)

0.5

0.8 (1.7)

0.2

1.2 (2.2)

0.5

Summed exposure (0 to 21)

2.6 (4.3)

1.0

3.7 (5.3)

1.4

1.7 (2.9)

0.7

2.2 (4.1)

0.7
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Table 4.3 presents the multivariate models predicting overall DTCA exposure for
patients diagnosed with breast, prostate, or colorectal cancers. Older patients consistently
reported less frequent overall exposure to DTCA across the three cancer types (decreased
frequency of exposure between 0.03 to 0.06 times per week for each additional year in
age). Among prostate cancer patients, African-American patients reported encountering
DTCA 1.1 times per week more than white patients. Prostate cancer patients with
advanced disease (stage IV) reported encountering DTCA 0.9 times per week more than
patients with stages 0 to II. Conversely, colorectal cancer patients who identified as
Hispanic or other groups reported being exposed to 1 ad/week less than white patients.
Across the three cancer types, the explanatory power of these multivariate models was
small (R2 ranged from 3% to 6%).
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Table 4.3 Predictors Of Summed Weekly Exposure To DTCA By Cancer Type

Predictor variables
Age at diagnosis
(years)
Gendera – Female
Educationb – Some
college and higher
Race-ethnicityc
African-American
Hispanic and other
Marital statusd –
Married
Stage of diseasee
Stage III
Stage IV
Intercept
R-squared

Breast cancer (n=679)
B
95% CI
-0.063**

-0.101 -

Prostate cancer (n=650)
B
95% CI

-0.024

-0.044***

-

-0.067 -

Colorectal cancer (n=684)
B
95% CI

-0.020

-

-0.031*

-0.058

-

-0.004

0.715

-0.096

-

1.526

-0.358

-1.419 -

0.702

0.196

-0.258 -

0.649

-0.324

-1.178

-

0.529

0.812
0.521

-0.774 -2.244 -

2.398
3.285

1.121**
-0.388

0.281 -1.217 -

1.960
0.442

1.131
-1.073*

-0.222
-1.905

-

2.483
-0.241

-0.288

-1.491 -

0.916

0.014

-0.596 -

0.625

-0.155

-1.043

-

0.734

0.002
0.673
7.629

-2.469 -0.620 -

2.473
1.965

-0.121
0.900**
4.101

-0.836 0.261 -

0.594
1.539

0.445
0.786
3.121

-0.501
-0.638

-

1.391
2.209

0.031

0.060

0.034

Notes. B denotes weighted full information maximum likelihood estimates of unstandardized coefficients.
*p<.05; **p<.01; ***p<.001.
a
Male is the reference category.
b
High school and lower is the reference category.
c
White is the reference category
d
Not married is the reference category
e
Stage 0 to II is the reference category (because there were no prostate cancer patients with stages 0 or I)
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Discussion
In this study population, patients diagnosed with breast, prostate, or colorectal
cancers reported modest levels of exposure since their diagnosis to DTCA that concern
cancer treatment alternatives, dealing with side effects of treatments, and hospitals or
doctors offering cancer treatment services. Median frequency ranged from 0 to 0.5 times
per week for each type of ad. The overall exposure to DTCA was correspondingly low
(median frequency ranged from 0.7 to 1.4 times per week out of a maximum of 21). This
level of reported exposure to DTCA is consistent with an earlier study reporting cancer
patients being treated for breast or hematologic malignancies were aware of a small
number of advertised cancer medications (median of 3 out of a list of 24 medications
advertised in print magazines) (Abel et al., 2009). The low levels of overall exposure
observed in this present study further corroborates findings that ad spending for DTCA is
generally much lower than DTCA for other conditions (Bell, Kravitz, & Wilkes, 2000;
Donohue et al., 2007; Larson et al., 2005; M. B. Rosenthal et al., 2002; Welch Cline &
Young, 2004; Wilkes et al., 2000; Woloshin et al., 2001). Although concerns that DTCA
may have substantial impact on patient outcomes appear less worrisome given the modest
exposures reported in this patient population as a whole, increasing trends of various
forms of DTCA in oncology through diverse channels warrant continued monitoring of
patient’ exposures. Furthermore, this study found that about 16% of the study population
reported encountering DTCA seven times per week, which can be considered a
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substantial amount of exposure for deliberate public health communication. The impact
of DTCA on this group of patients deserves careful study.
The analysis shows that patients diagnosed with breast cancer tend to report more
frequent DTCA exposure than prostate or colorectal cancer patients. Earlier content
analyses found that general DTCA and cancer-related DTCA are more likely to target
female audiences or occur in female-oriented print magazines (Abel et al., 2007; Bell,
Kravitz, et al., 2000). Therefore, one interpretation of this finding could be female cancer
patients are reporting higher DTCA exposures than male cancer patients. However, the
multivariate analysis among colorectal cancer patients indicated that gender is not a
significant correlate of DTCA exposure, meaning the differences observed in this study is
more likely a function of differences between cancer type than of gender-based targeting.
Potential reasons could be higher ad spending on breast cancer-specific treatments (e.g.,
anastrazole for breast cancer in women) leading to variations in cancer patients
encountering ads that are most salient for their diagnosis. Future research should consider
comparing the extent of cancer-specific DTCA and assessing the potential disparities
between patients with various cancer types in terms of patient awareness of approved
treatments, patient-provider discussions, and treatment decision-making.
The multivariate analysis of correlates of exposure to DTCA across cancer types
suggest that there is little evidence of communication disparities arising from DTCA
exposure across several patient characteristics. With the exception of age, the variation in
exposure to DTCA was not explained consistently by patient characteristics among
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patients with the three cancer types. For instance, while older patients consistently report
lower exposures across all cancer types, patient ethnicity is correlated to DTCA exposure
only among prostate and colorectal cancer patients. The implications for these observed
disparities in exposures on patient outcomes are uncertain at this point. Varying
recommendations for treatment, availability of safe and effective treatment options, and
risk versus benefit considerations for an advertised treatment or service for the different
cancer types and stages of disease complicate drawing implications from these
disparities. For instance, if an advertised treatment is appropriate based on treatment
guidelines, patients who report less exposure to such DTCA might be less aware and less
likely to receive this treatment. Conversely, if an advertised service entails greater risks
and costs but is no more effective than standard care, patients who have higher ad
exposure and pursue this treatment may be harmed.
A recent study by Abel and colleagues in the context of breast cancer treatment
offers an example for assessing the implications of disparities in exposures (Abel et al.,
2013). The authors reported that overall spending on DTCA for aromatase inhibitors
(anastrozole, exemestane, and letrozole) is associated with a small but significant
increase in appropriate prescriptions for women diagnosed with breast cancer (i.e.,
women aged above 60 years) at the population level. Conversely, ad spending is not
associated with an increase in inappropriate prescriptions (those for women aged below
40 years) (Abel et al., 2013). If older breast cancer patients are less exposed to DTCA
about aromatase inhibitors as might be implied in this present study, the age disparity in
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exposure could have a meaningful impact on older patients’ receipt of such medications.
Similar considerations depending on the specific treatment and cancer type and patient
subgroup may yield different implications.
There are some limitations in this study. First, the sample is limited to cancer
patients within the state of Pennsylvania. It is plausible that interstate variations in DTCA
by cancer facilities may occur due to varying levels of competition between local or
regional cancer centers. Future research involving a national sample of cancer patients
may be necessary to detect if geographical variation in DTCA exposure is present.
Second, there are limitations associated with the survey measures of DTCA exposure.
Patients had to summarize their encounters of categories of ads and were not asked to
recall specific advertised treatments. In contrast, Abel and colleagues measured
awareness to specific cancer prescription drugs advertising by listing 24 specific
medications that have appeared in print magazines (Abel et al., 2009). Furthermore, the
questions asked for recall of exposure to DTCA “since diagnosis” and that ranged
between 9 to 21 months prior to their responding. The measures may also be subject to
recall bias leading to under-reporting (e.g., if patients fail to recall exposure from over a
year ago) or over-reporting (e.g., if patients telescoped their exposure to include noncancer DTCA or across a longer period of time). Despite these limitations, the validation
study in this research (Study 1) offers evidence that the survey items for measuring
exposure used here in Study 2 compares favorably with more detailed versions across
multiple validity criteria. Still, additional research would be necessary to validate self83

reported exposure to DTCA with objective data including ad buys of DTCA on various
media channels (television, newspapers or magazines, radio, and internet). Such data on
DTCA spending at the aggregate level has been used extensively in prior research on
DTCA for cancer and other illnesses (Abel et al., 2013; Bradford et al., 2006; Donohue &
Berndt, 2004; Law, Majumdar, & Soumerai, 2008). Third, there may be potential
confounders that are not included in these analyses due to constraints of survey length.
Future research should incorporate a wider array of predictor variables.
This study is strengthened by a few design characteristics. First, although limited
to Pennsylvania, the population-based sample of cancer patients across three cancer types
compares favorably to earlier studies conducted with population-based samples who are
predominantly healthy and for whom DTCA was not personally salient (Aikin et al.,
2004; Bell, Kravitz, et al., 1999; DeLorme, Huh, & Reid, 2006; Deshpande et al., 2004;
Finney Rutten et al., 2012; Murray et al., 2004; Sumpradit et al., 2002; Weissman et al.,
2003; Wilkes et al., 2000). In addition, this study also represents a more diverse sample
of cancer patients when compared to studies that also focused on cancer patients but were
limited by convenience samples of patients treated within a single hospital (Abel et al.,
2009). Third, the study examines additional categories of DTCA including treatment
alternatives and hospitals or doctors offering treatment services. This enables a more
comprehensive assessment of cancer patients’ exposures to these additional forms of
cancer treatment advertising that are increasingly prevalent (American Medical
Association, 2006; Jin et al., 2011; Larson et al., 2005; E. T. Rosenthal, 2010a). In
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contrast, earlier research focused predominantly on DTCA of prescription medications,
imaging services, or genetic testing (Abel et al., 2007; Finney Rutten et al., 2012; Illes et
al., 2004).
In conclusion, this study finds that frequency of overall exposure to cancer-related
DTCA among a population-based sample of cancer patients in Pennsylvania is modest.
However, continued monitoring of the content, ad spending, and patient awareness to
various types of DTCA is recommended as some patients reported substantial frequency
of exposure. There is minimal evidence of major communication disparities in terms of
DTCA exposure across several patient characteristics. While patients’ exposure to DTCA
differs across cancer types and age, other patient characteristics are not consistently
associated with DTCA exposure.
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Chapter 5 HOW IS EXPOSURE TO DIRECT-TO-CONSUMER ADVERTISING
ASSOCIATED WITH ACTIVE HEALTH INFORMATION SEEKING
BEHAVIORS? RESULTS FROM A LONGITUDINAL ANALYSIS AMONG
CANCER PATIENTS (STUDY 3)
Abstract
Previous research on the communication impact of exposure to direct-toconsumer advertising (DTCA) of prescription treatments largely focused on patients’
inquiry about specific treatments or requests for these prescriptions as outcome
behaviors. In contrast, the spillover effect of DTCA exposure on general health
information seeking behaviors is less well-studied. The first part of this study examines
the effects of exposure to cancer-related DTCA on subsequent health information seeking
behaviors from clinician and non-clinician sources among a population-based panel of
cancer patients. The analyses indicate that exposure to DTCA is significantly associated
with increased levels of patients’ subsequent active health information seeking from their
clinicians at one year follow-up, controlling for prior seeking behavior and potential
confounders. In addition, exposure to DTCA is marginally significant in predicting active
health information seeking from non-clinician (lay media and interpersonal) sources.
Guided by the Integrative Model of Behavioral Prediction, the second part of this study
conducts a focused analysis on psychosocial mechanisms through which DTCA may
influence information seeking from non-clinician sources among cancer patients. This
analysis shows a significant indirect path between DTCA exposure and subsequent
information seeking from non-clinician sources at one year follow-up, mediated through
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attitudes and intention toward active information seeking from these sources. Research,
practice, and policy implications of this investigation are discussed.

87

Introduction
The ongoing debate over the benefits and harms of direct-to-consumer advertising
(DTCA) of medical treatments has spawned a significant amount of research over the
past three decades aimed at dissecting the impact of this unique form of public health
communication on patients, healthcare providers, and the broader healthcare ecosystem
(for comprehensive reviews of this debate, see Almasi, Stafford, Kravitz, & Mansfield,
2006; Auton, 2004, 2006; Gilbody, Wilson, & Watt, 2005; Harker & Harker, 2007;
White, Draves, Soong, & Moore, 2004). From a health communication perspective, this
accumulating body of research has accomplished much in terms of piecing together
important insights on the content and effects of DTCA on a variety of psychosocial
outcomes, communication behaviors, and relationships between patients and their
physicians (Aikin et al., 2004; Bell, Kravitz, et al., 1999; Deshpande et al., 2004; Murray
et al., 2004). The overall evidence appears to support viewing DTCA as a potentially
beneficial communication strategy—if harnessed appropriately to minimize potential
harms—that could shift the process of healthcare delivery away from a paternalistic
physician-centered model to a more patient-centered model that emphasizes shared
decision-making (Almasi et al., 2006; Deshpande et al., 2004; Harker & Harker, 2007).
This is echoed in a recent essay by Beltramini (2010, p. 574) summarizing the impact of
DTCA research on the field of health communication: “consumers have been empowered
with additional information to “level the field” with the health care community,
contributing to more efficient doctor-patient exchanges”.
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How DTCA might empower consumers and “level the field” in terms of health
and medical information is the subject of this present inquiry. Despite the large body of
DTCA research—a systematic review in 2005 identified 2835 publications on DTCA
(Gilbody et al., 2005)—significant gaps remain in two main areas. These include the
understanding of implications of DTCA on important communication behaviors among
patients and studying theoretically grounded mechanisms for possible effects of DTCA
on communication behaviors.
The majority of DTCA communication research focuses on whether DTCA
influences patients to inquire specifically about an advertised drug or to request a
prescription for the medication from their providers (Aikin et al., 2004; An, 2007; Bell,
Wilkes, Kravitz, & others, 1999; Deshpande et al., 2004; Herzenstein et al., 2004;
Khanfar, Polen, & Clauson, 2009; A. L. Lee, 2009; Liu et al., 2005; Mendonca,
McCaffrey, Banahan, Bentley, & Yang, 2011; Murray et al., 2004). This line of research
has important implications for clinical practice because it informs various stakeholders
including regulators and health professionals concerned with adverse changes in patientphysician relationships or undue pressure leading to inappropriate prescribing; patients
who are exposed to DTCA and receiving prescription treatments they may not need; and
advertisers who wish to know if the advertising campaign was effective in generating
drug sales.
Largely unstudied is the potentially beneficial spillover effects of DTCA in
prompting health information seeking about an advertised treatment and about other
important information relevant to managing the illness. In economic theory terms, these
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spillover effects are termed as positive externalities. Some examples of additional seeking
include seeking information related to illness prevention, screening and diagnosis for new
health symptoms, or non-drug ways to improve health (Calfee, 2002, p.185-186).
Notably, this concept of broad-based information seeking across health topics is widely
recognized in the field of health communication to be an essential determinant that
influences numerous health behaviors and outcomes (e.g., preventive health behaviors,
health screening, illness coping, and psychosocial outcomes). The impact of health
information seeking has been observed across individual and population levels in various
disease contexts including cancer care (Brashers, Goldsmith, & Hsieh, 2002; Cegala et
al., 2008; Cline & Haynes, 2001; Czaja, Manfredi, & Price, 2003; Dutta-Bergman, 2004;
Finney Rutten, Squiers, & Hesse, 2006; Johnson & Case, 2012; Kelly, Hornik, et al.,
2010; Lambert & Loiselle, 2007; J. Niederdeppe et al., 2007; Shim, Kelly, & Hornik,
2006; Tian & Robinson, 2008).
The first part of this present study is an attempt to address these research gaps in
DTCA communication research by examining the associations between DTCA exposure
and patients’ general health information seeking behaviors in a population-based panel of
cancer patients (Study 3A). In particular, this analysis centers on two active information
seeking behaviors—patient-clinician information engagement and active information
seeking from non-clinician sources. The second part of this study (Study 3B) is guided by
the Integrative Model of Behavioral Prediction (IM) (Fishbein & Ajzen, 2010; Fishbein
& Yzer, 2003; Fishbein, 2000, 2008) and elaborates the findings in Study 3A by
exploring potential psychosocial mechanisms for the associations between DTCA
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exposure and information seeking behaviors from non-clinician sources. The following
sections describe the extant literature, research hypotheses, and analyses of these two
studies separately. These are followed by a discussion of the overall findings and
implications for future research and practice surrounding DTCA and patient
communication behaviors.
Study 3A Main Effects of DTCA Exposure on Information Seeking Behaviors
DTCA and Health Information Seeking Behaviors
It is unsurprising to expect DTCA to stimulate information seeking specific to the
advertised treatment; after all, that is one of the primary objectives of product advertising.
But it is less obvious to expect that DTCA would also influence patients to seek more
generally about coping with one’s health condition or to search for related information
such as prevention and alternative treatment options.
Nonetheless, the idea that DTCA might motivate general health information
seeking appears at least plausible for a few reasons. First, ads for prescription treatments
are required by the Food and Drug Administration (FDA) guidelines on broadcast DTCA
to include “adequate provisions” to refer consumers to doctors and pharmacists for more
information as well as detailed product information through a website, toll-free number,
and print ads (FDA, 1999, p.326-328). For the most part, to comply with these FDA
provisions, DTCA frequently encourages viewers to ask their doctor if an advertised
treatment is appropriate for their condition (e.g., “Ask your doctor if XGEVA is right for
you to prevent these serious bone problems caused by bone metastases”). More relevant
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for this research, DTCA may also include more general messages for viewers to ask their
doctor about health symptoms and conditions apart from promoting seeking about the
medication (e.g., “Quitting isn’t easy; and when willpower isn’t enough, it’s time to talk
to your doctor” in an ad for Chantix, a prescription medication for smoking cessation).
Another reason for assuming DTCA’s potential effects on general health
information seeking is derived from prior studies that conducted content analyses on a
variety of DTCA of prescription drugs. These studies systematically quantified the
ubiquitous presence of cues or messages directing patients to look for drug-related
information and also general health information about the condition from different
sources. For instance, Kaphingst and colleagues (2004) analyzed the content of 23
broadcast ads for prescription drugs which were indicated for a variety of illnesses and
appeared on national television networks. All 23 ads included statements encouraging
viewers to seek for more information from other sources. As expected, the majority of
ads directed viewers to look for more information about the advertised drug (20 ads). All
the ads contained references to available additional information about the advertised
product through print ads (e.g., in consumer magazines), product website addresses, or
toll-free telephone numbers. In addition to promoting information seeking about the
advertised drugs, over half of the ads (13 ads) were coded as containing broader
statements that asked viewers to seek “more information” in general about the health
condition without specifying what topics the viewers should seek about. The most
common sources of information referred to in these ads were doctors and pharmacists.
Another study by Bell and colleagues (Bell, Kravitz, et al., 2000) analyzed 320 unique
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magazine print ads of 101 brands of prescription medications that were indicated for
different illnesses. The researchers coded these ads for the presence of offers for where to
get additional information about the drug or health condition available in print or
audiotape/video form and reported that 35% of these ads (112 ads) contained these offers
for more information. In another study, Abel and colleagues (2007) analyzed 49 unique
magazine print ads for 22 cancer-related medications. In contrast to Bell et al. (Bell,
Kravitz, et al., 2000), they found that 84% of these cancer-related ads (41 ads) mentioned
where to get more information about the advertised drug and about the condition more
generally, most frequently through a web site. These latter two studies were limited by
the coding for the inducements for additional information as it was not possible to
distinguish between ads offering additional sites for more information about the
medication only from those that also offered information about the health condition more
generally. Admittedly, evidence from DTCA content analyses cannot establish whether
patients would perceive these vague inducements to be encouraging them to seek more
broadly about their illness.
In the course of searching for specific information about an advertised drug,
patients may also be inclined to search for overlapping health information relevant for
their health condition. Evidence from national consumer surveys partially supports the
notion that DTCA would prompt patients to seek more general information about their
health condition and treatment from their healthcare provider or other information
channels. National surveys conducted by the U.S. Food and Drug Administration (FDA)
indicated most consumers agreed that DTCA increased their awareness of new drugs
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(77%) (Aikin et al., 2004, p.3). A sizable proportion of consumers (43%) reported DTCA
prompted them to look for more information about the advertised drug and also about
their health condition from their healthcare provider, reference books, interpersonal
contacts, and the internet (Aikin et al., 2004, p.2). Correspondingly, Weissman and
colleagues (2003) surveyed a national U.S. sample of 3000 adults and found that one in
three (35%) respondents reported a prescription drug ad had previously prompted them to
have a discussion about the advertised drug, a new health concern, or a possible change
in treatment for an existing illness with their physician. The above survey items were
limited by the inability to distinguish between being prompted to seek information about
the advertised drug alone, seeking about one’s health condition alone, or seeking about
both topics. Therefore it is unclear what proportion of respondents agreed that DTCAs
prompted broader searches about the condition in general.
Other studies among convenience patient samples added tentative support to the
expectation of spillover informational effects of DTCA. In one study, Abel and
colleagues (2009) surveyed patients undergoing active treatment for breast and
hematologic cancers at a cancer institute. Over half of the patients (62%) agreed that
cancer-related DTCA increased their awareness about treatments they did not know about
previously and 57% agreed DTCA “led to better discussions about health or medical
care” with their doctor or nurse. Bell and colleagues (2010) further found that among a
convenience sample of participants of an online depression support group, over half
(53%) reported they visited official websites of advertised antidepressants, 40% had
talked to their doctor about a specific brand or about antidepressants in general, and 18%
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talked to a friend or family member about possibly having depression. While the first two
communication behaviors are more directed at seeking about the advertised medications,
the last behavior is more clearly about discussion with others about health concerns apart
from the advertised treatment.
Additional evidence comes from a study by Iizuka and Jin (2005) that reported
aggregate levels of DTCA media expenditure were associated with administrative data of
physician visits in a nationally representative sample of patients. The study estimated that
every $28 increase in DTCA spending led to one additional physician visit within 12
months. However, the study was not designed to provide details about the content of
patient-physician discussions during these additional visits, only that they had occurred in
association with higher DTCA spending.
In sum, prior literature based on content analysis, patient surveys, and
administrative data analysis offer limited support for the potential effect of DTCA on
health information seeking behavior that could comprise specific information seeking
about an advertised treatment and also about the health condition in general. Drawing
from the above literature review, this study posits the following research question:
RQ1: How is exposure to DTCA associated with patients’ active health
information seeking?
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Methods
Study Population
Data was obtained from part of a longitudinal population-based study on cancerrelated information engagement behaviors and health outcomes among cancer patients in
Pennsylvania. The overall study population comprised patients who were diagnosed with
breast, prostate, or colorectal cancers and were notified to the Pennsylvania Cancer
Registry in 2005. The Pennsylvania State Health Department granted permission to
access patient data for this research. Patients with one of these three cancer types were
randomly invited to participate in the round 1 survey in September 2006, approximately 9
to 21 months after their diagnoses. Following the initial phase of data collection, an
oversample of colorectal cancer patients, those with Stage IV disease, and African
American patients was added to facilitate planned subgroup analyses (not presented
here). A total of 2013 participants (679 breast cancer patients, 650 prostate cancer
patients, and 684 colorectal cancer patients) completed the round 1 survey. The American
Association for Public Opinion Research response rates (AAPOR RR#4) (AAPOR, 2006)
for breast, prostate, and colorectal cancer patients were 68%, 64%, and 61%
respectively. In the fall of 2007, one year after they were first surveyed, 1293 respondents
(64.2% of participants from round 1) completed a follow-up survey (round 2). Nonresponse to the round 2 survey was due to refusal to be re-contacted after round 1 (255
patients; 12.7%) and non-response to a repeat mailed survey at round 2 (465 patients;
23%).

96

Survey questionnaires were designed following literature review, patient
interviews, and expert consultation. Questionnaires were mailed to participants based on
a standardized procedure for mail surveys (Dillman & Dillman, 2000). Briefly, a notice
letter with the study objectives and opt-out instructions were first mailed to potential
participants, followed by the survey, a small monetary incentive (either $3 or $5 in round
1 and $3 in round 2), and a stamped envelope to return survey questionnaires. For
participants who did not indicate their wish to opt out of the study and had not returned
the survey 2 weeks later, an additional letter and survey was mailed to them. Further
details of the data collection and survey instrument development procedures are
described fully elsewhere (Kelly, Fraze, et al., 2010; Martinez et al., 2009; Nagler, Gray,
et al., 2010; Smith-McLallen, Fishbein, & Hornik, 2011; Tan, Bourgoin, Gray,
Armstrong, & Hornik, 2011). The university’s institutional review board approved the
study.
Measures
Prior research suggests that seeking information from physician or health
professional sources is a distinct and complementary communication behavior compared
to seeking information from sources other than one’s health care provider (DuttaBergman, 2004; Finney Rutten et al., 2006; C. J. Lee, 2008, 2009; Ling, Klein, & Dang,
2006; Nagler, Romantan, et al., 2010; Tian & Robinson, 2008). Therefore, to evaluate the
first research question that DTCA would predict increased health information seeking,
two separate outcome measures were included—patient-clinician information
engagement and information-seeking from non-clinician sources, both measured at round
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2. The independent variable was exposure to DTCA since cancer diagnosis measured at
round 1. Survey items for these variables are provided in Appendix C. Potential
confounders in this analysis were prior PCIE and information-seeking from non-clinician
sources, demographic variables, and disease characteristics, all measured at round 1.
Patient-clinician information engagement (PCIE) is conceptualized as a measure
of cancer survivors’ reported engagement with their physicians and other health
professionals broadly about information related to their cancer that comprises treatments,
quality of life issues, and other topics. The PCIE measure is adapted from a similar
measure described in prior studies (Martinez et al., 2009; Tan, Moldovan-Johnson,
Parvanta, et al., 2012; Tan et al., 2011). The PCIE variable comprised 6 binary items
(yes/no) measured in the round 2 survey. Participants were asked to recall if they 1)
actively looked for information about their cancer (about treatments but also about other
topics) from their doctors, 2) actively looked for information about their cancer from
other doctors or health professionals, 3) actively looked for information about quality of
life issues from their doctors, 4) actively looked for information about quality of life
issues from other doctors or health professionals, 5) discussed information from other
sources with their doctors, and 6) received suggestions from their doctors to go to other
sources for more information. The average of these 6 items formed the PCIE scale at
round 2 (Cronbach’s α=0.73). Parallel survey items measured in round 1 of the survey
were averaged into PCIE scale at round 1 (Cronbach’s α=0.69). It should be noted that
while these survey items do not elicit patients’ information seeking about an advertised
cancer treatment, some of the items may conceivably capture patients’ underlying
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engagement with their clinicians about a specific ad that they have encountered (e.g.,
items 1 and 2 ask about looking for information about treatments while item 5 ask about
discussing other sources with doctors).
Information seeking from non-clinician sources is conceptualized as a measure of
cancer survivors’ seeking from sources other than their clinicians about information
related to their cancer including treatments, quality of life issues, and other topics. This
measure comprised 20 items in the round 2 survey and was adapted from a similar
measure described in previous research (Lewis et al., 2011; Tan, Moldovan-Johnson,
Gray, Hornik, & Armstrong, 2012). Participants were asked to recall if they actively
looked for two topics (information about their cancer or information about quality of life
issues) from 10 different sources (family members, friends or co-workers; other cancer
patients; face-to-face support groups; online support groups; telephone hotlines;
television or radio; books, brochures or pamphlets; newspapers or magazines; internet
other than personal email or online support groups; or other). The average of these 20
items formed the information seeking from non-clinician sources scale at round 2
(Cronbach’s α=0.82). In the same way, matching survey items in round 1 were averaged
to form the information seeking from non-clinician sources scale at round 1 (Cronbach’s
α=0.81). As in the PCIE measure, information seeking from non-clinician sources may
also capture patients’ active seeking about an advertised treatment from these sources.
This multi-item scale differs substantively from the variable analyzed in the study by
Smith-McLallen and colleagues (2011). That study utilized a binary measure categorizing
patients as seekers (sought from at least one source other than doctors or health
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professionals about issues related to their cancer) or nonseekers (did not seek from any
source or only from a doctor or health professional) and did not include information
seeking about quality of life issues.
Exposure to DTCA is operationalized as frequency of encountering DTCA since
cancer diagnosis. Participants were asked at round 1: “Since your cancer diagnosis, how
often have you seen or heard advertisements concerning each of the following? Check all
that apply.” Responses to three items (treatment alternatives for cancer, dealing with side
effects of treatment, and hospitals or doctors offering services for cancer) along a 5-level
scale (never, less than every month, about twice a month, about once a week, almost
every day) were averaged to form the exposure to DTCA scale at round 1 (Cronbach’s
α=0.72).
Potential confounders of the observed associations between DTCA recall and
PCIE or information seeking from non-clinician sources at round 2 included prior PCIE
and seeking from non-clinician sources at round 1, demographic variables (age, sex,
race/ethnicity, and education level) and disease characteristics (cancer type, stage, health
status, and worry about cancer (Lerman et al., 1991)) found in prior studies to be
significant predictors of information engagement behaviors (Nagler, Gray, et al., 2010) or
of exposure to DTCA (Study 2). Cancer stage was derived from the Pennsylvania Cancer
Registry and corresponded to the American Joint Committee on Cancer / International
Union Against Cancer TNM classification (Greene et al., 2002). All other covariates
were based on self-reports in the round 1 survey.

100

Analyses
Bivariate analyses were first performed to assess cross-sectional associations
between exposure to DTCA at round 1 and the dependent variables (PCIE and
information seeking from non-clinician sources) at round 2. The assumption of linearity
for the relationships between each of the outcome variables and exposure to DTCA was
evaluated through visual inspection of the respective scatterplots and tests of linearity.
The loess curves of the scatterplots approximated linear relationships closely.
Furthermore, tests of linearity were significant for the bivariate relationships between
each of the information seeking variables at Round 2 and exposure to DTCA in Round 1
(all Ps<.0005). The eta-squared and R-squared values for both associations were close in
value (difference of 0.014 in both instances). Tests of deviation from linearity were not
statistically significant.
Multivariate analyses were performed using the Mplus software version 7
(Muthén & Muthén, 1998) to fit full information maximum likelihood (FIML) models
predicting PCIE and information seeking from non-clinician sources at round 2 with
exposure to DTCA in round 1. To address the concern about causal direction and
potential spuriousness in inferences about these associations, lagged analyses were
performed controlling for the corresponding information engagement behaviors at round
1 and other potential confounders.
The FIML technique is reported to be superior to ad hoc methods for dealing with
missing data in predictor variables (e.g., listwise deletion, pairwise deletion, mean
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imputation) and has the benefit of reducing bias and sampling variability in multiple
regression models (Enders & Bandalos, 2001; Enders, 2001). Missingness in the
predictor and mediator variables mainly involved DTCA exposure (25%), attitudes
(29%), PNP (25%), PBC (24%), and intentions (24%). These missing values were largely
because 369 patients were randomly selected to answer a short version of the
questionnaire in round 1 that excluded these items. Missing values for PCIE and
information seeking at both rounds 1 and 2 were minimal (1-2%).
Huber-White covariance adjustments were applied to the estimated standard
errors to adjust for non-normality in the data. The models applied post-stratification
sample weights to adjust the final sample to represent the patient population from the
Pennsylvania Cancer Registry in terms of race, age, gender, marital status, time of
diagnosis, and stage at diagnosis; adjust for survey non-response; and account for the
oversampling of certain subgroups of patients. This permitted inferences to be made
about the broader population of patients with colon, breast, or prostate cancer in
Pennsylvania based on the present analyses. The analyses with and without sampling
weights were substantively identical. Therefore, only the weighted analyses are reported
here.
Results
Table 5.1 summarizes the distribution of the key measures and characteristics of
the study population. The average age of the study participants at round 1 was 66 years,
51% was female, 44% had some college education or higher, 83% were white, 67% were
102

married, and 71% had early stage cancer (stages 0 to II). Approximately equal numbers
of patients from each of cancer type were represented in the sample (684 colon cancer
patients, 679 breast cancer patients, and 650 prostate cancer patients). Preliminary
univariate analyses revealed that the distribution of the information seeking and DTCA
exposure variables were non-normal (skewness ranged from -0.866 to 1.040; kurtosis
ranged from -1.229 to 0.498; all univariate Shapiro-Wilk tests were significant at
p<.00005).
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Table 5.1 Summary Statistics And Characteristics Of Study Population At Round 1
(N = 2013)

Principal variables (Study 3A)
Exposure to DTCA at round 1
Patient-clinician information engagement (PCIE) at
round 2
Information seeking from non-clinician sources at
round 2
Mediator variables (for information-seeking from
non-clinician sources) (Study 3B)
Attitude at round 1
Perceived normative pressure at round 1
Perceived behavioral control at round 1
Intention at round 1
Control variables
Patient-clinician information engagement (PCIE) at
round 1
Information seeking from non-clinician sources at
round 1
Age (years)
Sex
Female
Male
Race/Ethnicity
White
African-American
Hispanic or other race/ethnicity
Education
High school or below
Some college or above
Cancer Type
Breast cancer
Prostate cancer
Colon cancer
Lerman Cancer Worry Scale (not at all to almost all
the time)
Cancer Stage
Stage 0 to II
Stage III
Stage IV
Health Status (poor to excellent)
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Range

Mean

SD

1.00 to 5.00

2.41

1.02

0.00 to 1.00

0.29

0.28

0.00 to 1.00

0.14

0.16

-3.00 to 3.00
-3.00 to 3.00
-3.00 to 3.00
-3.00 to 3.00

-0.15
-0.61
1.16
-0.92

1.98
1.93
1.92
2.16

0.00 to 1.00

0.51

0.29

0.00 to 1.00

0.20

0.17

66.2

12.4

%

50.9
49.1
83.1
12.8
4.2
56.5
43.5
33.7
32.3
34.0
1.00 to 5.00

2.43

1.00
71.0
12.9
16.1

1.00 to 5.00

3.11

0.94

From the bivariate correlation analyses, exposure to DTCA at round 1 is
significantly associated with PCIE at round 2 (Pearson’s r=0.213, p<.00005) and seeking
from non-clinician sources at round 2 (Pearson’s r=0.288, p<.00005). Table 5.2
summarizes the weighted FIML models predicting PCIE and information seeking form
non-clinician sources at round 2 with exposure to DTCA at round 1, controlling for the
respective information engagement behaviors measured at round 1 and other potential
confounders. The results show that exposure to DTCA at round 1 is significantly
associated with subsequent PCIE (unstandardized coefficient B=0.023, 95% CI = 0.005
to 0.040, p = 0.012). However, the association between exposure to DTCA and
information seeking from non-clinician sources at round 2 is marginally significant,
although as follow-up analyses reported below will show, the indirect path from DTCA
to information seeking from non-clinician sources reaches the conventional level of
significance. Other significant predictors for both analyses are prior PCIE or information
seeking from non-clinician sources at round 1, education level (higher active seeking
with some college or higher education), race/ethnicity (higher active seeking in AfricanAmerican compared to white patients), and cancer-related worry.
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Table 5.2 Predicting Patient-Clinician Information Engagement (PCIE) And Information Seeking From Non-clinician Sources
At Round 2 (N=1293)
PCIE at round 2
Independent variables

B

95% CI

Seeking at round 2
p

B

DTCA at round 1

0.023

0.005

-

0.040

0.012

0.009

PCIE at round 1

0.348

0.291

-

0.405

<0.001

-

Seeking at round 1
Age

-

95% CI

p

-0.001

-

0.018

0.067

0.466

0.410

-

0.522

<0.001

0.001

-0.001

-

0.002

0.334

0.000

0.000

-

0.001

0.361

0.043

0.013

-

0.074

0.005

0.015

0.000

-

0.030

0.056

African-American

0.090

0.038

-

0.142

0.001

0.041

0.011

-

0.071

0.008

Hispanic or other

0.026

-0.047

-

0.099

0.486

0.015

-0.033

-

0.064

0.533

Education
Some college or higher
Race/Ethnicity

Cancer Type
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Female colon cancer

0.043

-0.014

-

0.099

0.139

0.021

-0.006

-

0.048

0.120

Breast cancer

0.040

-0.011

-

0.091

0.123

-0.004

-0.027

-

0.019

0.709

Prostate cancer

0.024

-0.029

-

0.078

0.377

-0.024

-0.047

-

-0.001

0.038

0.039

0.021

-

0.057

<0.001

0.013

0.004

-

0.022

0.003

Stage III

0.051

-0.007

-

0.110

0.084

-0.009

-0.033

-

0.014

0.431

Stage IV

0.071

0.016

-

0.126

0.011

0.013

-0.013

-

0.038

0.329

Health Status

-0.003

-0.021

-

0.014

0.700

-0.001

-0.010

-

0.008

0.772

Constant

0.161

R2

0.243

Lerman Cancer Worry Scale
Cancer Stage

0.044

0.348

Notes. Full information maximum likelihood models presented here; B refers to unstandardized maximum likelihood coefficients;
referent group for education level is high school and below; referent group for race/ethnicity is white; referent group for cancer type is
male colon cancer; cancer type and gender was combined into a single variable to reflect the different gender-specific cancer types
(breast and prostate cancers); referent group for cancer stage is stage 0-II.

107

Study 3B Mediational Analysis of DTCA Exposure on Information Seeking from
Non-Clinician Sources Through Integrative Model Variables
Extending from the above findings described in Study 3A, Study 3B explores
potential psychosocial mechanisms for the associations between DTCA exposure and
information seeking behaviors. I first review prior literature on the psychosocial
pathways of DTCA effects on patients’ inquiry about the advertised medication to draw
general hypotheses about theoretical mechanisms between DTCA exposure and health
information seeking behaviors more broadly. Next, guided by the Integrative Model of
Behavioral Prediction (IM), I elaborate specific hypotheses about the relationships
between DTCA exposure, IM variables, and active information seeking and test these
hypotheses with a structural equation modeling approach.
Psychosocial Mediators of DTCA Effects on Drug Information Seeking
Prior research relied on wide-ranging theoretical models or constructs in
examining psychosocial mechanisms through which DTCA may influence health
knowledge acquisition in consumers. For example, in a series of content analyses based
on Social Cognitive Theory to evaluate visual and textual cues of DTCA, Welch Cline
and Young (2004, 2005) reported frequent occurrences of cues that modeled identity
rewards (e.g., models depicted as healthy, active, or friendly in the ads) and relational
rewards (e.g., models depicted as a family or as romantic partners) in conjunction with
the advertised product. The authors posited that these cues served as vicarious motivators
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for patients to either find out more about the advertised treatment or to seek treatment for
symptoms similar to those in the ads. Subsequent survey research by the same authors
among young women further suggested that positive outcome expectancies of discussing
about an advertised drug with their physicians were associated with increased intention to
communicate with physicians about the drug (H. N. Young et al., 2005). However, the
study did not elaborate on the role of outcome expectancies of discussing health
information more generally in predicting patient-physician discussions about health
concerns.
Grounded in the Theory of Planned Behavior and Self-Efficacy Theory, Liu and
colleagues (2005) found that attitudes and subjective norms toward seeking drug
information from physicians and pharmacists predicted intention to seek from these
sources among a sample of patients with osteoarthritis. In contrast, only attitudes toward
seeking drug information from the internet predicted intention to seek from the internet.
Perceived difficulty was not predictive of intentions to seek from all three sources.
Moreover, as predicted by the theoretical models, intentions predicted actual behavior of
seeking drug information from all three sources at 6-weeks follow-up. Similar to the
studies by Welch Cline and Young (Welch Cline & Young, 2004; H. N. Young et al.,
2005; H. N. Young & Welch Cline, 2005), the study was focused on specific drug
information seeking behaviors and did not examine parallel models to explain patients’
general information seeking about osteoarthritis.
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Deshpande and colleagues (2004) investigated a shared decision-making model of
public perceptions of DTCA and showed that more favorable opinions about DTCA
utility (a scale derived from items asking participants to rate their agreement with three
statements of whether DTCA allowed people to be more involved with their health care,
make decisions about prescription medicines, and educate people about risks and benefits
of prescription medicines) were associated with increased likelihoods of engaging in drug
inquiry behavior about a drug with physicians, requesting a drug from physicians, and
inquiring about a medical condition or illness. Of particular relevance to the present
dissertation research is the finding that positive opinion about DTCA utility was
associated with an increased odds of 2.12 times that respondents utilized ad information
to talk to their doctor about a medical condition. In comparison, positive opinion of
DTCA utility was associated with increased odds of 2.25 times that respondents used ad
information to talk to their doctor about a prescription drug. The parallel findings suggest
that similar pathways through opinions of DTCA utility may be operating in the
associations between DTCA and drug inquiry or more general information seeking
behaviors.
Two recent studies examined the role of general attitudes toward DTCA on
intentions to search for specific medication information. In the first, Herzenstein and
colleagues (2004) found that favorable attitudes toward DTCA was associated with
increased likelihood to search for more information about an advertised drug and
increased likelihood to ask their physician about such a drug in a cross-sectional survey
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among a national telephone sample of 1081 adults. Independently, the second study by
An (2007) noted similar findings that positive general attitudes toward DTCA predicted
higher intentions to ask doctors about a specific medication or advertised treatment in a
cross-sectional telephone survey of 203 residents in a Midwestern town.
To summarize, the majority of existing literature exploring the psychosocial
mechanisms of DTCA effects on patient information seeking behaviors focused primarily
on drug information seeking. There is limited empirical research available to identify the
psychosocial mediators of DTCA effects on more general health information seeking
related to patients’ condition. Study 3B is aimed at addressing this research gap to
analyze whether similar pathways may be operating in explaining the associations
between DTCA and broader health information seeking behaviors.
The Integrative Model of Behavioral Prediction
Extending from the findings in Study 3A and the prior research evidence on the
predictors of drug inquiry behavior, this study explores the roles of psychosocial
mediators of health information seeking guided by the Integrative Model (IM) of
Behavioral Prediction—a model that is based on well-established explanatory models of
health behaviors (i.e., Health Belief Model (Rosenstock, 1974), Theory of Reasoned
Action/ Theory of Planned Behavior (Ajzen, 1991; Fishbein & Ajzen, 1975, 2010), and
Social Cognitive Theory (Bandura, 1986)).
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The IM specifies a causal pathway between one’s intention to perform a behavior
and the actual engagement in the behavior. Additionally, behavioral intention is theorized
to be influenced by individuals’ underlying attitudes toward the behavior, perceived
normative pressure (PNP) to perform the behavior, and perceived behavioral control
(PBC) associated with enacting the behavior. Intention is operationalized as an
individual’s self-reported likelihood of performing a behavior in a future timeframe.
Intention is further defined in terms of specific time, action, context, and target to be
compatible with the behavior of interest. Attitude toward the behavior is defined as
“degree to which a person has a favorable or unfavorable evaluation or appraisal of the
behavior in question” (Ajzen, 1991, p.188) (i.e., whether performing the behavior would
be good or bad for oneself, beneficial or harmful, wise or foolish). PNP is a person’s
“perceived social pressure to perform or not to perform the behavior” (Ajzen, 1991,
p.188) or whether important others think one should or should not perform the behavior
and whether others who are similar are also performing the behavior. PBC refers to
“people’s perception of the ease or difficulty of performing the behavior of interest”
(Ajzen, 1991, p183), that is whether someone believes that he or she would have the
ability to perform the behavior and that it would be under his or her control to engage in
the behavior.
Based on these constructs of attitudes, PNP, and PBC from the IM, SmithMcLallen and colleagues (2011) conducted an earlier study using the same data source as
this present analysis to examine the predictors of cancer patients’ information seeking
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from sources other than their doctor. The analysis showed that attitudes, PNP, and PBC
were significantly associated with intentions to seek information. In addition, consistent
with the predictions in the IM, intentions to seek information predicted actual behavior or
information seeking at one-year follow-up. This present study aims to build on the above
analysis in assessing the relationships between DTCA exposure and these IM constructs
and evaluating whether the IM variables mediate the association between DTCA
exposure and active information seeking.
Applying the above IM constructs to this present study, DTCA exposure is
hypothesized to influence attitudes, PNP, and PBC regarding active information seeking
in the following ways. For instance, spokespersons featured in DTCA may serve as role
models for patients to actively engage with their physicians to talk about their health
condition. These portrayals of patient-doctor discussions convey positive outcome
expectations about the health information seeking that are associated with positive
attitudes toward the behavior. They may also influence perceived descriptive norms that
other patients in a similar situation are likely to consult their doctor for information about
treatment options. DTCA may further improve behavioral control through observing
spokespersons enacting discussions effectively in the ad. In addition, DTCA may offer
additional information aimed at empowering patients’ ability or self-efficacy to discuss
with their doctor about their condition. Existing DTCA for prescription drugs serve to
illustrate the potential mechanisms through these IM constructs. For example, in an ad for
Detrol LA (tolterodine), an actor depicted having overactive bladder symptoms. She
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modeled the behavior of navigating a dedicated website (DetrolLA.com) that provided
tips on how she could get the discussion started with her physician about her symptoms.
The ad concluded with this actor having improved symptoms and the message to “Have
the Detrol Discussion with your doctor”. A second example is the Chantix ad described
earlier in Study 3A. In these examples, the main message was for viewers to talk to their
physician about their symptoms and secondarily about whether the advertised medication
would be appropriate for them. In both cases, cues corresponding to positive outcome
expectancies, descriptive norms, and self-efficacy associated with enacting information
seeking (e.g., about tips to manage health concerns or about how to discuss a health
concern with one’s doctor) are featured in varying extents and may potentially influence
patients’ attitudes, PNP, and PBC regarding information seeking behaviors.
The above review of prior literature precludes generalizing from the observed
psychosocial mechanisms underlying DTCA effects on drug inquiry to explain DTCA
effects on general information seeking behaviors. Thus far, there is insufficient research
directly related to general information seeking following DTCA exposure. However,
conceptually there is an argument to be made that seeking information about an
advertised treatment, while a distinct behavior, may be a subset of general cancer-related
information seeking. Therefore, it is reasonable to assume that parallel mechanisms may
be operating in the relationship between DTCA and general information seeking,
mediated through the IM constructs of attitudes, PNP, and PBC. Furthermore, existing
examples of broadcast DTCA indicate the presence of cues that correspond closely with
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these IM constructs pertaining to general information seeking behaviors. Therefore, this
study proposes to test the following hypothes
hypothesis:
H1:: The association between DTCA and active health information seeking would
be mediated by the psychosocial constructs of the Integrative Model (see Figure
5.11 for a graphical representation).

Figure 5.1 Hypothesized Mediation Model Predicting Information Seeking From
Non-clinician Sources At Round 2

Notes. DTCA = cancer-related
related direct
direct-to-consumer
consumer advertising exposure; PNP = perceived
normative pressure; PBC = perceived behavioral control; all predictor and mediator
variables are measured at round 1 of the survey; each path implied in the above model
was adjusted for information seeking at round 1 and other confounders (age, education,
race/ethnicity, cancer type, gender, Lerman worry scale, cancer stage
stage,, and health status)
which are omitted in the figure for clarity; disturbance terms of attitudes, PNP, and PBC
are specified to be correlated with one other.
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Method
Study Population
The study population for Study 3B is as described in Study 3A above. This
analysis utilized data from Rounds 1 and 2 of the longitudinal survey among breast,
prostate, and colorectal cancer patients in Pennsylvania.
Measures
To test the above mediation hypothesis, IM variables included intention, attitudes,
perceived normative pressure (PNP), and perceived behavioral control (PBC) associated
with information-seeking from non-clinician sources, all measured at round 1. Due to
survey constraints, parallel IM measures for patient-clinician information engagement
were not collected in this study and are not tested here.
The IM variables are defined as described in an earlier study with this data source
by Smith-McLallen and colleagues (2011). Survey items for these variables are provided
in Appendix C. Intention to actively seek information from non-clinician source was
measured with a single item: “How likely is it that you will actively seek information
about issues related to your cancer from a source other than your doctor in the next 12
months?” along a 7-point scale (anchored between unlikely to likely).
Attitudes comprises three semantic differential items that asked participants if
their actively seeking information about issues related to their cancer from a source other
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than their doctor in the next 12 months would be “useless/useful”, “unenjoyable/
enjoyable”, and “foolish/wise” along a 7-point scale. The average of these three items
formed the attitude scale (Cronbach’s α=0.89).
Perceived normative pressure (PNP) is the average of ratings of two statements
along a 7-point scale from “disagree” to “agree”: “Most people who are important to me
think I should actively seek information about issues related to my cancer from a source
other than my doctor in the next 12 months” and “Most people like me (e.g., other cancer
patients) actively seek information about issues related to their cancer from a source other
than their doctors” (inter-item correlation r=0.53).
Perceived behavioral control (PBC) is the average of ratings of two items. The
first item asked participants if their actively seeking information from a source other than
their doctor in the next 12 months would be “not up to me/ up to me”. The second item
asked participants to rate the statement “If I really wanted to, I could actively seek
information about issues related to my cancer from a source other than my doctor in the
next 12 months” along a 7-point scale from “disagree” to “agree” (inter-item correlation
r=0.37). All above mediator variables were measured at round 1 and ranged from -3 to 3.
Analyses
The structural equation model implied in Figure 1 is fitted using the Mplus
software to assess the mediation hypothesis. In short, exposure to DTCA is modeled to
predict attitudes, PNP, and PBC associated with information seeking from non-clinician
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sources at round 1. Consistent with the IM, these constructs are modeled to predict
intention at round 1 which in turn predicts information seeking from non-clinician
sources at round 2. As recommended by Preacher and Hayes (2008, p.882), covariances
between the IM constructs (attitudes, PNP, and PBC) are permitted by specifying
correlations between the disturbance terms of these endogenous variables. The model
further controls for prior information seeking from non-clinician sources at round 1 and
potential confounders and applies post-stratification sample weights as described in the
earlier section. Model goodness of fit is assessed using a combination of indices
including the overall χ2 test of model fit, comparative fit index (CFI), Tucker-Lewis
Index (TLI), root mean square error of approximation (RMSEA), and the standardized
root mean square residual (SRMR). Parameter residuals and modification indices are
inspected for areas of poor fit and examined for theoretically supported alternative
models.
Results
Figure 5.2 summarizes the results from the mediation analysis testing the indirect
effects of DTCA exposure on information seeking from non-clinician sources through the
IM variables. Standardized parameter estimates for the structural coefficients are
presented along with the unstandardized estimates in parentheses. The overall χ2 test for
model fit is statistically significant (χ2(5)=14.948, p=0.011). However, this test is
sensitive to large sample sizes (Kline, 2011). Other indices of model fit suggest that the
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model is a reasonably good fit to the observed data RMSEA=.031, CFI=.995, TLI=.924,
SRMR=.007). An inspection of residuals and modification indices did not reveal
theoretically meaningful points of poor fit in the model and the hypothesized model is
retained. The analysis shows that controlling for prior information seeking from nonclinician sources and potential confounders, intention at round 1 is a significant predictor
of active seeking from non-clinician sources at round 2. Attitudes and PNP are
significantly associated with intention but PBC is not significantly associated with
intention. DTCA exposure is significantly associated with all three IM constructs of
attitudes, PNP, and PBC related to active seeking from non-clinician sources. Table 5.3
displays standardized estimates of the indirect mediational chains from DTCA exposure
through the IM variables to information seeking from non-clinician sources based on the
structural model. The results show that the total indirect path from DTCA through the IM
variables is statistically significant and suggest evidence partially supporting Hypothesis
2. Of the three possible mediated pathways, the indirect effect from DTCA through
attitudes and intention is statistically significant while the indirect effect through PNP and
intention approaches significance.
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Figure 5.2 Mediation Model Predicting Information Seeking From Non-clinician
Sources At Round 2 (N=2013)

Notes. Model fit was assessed based on the overall χ2 test (χ2(5)=14.948, p=0.011) and
other fit indices (RMSEA=.031,
SEA=.031, CFI=.995, TLI=.924, SRMR=.007); DTCA = cancercancer
related direct-to-consumer
consumer advertising exposure; PNP = perceived normative pressure;
PBC = perceived behavioral control; all predictor and mediator variables are measured at
round 1 of the survey; sta
standardized
ndardized coefficients for each parameter (and unstandardized
coefficients in parentheses) based on full information maximum likelihood models are
presented here; *p<.05, **p<.01, ***p<.0005; each path implied in the above model was
adjusted for informationn seeking at round 1 and other confounders (age, education,
race/ethnicity, cancer type, gender, Lerman worry scale, cancer stage, and health status)
which are omitted in the figure for clarity; error terms of attitudes, PNP, and PBC are
assumed to be correlated
elated with one other.
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Table 5.3 Indirect Effects Of Exposure Cancer-Related Direct-To-Consumer
Advertising (DTCA) On Information Seeking From Non-clinician Sources At
Round 2 (N=2013)
Paths

b

95% CI

DTCA to Attitude to Intention to Seeking

0.007

0.001

- 0.012 0.017

DTCA to PNP to Intention to Seeking

0.002

0.000

- 0.005 0.067

DTCA to PBC to Intention to Seeking

-0.001 -0.001 - 0.000 0.176

Total indirect effects

0.008

0.002

p

- 0.015 0.016

Notes. b refers to standardized maximum likelihood estimates of indirect effects through
each path; DTCA = cancer-related direct-to-consumer advertising exposure; PNP =
perceived normative pressure; PBC = perceived behavioral control; the model controlled
for prior information seeking at round 1 and other confounders (age, education,
race/ethnicity, cancer type, gender, Lerman Cancer Worry Scale, cancer stage and health
status) which are omitted in the table for clarity.

Discussion
Much of the controversy surrounding the societal value and risks of DTCA
centers around the argument over the idea that patients’ interests are better served with
this form of public health communication. From a patient empowerment standpoint,
proponents contend that DTCA places valuable health information in the hands of
patients, fosters a patient-centered model of health care delivery, and strengthens patientphysician communications by emphasizing patients to be active participants in managing
their health conditions and treatment decisions (Calfee, 2002; Holmer, 1999, 2002).
121

Opponents counter that reliance on DTCA, which is at heart motivated by profit
generation for advertisers and manufacturers, to perform such a crucial public education
role would be a “haphazard approach to health promotion” (Hollon, 2005) and could
undermine the public’s health (Avorn, 2003; Hollon, 1999; Wilkes et al., 2000).
This current study offers new empirical evidence to inform the ongoing debate of
the communication impact of DTCA by assessing the spillover effect of DTCA on cancer
patients’ active health information seeking behaviors from clinicians and non-clinician
sources. The analyses in Study 3A indicate that exposure to DTCA is significantly
associated with subsequent cancer patients’ active information seeking from physicians
and other health professionals. In comparison, the relationship between DTCA exposure
and subsequent information seeking from non-clinician sources approaches significance.
The first substantive finding supports the inference that DTCA about cancer
treatment is associated with the beneficial externalities of increasing patient information
engagement with health professionals about general cancer-related information,
consistent with such benefits outlined in a review about DTCA in general by Calfee
(2002). This finding supplements earlier empirical evidence from patient or consumer
surveys that showed associations between DTCA and information inquiry about
advertised medications (Abel et al., 2009; Aikin et al., 2004; Bell et al., 2010; Weissman
et al., 2003). A related assumption made here is increased patient-clinician
communication about health information is a beneficial outcome for patients’ well-being
and this assumption is supported by previous theorizing and empirical findings from this
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research group and elsewhere (Epstein & Street Jr., 2007; Martinez et al., 2009; Mello,
Tan, Armstrong, Schwartz, & Hornik, 2012; Street Jr. & Epstein, 2008; Street Jr. et al.,
2009).
The current study contributes new evidence to the debate on the societal value of
DTCA by emphasizing that DTCA may have a previously unmeasured and unintended
benefit of gradually shifting the paradigm of a paternalistic health care delivery model to
a patient-centered one by encouraging patients to be more active participants in
understanding their health condition and treatment options (Beltramini, 2010; Deshpande
et al., 2004). This inference about possible DTCA externalities invites consideration of
the potential implications on practice and policy regulations surrounding DTCA. On one
hand, the inference would lend support to the argument by proponents that DTCA
indirectly benefits patients by encouraging broader health information seeking behaviors.
As a result, policies governing DTCA should be relaxed to promote greater dissemination
of valuable health information to consumers (Calfee, 2002). On the other, the question
arises as to whether there might be more cost-effective and direct means than DTCA to
achieve improved patient information seeking from health professionals (Avorn, 2003).
One limitation in Study 3A is the information seeking measures may have
included patients’ drug inquiry behaviors as well. The outcome measures therefore do not
clearly distinguish between specific information seeking about advertised cancer
treatments from seeking about other health topics related to cancer (e.g., other treatment
options or quality of life issues). However, it is unlikely that the seeking measures are
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fully accounted for by patients’ inquiries about advertised treatment alone. First, the
survey items asked participants about their seeking of broad topics over the course of 12
months and not just about advertised treatments. Moreover, multiple items pertain to
seeking information about quality of life issues and these are less likely to overlap with
drug inquiry behaviors. Third, unlike prior studies that relied on single items to elicit the
impact of DTCA on patient behaviors (e.g., “Has an advertisement for a prescription drug
prompted you to talk to your cancer doctor or nurse about a drug for yourself?” (Abel et
al., 2009)), this research relies on independent items for DTCA exposure and information
seeking behaviors. There is less risk that participants were only responding about their
seeking of information about advertised treatment in answering the survey items on
active information seeking. Despite these reasons, future surveys should consider
designing items that measure patients’ inquiry about advertised treatments independently
from patients’ health information seeking about other cancer-related topics following
DTCA exposure.
This research further draws on the IM to identify the psychosocial mechanisms
that may account for the relationship between DTCA exposure and health information
seeking behaviors. Expanding from the findings in Study 3A and relying on available
survey items related to information seeking from non-clinician sources, the analyses in
Study 3B found an indirect mediation pathway between DTCA exposure and active
seeking from non-clinician sources through patients’ attitudes and intention associated
with seeking from these sources. This analysis points to an inference about a potential
124

mediational pathway for the influence of DTCA on information seeking behaviors
through favorable attitudes about active information seeking and intention to seek cancerrelated information from non-clinician sources. These findings corroborate those reported
in earlier research describing the roles of similar psychosocial constructs (e.g., favorable
outcome expectancies or attitudes toward DTCA) in predicting intention or behaviors of
drug inquiry and prescription requests (An, 2007; Deshpande et al., 2004; Herzenstein et
al., 2004; Liu et al., 2005; H. N. Young et al., 2005). The accumulated evidence so far
offers intriguing insights into one possible underlying mechanism to explain the spillover
effects of DTCA on patients’ health information seeking behaviors. These insights may
generate additional research hypotheses for programmatic research to study the
communication effects and pathways of DTCA.
Due to survey limitations, parallel IM measures for patient-clinician
communication were not available to test a similar mediation pathway leading from
DTCA exposure to active seeking from clinician sources. Additional research to examine
whether corresponding patterns of mediation by IM constructs may be required. Building
on the present study, a follow-up content analysis may be directed at describing the
prevalence and content of specific DTCA messages that are likely to be associated with
the IM constructs of attitudes or perceived norms about engaging in active health
information seeking. Documenting the presence of these messages linked to the
theoretical constructs systematically would strengthen the explanatory inference of the
observed relationships between exposure to DTCA and attitudes, PNP, and PBC in this
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study. Despite the efforts to establish temporal order and controlling for prior information
seeking and other potential confounders, the causal direction between DTCA exposure
and the IM constructs remain unclear since these variables were all measured at round 1.
For instance, it is plausible that attitudes about information seeking may have led to
patients’ recalling more DTCA exposures. Another follow-up study may focus on
assessing the causal relationship between DTCA exposure, IM constructs, and
information seeking behaviors using an experimental design to compare patients’
information seeking behaviors following random assignment to a treatment condition
receiving DTCA (e.g., embedded in patient-directed health magazines) or a control
condition receiving no DTCA. Findings from the follow-up would provide additional
evidence about the causal relationships between DTCA and information seeking
behaviors through the IM constructs.
It is essential to exercise caution in interpreting these results more generally to be
applicable for all forms of DTCA or across diverse types of patients with different health
conditions. Because the severity, nature of treatment, and characteristics of afflicted
patients may differ dramatically across various health conditions, it is plausible that the
relationships observed in this study among cancer patients may not be identical for other
patient populations. To illustrate, cancer treatment is considerably more complex, often
requires care across multiple specialties, and involves significant risks and adverse effects
compared to other forms of treatments that commonly appear in DTCA. Instead of
advertising limited to just prescription medications, cancer treatment advertising also
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extends to marketing campaigns by health care providers (e.g., physicians, hospitals, or
comprehensive treatment centers) and ads related to non-drug therapies such as
radiosurgery. Further research would be necessary to investigate if the relationships
observed in this study may be replicated in other health conditions and patient
populations before drawing more general inferences about overall DTCA effects on
health information seeking behaviors. Another limitation in this study, inherent in survey
research, is the reliance on self-reported measures for exposure to DTCA and other
principal variables, which may be subject to recall bias (Schutt, 2009). A separate study
evaluated the validity of the DTCA exposure measure used in this present research
among an independent sample of cancer patients and is described earlier (Study 1).
This present study differs from previous research on informational effects of
general DTCA that strengthens the study inferences in a few ways. First, recognizing the
unique context of cancer treatment in comparison to other disease conditions, this study
focuses on the effects of exposure to a specific subset of advertising (i.e., cancer-related
DTCA) among cancer patients. This ensures that the DTCA exposure in question is
highly salient for the study population. In contrast, earlier research typically measured
exposure to DTCA in general among healthy consumers for whom the DTCA may have
little salience (Aikin et al., 2004; Weissman et al., 2003). Second, prior surveys tended to
rely on cross-sectional survey designs in analyzing associations between DTCA exposure
with information seeking behaviors or psychosocial measures. These surveys were
therefore limited in their ability to untangle the causal direction of the associations. In
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comparison, this study relies on panel data to establish temporal order between DTCA
exposure and information seeking behaviors and further controls for prior information
seeking behaviors as means to strengthen inferences about the causal direction. Third, the
majority of research on DTCA effects has insufficiently integrated study findings within
theoretical frameworks to inform future research programs. This study is an attempt to
add to the understanding of DTCA influences on communication behaviors using the IM
approach.
In sum, this study analyzes the effects of exposure to DTCA on subsequent
cancer-related health information seeking behaviors (from health professionals and nonclinician sources) in the context of cancer treatment advertising in a population-based
panel of cancer patients. The findings show that increased exposure to DTCA
significantly predicts increased levels of active health information seeking from health
professionals. DTCA is marginally significant in predicting information seeking from
non-health professional sources and attitudes and intention toward active information
seeking mediate this relationship. These results offer important insights into the practice
and policy debate surrounding DTCA and stimulate additional research questions to
explore theoretical mechanisms of the impact of DTCA on patient communication
behaviors.

128

Chapter 6 EXPLORING COMMUNICATION INEQUALITIES ASSOCIATED
WITH EXPOSURE TO CANCER-RELATED DIRECT-TO-CONSUMER
ADVERTISING IN CANCER SURVIVORS (STUDY 4)
Abstract
This study draws from the Structural Influence Model of Communication as a
framework to explore potential communication inequalities arising from patients’
exposure to cancer-related direct-to-consumer advertising (DTCA). The model posits that
communication inequalities associated with cancer-related DTCA may arise at three
distinct but related levels: 1) certain groups may be less likely to gain exposure to DTCA,
2) differential attention and processing of DTCA may occur, and 3) some groups may not
engage in additional information seeking after viewing DTCA. These inequalities, if
substantial, may in turn propagate disparities in cancer outcomes in certain disadvantaged
patient populations. Earlier studies from this dissertation research and prior literature
support the claim that there are inequalities in exposure to cancer-related DTCA across
various patient characteristics. However, studies that examine attention and processing or
additional information seeking following DTCA exposure show mixed results regarding
inequalities in these communication outcomes. To contribute to the literature in
communication inequalities associated with public health information, this study analyzes
the moderation effects of age, educational level, race/ethnicity, and cancer type on the
associations between cancer patients’ reported exposure to DTCA and their active
information seeking behaviors from their clinicians or from non-clinician sources of
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health information. Based on a series of cross-sectional and lagged analyses of
longitudinal survey data from a population-based sample of 2013 cancer patients from
Pennsylvania, the results do not suggest that the association between DTCA exposure and
active information seeking behaviors are contingent on patients’ age, educational level,
race/ethnicity, or cancer type. Implications on the debate about communication
inequalities of DTCA and suggestions for future research questions are discussed.
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Introduction
Recent critical reviews and extant research surrounding both general and cancerrelated direct-to-consumer advertising (DTCA) highlight increasing concerns that given
the presence of communication inequalities among different social groups in the
population (e.g., by class, race, ethnicity), these forms of advertising may inadvertently
result in widening disparities in cancer outcomes between social groups. In a review
focusing on the potential for disparate effects of cancer-related DTCA in the population,
Kontos & Viswanath (2011) advocated “…closer and critical scrutiny of the effects of
DTCA and other types of marketing communications on a variety of cancer-related
outcomes, including patient engagement, patient-provider relationships, adherence,
compliance and treatment outcomes, is warranted.” Thus far, few empirical studies have
directly assessed the presence of social inequalities of cancer-related health behaviors or
outcomes in association with DTCA exposure despite the prevalence of consumer
advertising of medical products and services for the past thirty years.
The previous study of this dissertation project (Study 3) examined whether cancer
survivors’ exposure to cancer-related DTCA predicted subsequent information seeking
behaviors (i.e., patient-clinician information engagement (PCIE) and seeking from nonclinician sources) and explored potential mechanisms for this relationship. The present
study examines whether such DTCA may have disproportionate influences on cancerrelated information seeking behaviors across different social groups. I first summarize
theoretical and practical justifications for expecting such differential effects by describing
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various levels of communication inequalities based on a literature review. Next, I propose
hypotheses and research questions testing specific moderating factors pertaining to
DTCA exposure and information seeking behaviors. Following this, research methods
and results based on an analysis using data from the Cancer Patient Survey (2006 and
2007) are described. Finally, implications of the findings for future research, practice, and
policies relevant to DTCA will be discussed.
Structural Influence Model of Communication
Kontos & Viswanath (2011) described the Structural Influence Model of
Communication as a framework to study disparities in health communication and the
roles these disparities play in mediating relationships between social determinants (e.g.,
race, education, and income), access to healthcare resources, and more distal health
outcomes (e.g., health behaviors, adherence, and treatment outcomes). As outlined in an
earlier chapter, the underlying premise for this model is the notion that “control of
communication is power and that whoever has the capacity to generate, access, use and
distribute information enjoys social power and advantages that accrue from it”.
According to the model, communication inequalities that may lead to health outcomes
disparities include differences between social groups in terms of their: 1) exposure, 2)
attention, 3) external information seeking, and 4) processing of health information.
Applying concepts of this model to the studying the population impact of cancerrelated DTCA, Kontos & Viswanath (2011) hypothesized communication inequalities
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associated with DTCA may arise at three distinct but related levels: 1) certain groups may
be less likely to gain exposure to DTCA, 2) differential attention and processing of
DTCA may occur, and 3) some groups may not engage in additional information seeking
after viewing DTCA. If such inequalities exist, DTCA may have differential effects on
cancer outcomes between certain groups of patients. One concrete example is if some
groups were more likely to be exposed to DTCA or attend to such ads, they may be more
aware of a wider variety of effective treatment options available for their cancers than
others. Second, if certain groups were better able than others to process the risk and
benefit information of advertised treatments for their specific cancer diagnosis conveyed
in DTCA, they may be more likely to participate more actively in shared treatment
decision-making with their physicians. Third, if some groups had greater access to
resources for additional information seeking about advertised treatments, they may be
better informed of potential side-effects and be more prepared to cope with these
problems during treatment. These communication disparities may widen cancer outcomes
disparities between these groups of patients. Therefore, research is necessary to assess
whether certain groups of cancer patients have higher exposure to DTCA than others (as
described in Study 2) and whether certain groups are more likely to engage in additional
information seeking following exposure to DTCA (Study 4).
Communication Inequalities and DTCA
For the purposes of this research, communication inequalities among cancer
survivors associated with DTCA are categorized broadly in terms of: 1) exposure, 2)
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attention and information processing, and 3) external information seeking (adapted from
Kontos & Viswanath (2011) and Viswanath et al., 2006). I discuss each of these levels of
inequalities as they relate to DTCA and where relevant, implications of these inequalities
for the present research on cancer survivors’ information seeking behaviors.
First, opportunities for exposure to DTCA may differ between social groups and
this in turn may lead to different levels of actual exposure. Disparities in exposure arise
because ads tend to be intentionally placed in media outlets that target specific social or
ethnic groups and not others. To illustrate, Omunuwa (2001) reported in a content
analysis of women’s magazines that frequency and type of pharmaceutical ads differed
depending on the target audience of magazines. The author found the overall number of
pharmaceutical ads in white-oriented magazines exceeded those in black-oriented
magazines by four to eight times during the study period. Additionally, ads in whiteoriented magazines but absent in black-oriented magazines promoted medications for
conditions such as osteoporosis, menopause, Alzheimer’s disease, weight reduction,
arthritis, high cholesterol, and tobacco cessation. In contrast, certain ads in black-oriented
magazines did not appear in white-oriented magazines, including those that promoted
antiviral treatment for HIV or oral contraception. It should be noted the study did not
measure actual exposure among women across ethnic groups. Rather, the focus was on
opportunity for exposure through magazines. It is possible that black women’s overall
exposure to prescription ads may not differ appreciably from white women if they also
read white-oriented magazines, which are more prevalent and widely circulated. Another
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related reason for differential exposure across groups could be selective media use or
limited access to certain media by different groups. One example of such a scenario is
when a health service or treatment is advertised through the internet but certain groups
would not view these ads because they are less likely to use the internet (e.g., those with
lower educational attainment, low household income, and Hispanics are least likely to
have access to the internet) (Kontos, Emmons, Puleo, & Viswanath, 2010). Together,
selective placement by advertisers and selective media usage by groups may result in
communication inequalities among cancer survivors and create situations where some
groups are more likely to be exposed to DTCA while others are not. To the extent that the
above exposure inequalities may be operating, this may lead to some groups benefitting
disproportionately from the availability of DTCA compared to others in the population,
and perpetuate further disparities in cancer outcomes.
The second level of inequality is the presence of differential attention and
processing of cancer treatment information presented in DTCA. One important reason for
differential attention and information processing across groups is the high level of
literacy demanded to comprehend content presented in many ads or supplemental
information materials. This is supported by studies reporting that content in the majority
of general DTCA of prescription medications (83%) exceeded the eighth-grade reading
level typically recommended for the public (Chao, 2005). Correspondingly, Kaphingst et
al. (2004) reported the average reading grade level of supplemental information for
DTCA—print ads in magazines, drug manufacturer websites, and mailed brochures—was
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in the high school range (grades 10.5-11.6) for main texts of these materials and in the
college-level range (grades 13.7-14.1) for summary sections of materials. Another related
issue for differential processing is the format of DTCA that typically emphasized benefits
of products over risks involved (Kaphingst & DeJong, 2004). Particularly for those with
limited literacy skills, existing DTCA formats which privilege promotion of benefits of
medications may result in poorer comprehension of adverse side effects of advertised
drugs. In a study among a convenience sample of 50 adults with limited literacy,
researchers found respondents were less likely to answer comprehension questions about
risks of three advertised drugs correctly than questions about benefits of these drugs
(Kaphingst, Rudd, DeJong, & Daltroy, 2005). The interaction between health literacy
level (as measured using the Rapid Estimate of Adult Literacy in Medicine or REALM
score) and country of birth adds another complexity in predicting comprehension of
information presented in DTCA in that study. Extending the results from these studies
based on general DTCA of prescription medications, the implications for potential
inequalities in attention and processing of cancer-related DTCA (not just about
medications, but also about health providers and alternative treatments) by different
groups would be concerns that cancer patients with average health literacy may find it
difficult to understand and process treatment-related information in such advertising,
assess the attendant risks of treatments, and make meaningful decisions about treatments
based on their exposure to DTCA.
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Third, additional health information seeking arising from cancer-related DTCA
may differ between social groups, even with adequate exposure, attention, and processing
of content in such DTCA. Given short durations of most televised DTCA (usually one
minute or shorter), which precludes presentation of detailed or complex information
about treatments, viewers are typically directed to find out more information from
external sources (e.g., print ads, toll-free number, health providers, and manufacturer’s
website). This is especially necessary for cancer-related DTCA because cancer treatments
entail higher risks and can involve multiple complex decisions that include consultations
with a variety of medical specialists. There is evidence to support the notion that health
information seeking behaviors are driven by social determinants including education,
social class, or ethnicity (Jeff Niederdeppe, 2008; Ramanadhan & Viswanath, 2006). One
reason leading to differential information seeking is the issue of barriers to access media
channels or medical advice. Barriers including time or financial costs associated with
searching information on the internet or arranging for physician consultations may
prevent certain social groups from seeking external information after viewing a specific
cancer treatment ad. A related explanation is that differences in information seeking
behavior are due to variations between groups in their ability or motivation to act on the
information from DTCA. For instance, patients from low socioeconomic statuses are less
likely to request advertised medications from their health providers (Parnes et al., 2009).
This is partially attributable to medication costs being a substantial financial burden for
these patients, thereby discouraging low-income patients from requesting advertised
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brand-name medications. One key implication for the above disparity in the context of
cancer survivors following exposure to DTCA is the potential that some vulnerable
groups may miss getting important additional relevant information for their treatment
decision-making process. If so, a crucial gap may arise between those who are seeking
information and those who do not seek external information following DTCA exposure,
leading to widened disparities in downstream cancer outcomes.
To summarize, communication inequalities associated with cancer-related DTCA
may arise at three distinct but related levels: 1) certain groups may be less likely to be
exposed to DTCA, 2) differential attention and processing of DTCA may occur even with
adequate exposure, and 3) some groups may not engage in additional information seeking
after viewing DTCA. Arising from these inequalities, the concerns are that DTCA may
have differential effects among certain social groups. For example, beneficial effects of
DTCA information and knowledge may accrue disproportionately in one group and not in
others. Conversely, detrimental effects of DTCA leading to inappropriate use of
treatments may affect one group more than others due to differential processing and
comprehension of the information. The net impact of these contingent effects is DTCA
may exacerbate existing disparities in cancer outcomes.
The Current Study
Information-Seeking Behaviors in Cancer Survivors

138

This present study primarily addresses concerns arising from the third level of
communication inequality described above—the potential for DTCA to generate higher
levels of external information seeking behaviors in certain groups of cancer survivors and
not others. Specifically, extending from the results in Studies 2 and 3 in this dissertation
and relevant published literature, this study will assess the presence of moderation effects
due to individual patient characteristics on the relationship between DTCA exposure and
information-seeking behaviors (from clinicians and non-clinician sources). The four
moderating factors tested in this study are 1) age, 2) educational attainment, 3) ethnicity,
and 4) cancer type (by gender). Each of the research hypotheses and questions pertaining
to these moderators is accompanied by justifications based on prior empiric evidence,
where available, and a regression equation to illustrate the planned moderation analyses.
Age. Prior research is lacking on whether DTCA is associated with
communication inequalities based on the age of cancer survivors. One study showed
older cancer survivors receiving active treatment in a comprehensive cancer institute
reported less awareness of DTCA of prescription cancer drugs (Abel et al., 2009). The
analysis of predictors of DTCA exposure among Pennsylvanian cancer survivors (Study
2) was consistent in finding older cancer survivors reported lower levels of DTCA
exposure. In addition, an earlier analysis by Nagler et al. (2010) reported older
Pennsylvanian cancer survivors actively sought information about fewer topics related to
their cancer and sought information from fewer sources compared to younger survivors,
after adjusting for demographic and disease characteristics. In a study to assess age
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differences in consumer behaviors prompted by exposure to DTCA, DeLorme et al.
(2006) found healthy older (65 years and older) and mature (45-64 years) participants
were more likely than younger participants (18-44 years) to talk to a pharmacist about an
advertised prescription drug. However, talking to a doctor, talking with friends or
relatives, or searching for more information about an advertised drug did not differ
significantly between participants in these age groups. Owing to the equivocal findings of
the moderation effect of age, the following research questions were proposed:
Research Question 1: Does the association between DTCA exposure and patient clinician
information engagement (PCIE) differ by age of cancer survivors?
PCIE = b0 + b1 DTCA + b2 Age + b3 DTCA*Age
Research Question 2: Does the association between DTCA exposure and informationseeking from non-clinician sources (Seeking) differ by age of cancer survivors?
Seeking = b0 + b1 DTCA + b2 Age + b3 DTCA*Age
Education. Educational attainment is another potential moderator of the
relationship between DTCA and information engagement with physician sources. Abel et
al. (2009) reported that among cancer patients undergoing active treatment for breast or
hematologic malignancies, those without college education were more likely to report
that DTCA (of prescription cancer medications) led to better discussions about health or
medical care with their health provider compared to those with college education (65%
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vs. 52%, p=.03). Based on this finding, one expectation would be education might
interact with DTCA such that those with lower education would benefit more from
exposure to DTCA in terms of additional information seeking. Conversely, prior studies
indicate that DTCA content as well as the supplemental information in other forms tend
to be at high difficulty reading levels (Chao, 2005; Kaphingst, Rudd, et al., 2004), which
may in turn deter patients with lower educational levels from external information
seeking. Therefore, a counter hypothesis would be DTCA has a lower effect on
information seeking among survivors with lower education. Due to these competing
hypotheses, the moderation effects of education are posed as research questions:
Research Question 3: Does the association between DTCA exposure and patient clinician
information engagement (PCIE) differ between cancer survivors with higher education
attainment and those with lower education attainment?
PCIE = b0 + b1 DTCA + b2 Education + b3 DTCA*Education
Research Question 4: Does the association between DTCA exposure and informationseeking from non-clinician sources (Seeking) differ between cancer survivors with higher
education attainment and those with lower education attainment?
Seeking = b0 + b1 DTCA + b2 Education + b3 DTCA*Education
Ethnicity or race. As raised in the earlier discussion about inequalities in access
and information processing, Kontos and Viswanath (2011) proposed social determinants
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including race and ethnicity may influence whether people seek additional information.
There is however scant evidence or theoretical justification for ethnic or racial disparities
in cancer communication behaviors above and beyond other important indicators of
socio-economic status including education and household income. For instance, adjusting
for household income, education, and employment, results from the 2007 HINTS
indicated black and Hispanic adults were not significantly different from white adults in
terms of having heard about genetic testing or finding medical statistics difficult to
understand (Kontos & Viswanath, 2011). Moreover, results from the analysis in Study 2
were mixed with regards to race/ethnicity as a predictor of DTCA. Among breast cancer
patients, there were no significant differences in reported exposure to DTCA between
patients across groups. However, in patients diagnosed with prostate cancer, white
patients reported less exposure to DTCA compared to black patients. Hispanic patients
(and those who identified as being other than white or black) who were diagnosed with
colorectal cancer reported less exposure to DTCA than white patients. Likewise, other
large population studies have not found empirical evidence that ethnicity is associated
with cancer information seeking behaviors. For instance, Hesse et al. (2008) reported
ethnicity did not predict cancer survivors’ level of information seeking, information
source preference, information source use, or their information seeking experiences. This
was corroborated by earlier findings from the Pennsylvanian Cancer Patient Survey that
black and Hispanic cancer patients were similar in numbers of information sources and
cancer topics they sought compared to white patients (Nagler, Gray, et al., 2010).
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Furthermore, cancer patients’ ethnicity was not associated with information seeking
beyond that given by the health provider or with patients’ level of health information
seeking behaviors (HISB) for a variety of cancer-related topics (Galarce et al., 2011;
Ramanadhan & Viswanath, 2006). Despite the above information, this study submits that
research to understand the role of ethnicity in potentially moderating associations
between DTCA and information seeking behaviors would be practically important and
meaningful. Therefore, the assessment of ethnicity as a potential moderator proceeded
with the following research questions:
Research Question 5: Does the association between DTCA exposure and patient clinician
information engagement (PCIE) differ between cancer survivors of different ethnic
groups (referent group is white)?
PCIE = b0 + b1 DTCA + b2 black + b3 Hispanic/other + b4 DTCA*black +
b5 DTCA*Hispanic/other
Research Question 6: Does the association between DTCA exposure and informationseeking from non-clinician sources (Seeking) differ between cancer survivors of different
ethnic groups (referent group is white)?
Seeking = b0 + b1 DTCA + b2 black + b3 Hispanic/other + b4 DTCA*black +
b5 DTCA*Hispanic/other
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Cancer type. Prior research based on the Cancer Patient Survey data found
patients diagnosed with colon cancer consistently reported less information seeking from
different sources when compared with breast and prostate cancer patients (Nagler, Gray,
et al., 2010). The authors proposed these differences may be due to cancer-specific needs
varying between patients diagnosed with these cancers and differing levels of relevant
health information available in the overall media environment for each of these cancers.
In addition, analysis of the predictors of DTCA (Study 2) found exposure to DTCA
differed by gender and cancer types. Breast cancer patients reported more frequent
DTCA exposure, more so than patients diagnosed with colon cancer or prostate cancer.
These findings may be due to differences in availability of DTCA targeted at female and
male patients or variations in levels of advertising targeted at specific types of cancer
patients. In a content analysis of cancer-related DTCA of prescription drugs, Abel et al.
(2007) found such DTCA in popular magazines were predominantly placed in women’s
magazines. In contrast, no cancer-related DTCA was found in any of the men’s popular
magazines analyzed in the study. The above observations warrant further assessment into
whether communication inequalities pertaining to information seeking and DTCA
exposure exist across patients diagnosed with specific cancers. Due to the lack of prior
studies addressing this concern, the following research questions were posed to assess
potential moderation effects of cancer type and gender:
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Research Question 7: Does the association between DTCA exposure and patient clinician
information engagement (PCIE) differ between survivors diagnosed with breast,
colorectal, or prostate cancers (reference category is male colon cancer survivors)?
PCIE = b0 + b1 DTCA + b2 Female colon cancer + b3 (female) Breast cancer + b4
(Male) Prostate cancer + b5 DTCA*Female colon cancer + b6 DTCA*Breast cancer + b7
DTCA*Prostate cancer
Research Question 8: Does the association between DTCA exposure and informationseeking from non-clinician sources (Seeking) differ between survivors diagnosed with
breast, colorectal, or prostate cancers (reference category is male colon cancer
survivors)?
Seeking = b0 + b1 DTCA + b2 Female colon cancer + b3 Breast cancer + b4
Prostate cancer + b5 DTCA*Female colon cancer + b6 DTCA*Breast cancer + b7
DTCA*Prostate cancer
Method
Study Population
This study relies on data collected for the Cancer Patient Survey described in
detail earlier in Studies 2 and 3. The present analyses will focus on data collected during
baseline and follow-up surveys (conducted in 2006 and 2007).
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Measures
The dependent variables are Patient-Clinician Information Engagement (PCIE)
and information-seeking from non-clinician sources measured at baseline (Round 1) and
in the follow-up (Round 2) survey as described in Study 3. Briefly, PCIE represents
cancer survivors’ reported engagement with their physicians and other health
professionals on information related to their cancer and quality of life issues. The PCIE
variable comprised survey items that asked participants if they actively looked for
information about their cancer from their doctors or other health professionals.
Conversely, seeking from non-clinician sources comprised items that asked participants
to recall if they actively looked for information about their cancer and quality of life
issues from 10 different lay interpersonal sources (i.e., family members, friends or coworkers; other cancer patients; face-to-face support groups; online support groups; or
telephone hotlines) or media sources (i.e., television or radio; books, brochures or
pamphlets; newspapers or magazines; internet other than personal email or online support
groups; or other).
The independent variable is participants’ exposure to DTCA since their cancer
diagnosis measured at baseline (ranges from 9 to 21 months from diagnosis). As
described in earlier chapters, this is operationalized as self-reported DTCA exposure and
comprises ads about treatment alternatives for cancer, dealing with side effects of
treatment, and hospitals or doctors offering services for cancer. The DTCA exposure
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measure is formed from the average of individuals’ responses to each of the three survey
items.
Four moderating variables are tested in these analyses. They include age at cancer
diagnosis (measured in years), highest educational attainment (some high school and
below, high school or GED, some college, and college and above), ethnicity (white,
black, or Hispanic and other), and cancer type (male colon cancer, female colon cancer,
breast cancer, prostate cancers).
Analyses
The analyses include cross-sectional multiple regressions (associations with PCIE
and seeking from non-clinician sources at Round 1) and lagged multiple regressions
(predicting PCIE and seeking at Round 2 while controlling for these behaviors at Round
1) to assess moderating roles of individual predictors described in the hypotheses and
research questions above. Individual moderators are tested by introducing interaction
terms between a moderating variable and DTCA exposure as implied in each of the 8
research questions. For each model, the main effects of the other moderators were
included even when they were not the moderator of interest. As an example, in evaluating
Research Question 1 (moderation by age analysis), education, ethnicity, and cancer type
were included in the model as covariates. In addition, other potential confounders were
included in the regression models (cancer stage at diagnosis, Lerman cancer worry scale,
and self-reported health status).
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The rationale for testing the presence of moderation by these covariates in both
cross-sectional and lagged models was threefold. First, the interactions between DTCA
and each of the covariates might influence more immediate health information seeking
behaviors in survivors. Performing the cross-sectional tests would permit the ability to
detect such short-term impacts. However, cross-sectional analyses are limited in terms of
establishing causal direction of the associations. Therefore, the second rationale for
including lagged models was to strengthen causal inferences by addressing concerns
about temporal precedence of predictors in relation to PCIE and seeking from nonclinician sources. Third, patterns of moderation by the four covariates may differ over
time. Moderation analyses for PCIE and seeking from non-clinician sources at baseline
and follow-up would provide additional insights of such possibilities.
To address the presence of missing values in the predictor variables, the Mplus
software (Muthén & Muthén, 1998) was utilized to fit full information maximum
likelihood (FIML) models. The majority of missing values occurred in the DTCA
exposure variable because of 369 participants who were randomly assigned to answer a
shortened version of the survey at Round 1 that excluded items about DTCA exposure.
The models further applied post-stratification sample weights to adjust the final sample to
represent the Pennsylvania Cancer Registry patient population diagnosed with breast,
prostate, or colorectal cancers in terms of race/ethnicity, age, gender, marital status, time
of diagnosis, and stage at diagnosis. These weights also adjusted for survey non-response
and accounted for the oversampling of certain subgroups of patients.
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Preliminary univariate analyses revealed that the distribution of the key variables
(DTCA exposure, PCIE, and information seeking from non-clinician sources) were nonnormal (skewness ranged from -0.058 to 1.040; kurtosis ranged from -0.882 to 0.498; all
univariate Shapiro-Wilk tests were significant at p<0.0005). Huber-White covariance
adjustments were applied to the estimated standard errors as these are robust to nonnormality in the data.
Results
Table 6.1 summarizes the characteristics of the study population at Round 1 and
Round 2 including the four moderating variables and additional covariates measured at
Round 1. The average age of the sample in Round 1 was 66 years, 44% had some college
education or higher, 83% were white, and 71% had early stage cancer (stages 0 to II).
These characteristics of the sample who participated at Round 2 were similar.
Participation in Round 2 was higher among patients who were white (versus AfricanAmerican) or those who had higher education levels (versus some high school or below),
stage 0 to 2 disease (versus stage 4), lower Lerman worry, or higher health status.
Summary statistics for DTCA exposure, PCIE, and information seeking from nonclinician sources are displayed in Table 6.2. Post-stratification sample weights were
applied to adjust the analyzed samples in Round 1 and Round 2 to represent the
Pennsylvania Cancer Registry patient population in the moderation analyses.
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Table 6.1 Characteristics Of Study Population At Round 1 and 2

Age at round 1 (years) a

Round 1 (N=2013)

Round 2 (N=1293)

Range

Mean

SD

Mean

SD

24 to 105

66.2

12.4

65.5

11.9

%

%

Educationb
Some high school or below

15.8

12.8

High school or GED

40.7

39.5

Some college or 2 year degree

21.9

22.5

College degree and above

21.6

25.0

White

83.1

86.2

African-American

12.8

10.4

Hispanic or other race/ethnicity

4.2

3.4

Male colon cancer

16.7

15.4

Female colon cancer

17.1

16.6

Breast cancer

33.7

34.8

Prostate cancer

32.3

33.3

Race/Ethnicity

Cancer Typec

Lerman Cancer Worry Scale at round 1d 1 to 5

2.43

1.00

2.35

0.97

Cancer Stagee
Stage 0 to II

71.0

73.8

Stage III

12.9

13.0

Stage IV

16.1

13.2

Health Status at round 1f

1 to 5

3.11

0.94

3.22

0.9

Notes. Missing values at round 1: a1; b34; c3 (gender was unknown for three patients);
d

62; e132; f113. Missing values at round 2: a0; b3; c0; d29; e77; f60.
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Table 6.2 Summary Statistics Of Key Variables
Range

Mean

SD

Exposure to DTCA at round 1a

1 to 5

2.41

1.02

Patient-clinician information engagement (PCIE) at
round 1b

0 to 1

0.51

0.29

Patient-clinician information engagement (PCIE) at
round 2c

0 to 1

0.29

0.28

Information seeking from non-clinician sources at
round 1d

0 to 1

0.20

0.17

Information seeking from non-clinician sources at
round 2e

0 to 1

0.14

0.16

Notes. n=2013 at round 1 and n=1293 at round 2.
Missing values: a508 (369 participants were not asked these items because they were
randomly selected to receive a short form of the survey that omitted these items); b26;
c
14; d20; e14.
Results of the cross-sectional and lagged moderation analyses are summarized in
Tables 6.3 through 6.6. The parameters of note are the respective interaction terms
between DTCA exposure and each of the four moderating variables. The cross-sectional
analyses indicated that controlling for potential confounders, age, educational level,
race/ethnicity, and cancer type did not significantly moderate the association between
DTCA exposure and PCIE or information seeking from non-clinician sources at Round1.
Similarly, based on the lagged analyses controlling for PCIE or information seeking from
non-clinician sources at Round 1, no significant moderation was detected in the
associations between DTCA exposure and these information engagement behaviors at
Round 2 by the four moderators investigated here.
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Table 6.3 Cross-Sectional And Lagged Moderation Analyses By Age
Crosssectional
analyses
(n=2010)
DTCA at
round 1
Age (years)
DTCA by
age

B

95% CI

p

B

0.023

-0.055 - 0.102

0.559

0.049

-0.004 -0.007 - -0.001 0.022
0.000

Lagged
analyses
(n=1293)
DTCA at
round 1
Age (years)
DTCA by
age

Seeking from non-clinician
sources at round 1

PCIE at round 1

-0.001 - 0.001

0.670

95% CI
0.006

- 0.091

p
0.026

-0.003 -0.004 - -0.001 0.002
0.000

-0.001 - 0.000

0.572

Seeking from non-clinician
sources at round 2

PCIE at round 2
B

95% CI

p

B

95% CI

p

0.061

-0.031 - 0.154

0.194

0.038

-0.014 - 0.089

0.152

0.002

-0.002 - 0.006

0.285

0.001

-0.001 - 0.003

0.184

-0.001 -0.002 - 0.001

0.444

0.000

-0.001 - 0.000

0.268

Notes. B = unstandardized regression coefficients estimated using full information
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95%
confidence intervals based on Huber-White standard errors; baseline post-stratification
weights could not be computed for 3 cases because of missing information about gender
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity,
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for
the same covariates as well as PCIE or seeking from non-clinician sources at round 1.
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Table 6.4 Cross-Sectional And Lagged Moderation Analyses By Highest
Educational Level
Cross-sectional
analyses (n=2010)
DTCA at round 1
Some high school or
below (referent)
High school or GED
Some college or 2
year degree
College degree and
above
DTCA by high
school
DTCA by some
college
DTCA by college
and above
Lagged analyses
(n=1293)
DTCA at round 1
Some high school or
below (referent)
High school or GED
Some college or 2
year degree
College degree and
above
DTCA by high
school
DTCA by some
college
DTCA by college
and above

PCIE at round 1
B
0.020

95% CI
p
-0.033 - 0.072 0.464

Seeking from non-clinician
sources at round 1
B
95% CI
p
0.032 0.010 - 0.054 0.004

-

-

-0.062 -0.199 - 0.074 0.371

0.011

-0.044 - 0.067 0.694

-0.059 -0.205 - 0.087 0.429

0.007

-0.052 - 0.066 0.816

0.090

-0.062 - 0.242 0.247

0.064

-0.001 - 0.129 0.054

0.028

-0.028 - 0.084 0.323

0.002

-0.024 - 0.027 0.903

0.036

-0.022 - 0.095 0.227

0.015

-0.011 - 0.042 0.255

0.012

-0.050 - 0.073 0.710

0.001

-0.028 - 0.031 0.927

PCIE at round 2
B
0.026

95% CI
p
-0.020 - 0.071 0.271

Seeking from non-clinician
sources at round 2
B
95% CI
p
0.001 -0.021 - 0.022 0.937

-

-

-0.002 -0.137 - 0.134 0.982

-0.018

-0.079 - 0.043 0.561

0.065

-0.080 - 0.210 0.379

-0.002

-0.066 - 0.063 0.954

0.016

-0.131 - 0.163 0.829

-0.011

-0.082 - 0.061 0.769

0.000

-0.054 - 0.053 0.987

0.010

-0.015 - 0.035 0.448

-0.010 -0.064 - 0.045 0.734

0.010

-0.016 - 0.036 0.451

0.009

0.011

-0.018 - 0.040 0.470

-0.049 - 0.067 0.762

Notes. B = unstandardized regression coefficients estimated using full information maximum likelihood
and adjusted with post-stratification weights; 95% CI = 95% confidence intervals based on Huber-White
standard errors; baseline post-stratification weights could not be computed for 3 cases because of missing
information about gender and these cases were dropped from the cross-sectional analyses, resulting in an
analyzed sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity, cancer type,
Lerman worry, cancer stage, and health status; lagged analyses adjusted for the same covariates as well as
PCIE or seeking from non-clinician sources at round 1.
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Table 6.5 Cross-Sectional And Lagged Moderation Analyses By Race/Ethnicity
Cross-sectional
analyses
(n=2010)
DTCA at round 1
White (referent)
Black
Hispanic or other
DTCA by Black
DTCA by
Hispanic
Lagged analyses
(n=1293)
DTCA at round 1
White (referent)
Black
Hispanic or other
DTCA by Black
DTCA by
Hispanic

Seeking from non-clinician
sources at round 1

PCIE at round 1
B
0.041
0.009
-0.025
-0.006

95% CI
p
0.022 - 0.061 <0.001

95% CI
p
0.024 - 0.044 <0.001

- 0.135 0.892
- 0.172 0.801
- 0.037 0.790

B
0.034
-0.041
-0.013
0.016

-0.118
-0.223
-0.049

-0.109
-0.117
-0.009

- 0.028 0.247
- 0.091 0.804
- 0.042 0.210

0.006

-0.073

- 0.085 0.888

0.012

-0.031

- 0.055 0.576

B
0.025
0.115
0.011
-0.010

95% CI
p
0.006 - 0.045 0.010
-0.022
-0.162
-0.057

- 0.253 0.100
- 0.183 0.904
- 0.037 0.680

Seeking from non-clinician
sources at round 2
B
95% CI
p
0.011 0.001 - 0.021 0.024
0.101 0.018 - 0.184 0.017
0.034 -0.152 - 0.220 0.720
-0.022 -0.050 - 0.006 0.121

0.006

-0.061

- 0.073 0.860

-0.008 -0.075

PCIE at round 2

- 0.060 0.826

Notes. B = unstandardized regression coefficients estimated using full information
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95%
confidence intervals based on Huber-White standard errors; baseline post-stratification
weights could not be computed for 3 cases because of missing information about gender
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity,
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for
the same covariates as well as PCIE or seeking from non-clinician sources at round 1.
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Table 6.6 Cross-Sectional And Lagged Moderation Analyses By Gender And
Cancer Type
Cross-sectional
analyses (n=2010)
DTCA at round 1
Male colon cancer
(referent)
Female colon cancer
Breast cancer
Prostate cancer
DTCA by female
colon cancer
DTCA by breast
cancer
DTCA by prostate
cancer
Lagged analyses
(n=1293)
DTCA at round 1
Male colon cancer
(referent)
Female colon cancer
Breast cancer
Prostate cancer
DTCA by female
colon cancer
DTCA by breast
cancer
DTCA by prostate
cancer

PCIE at round 1
B
0.049

95% CI
p
-0.002 - 0.100 0.060

0.046
0.084
0.156

Seeking from non-clinician
sources at round 1
B
95% CI
p
0.037 0.014 - 0.060 0.002
-

-0.104 - 0.195 0.549
-0.049 - 0.218 0.216
0.028 - 0.283 0.017

0.039
0.099
0.033

-0.030 - 0.109 0.267
0.040 - 0.157 0.001
-0.023 - 0.090 0.251

-0.029 -0.094 - 0.036 0.377

-0.009

-0.043 - 0.024 0.584

-0.007 -0.064 - 0.050 0.808

-0.011

-0.038 - 0.016 0.427

-0.001 -0.059 - 0.057 0.982

0.020

-0.008 - 0.049 0.165

PCIE at round 2
B
0.016

95% CI
p
-0.027 - 0.059 0.470

Seeking from non-clinician
sources at round 2
B
95% CI
p
-0.006 -0.024 - 0.013 0.552

-

-

-0.035 -0.179 - 0.108 0.629
0.033 -0.094 - 0.160 0.610
0.008 -0.124 - 0.141 0.902

-0.034
-0.045
-0.058

-0.097 - 0.029 0.291
-0.101 - 0.010 0.106
-0.116 - 0.001 0.053

0.036

-0.025 - 0.097 0.252

0.025

-0.002 - 0.052 0.070

0.004

-0.045 - 0.054 0.868

0.018

-0.005 - 0.040 0.121

0.008

-0.046 - 0.063 0.769

0.016

-0.010 - 0.042 0.239

Notes. B = unstandardized regression coefficients estimated using full information
maximum likelihood and adjusted with post-stratification weights; 95% CI = 95%
confidence intervals based on Huber-White standard errors; baseline post-stratification
weights could not be computed for 3 cases because of missing information about gender
and these cases were dropped from the cross-sectional analyses, resulting in an analyzed
sample of 2010; cross-sectional analyses adjusted for age, education, race/ethnicity,
cancer type, Lerman worry, cancer stage, and health status; lagged analyses adjusted for
the same covariates as well as PCIE or seeking from non-clinician sources at round 1.
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Discussion
This research was conceptualized based on the premise that communication
disparities may arise as a result of differential levels of cancer-related DTCA exposure,
attention and processing, or additional information seeking following exposure as
described in the Structural Influence Model of Communication. The series of studies
presented in this dissertation project thus far examined various aspects of this underlying
premise of communication disparities. Study 2 analyzed the predictors of DTCA
exposure to evaluate if exposure differed based on several patient characteristics. Study 3
focused on testing the hypotheses that DTCA exposure was associated with additional
information seeking behaviors. Building upon Studies 2 and 3, Study 4 explored whether
the associations between DTCA and seeking behaviors were contingent upon patients’
age, education, race/ethnicity, or cancer type.
The findings from these three studies reveal interesting insights into the
postulated communication disparities of DTCA in terms of exposure levels and additional
information seeking. Study 2 found that breast cancer patients reported more DTCA
exposure than prostate and colorectal cancer patients; older patients had lower exposures
than younger patients; African-American prostate cancer patients had higher exposures
than white patients; and Hispanic colorectal cancer patients reported lower exposures
than white patients. These findings supported the notion that there are differential levels
of DTCA exposure across patient subgroups within this study population. Study 3 further
described a significant lagged association between DTCA exposure and patients’ active
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information seeking from their clinicians at follow-up; the association between DTCA
exposure and active seeking from non-clinician sources was positive but marginally
significant. Study 4 found that age, education, race/ethnicity, or cancer type did not
moderate the associations between exposure to DTCA and active information seeking
behaviors in the cross-sectional or lagged analyses. Taken together, it can be concluded
that although DTCA exposure varied by patient characteristics, there was little evidence
to warrant concern that DTCA exposure was associated with communication disparities
associated with differential additional information seeking between patient subgroups.
In response to concerns about DTCA resulting in communication disparities in
cancer patients and exacerbating cancer outcomes disparities, results from Study 4
provide empirical evidence that is reassuring. These findings are likely to contribute to
the ongoing practice and policy debates surrounding DTCA of medical treatments in a
few ways. First, although DTCA of medical treatments have existed and attracted much
debate and research in the past three decades, few studies have been conducted to
systematically examine social inequalities of communication behaviors and health
outcomes in association with DTCA exposure. This current research represents an
attempt to evaluate the issue of communication disparities in DTCA in the specific
context of cancer treatment. Second, contrary to claims that DTCA exposure might result
in disadvantaged groups of patients to be disproportionately less informed about their
treatment because they do not seek additional health information, this population-based
study among colorectal, breast, and prostate cancer patients found little indication that
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DTCA exposure influenced differential levels of active information seeking from
clinicians or non-clinician sources. Rather, DTCA exposure was significantly associated
with improved patient-clinician information engagement (results from Study 3) and this
relationship was similar across the different patient characteristics tested in the present
study.
It is important to stress here that the findings in this research should not be taken
to infer that DTCA does not contribute to any disparities in cancer outcomes. Notably,
this study only analyzed one form of communication behavior (active information
seeking) as the outcome. It did not assess whether attention or information processing of
DTCA messages—one of the levels of communication disparities in the Structural
Influence Model—differed across patient characteristics. Furthermore, the study did not
consider other important outcomes (e.g., healthcare utilization or health outcomes) that
might differ following DTCA exposure or other important social determinants as
potential moderators (e.g., access to healthcare, socio-economic position, or social
capital). This study was constrained by the availability of survey information relevant for
studying these outcomes and moderating variables. Future research will be necessary to
examine if DTCA exposure might produce or widen disparities in other important cancer
outcomes and across additional patient characteristics.
There were other limitations in this study that deserve mention. First, the study
was limited to cancer patients who were diagnosed with colorectal, breast, or prostate
cancers. Because of the diversity in the availability and complexity of treatments for
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other forms of cancers, the lack of supporting evidence for communication disparities in
this study population may not necessarily apply to other cancer patients. In addition, the
study also pertains to the specific context of cancer-related DTCA and active information
seeking about cancer care. The results may differ for other forms of DTCA and health
conditions. A second limitation in this study was the reliance on self-reported measures
for exposure to DTCA and the information seeking behavior measures. These may be
subject to social desirability bias to misreport recalling DTCA exposure or seeking
behaviors in certain patient groups and result in attenuation of contingent effects. Third,
there was an underrepresentation of cancer patients from certain groups (e.g., patients
who were Hispanic or of other race/ethnicity). This may have restricted the ability to
obtain reliable estimates of the associations between DTCA and information seeking
behaviors in these groups and reduced the statistical power to detect significant
contingent effects.
The study was strengthened by the multi-wave cohort design which enabled
testing the presence of communication disparities at baseline and at round 2. This was
important in testing for both short and longer term communication disparities associated
with DTCA that would not be possible with a cross-sectional survey. Compared to prior
DTCA research involving convenience samples of cancer patients (e.g., within a single
treatment facility), this study invited a population-based sample from the Pennsylvania
Cancer Registry. While not generalizable to cancer patients across the United States, the
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results here could be viewed as representative of Pennsylvanian cancer patients with the
most commonly occurring cancers (i.e., colorectal, breast, and prostate).
In sum, this study analyzed the effects of cancer patients’ exposure to DTCA on
subsequent active information seeking behaviors across various characteristics based,
drawing from levels of communication disparities described in the Structural Influence
Model of Communication. Contrary to concerns about potential communication
disparities due to cancer-related DTCA, the analyses here did not indicate that the
association between DTCA exposure and active information seeking behaviors were
contingent on patients’ age, educational level, race/ethnicity, or cancer type. This study
provides empirical research to inform the ongoing policy debates on the utility of DTCA
as a form of public health communication.
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Chapter 7 DISCUSSION AND LIMITATIONS
Discussion
The practice of DTCA is likely to endure in the foreseeable future, not only in the
specific context of cancer treatment, but also for promoting novel treatments or medical
services targeting other health conditions. This trend will invariably trigger further
debates concerning the risks and benefits of DTCA as a ubiquitous source of public
health information.
This dissertation research contributes to the broader debate about DTCA in
multiple ways. First, it offers empirical evidence that enhances the understanding of
implications of cancer-related DTCA exposure on cancer patients’ health information
seeking behaviors. Second, it further explores potential communication disparities that
may arise from DTCA exposure. The key findings can be summarized as follows:

•

The present research suggests there are positive informational spillover effects of
DTCA exposure about cancer-related treatments in terms of increased patients’
health information engagement with their physicians and other healthcare
professionals. While it is recognized that these communication behaviors overlap
with patients’ inquiry about advertised cancer treatments to a small extent, these
behaviors are believed to involve a broader range of cancer-related health topics
that would be relevant and potentially beneficial for patients’ ability to manage
and cope with their condition. The finding that DTCA exposure is associated with
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higher levels of patient-clinician communication is therefore reassuring given that
previous research strongly suggests effective communication is an important
determinant of improved patient outcomes and constitutes a core component of a
patient-centered model in healthcare delivery.
•

Guided by the Integrative Model, a focused analysis involving one form of
information seeking behavior—active seeking from non-clinician sources—
provides new evidence that DTCA exposure may indirectly influence information
seeking through attitudes and intentions related to seeking from these sources,
even though the direct effect between DTCA and seeking from non-clinician
sources was marginally significant. This finding offers theoretical insights into
one possible underlying mechanism of how DTCA exposure impacts patients’
health information seeking behaviors and contributes to the understanding of
communication effects of DTCA.

•

Addressing concerns about potentially harmful communication disparities arising
from DTCA, this research observed mostly small differences in terms of exposure
levels to cancer-related DTCA across patient characteristics including cancer
type, age, race/ethnicity, and cancer stage. Apart from age, the correlates of
DTCA exposure were inconsistent between patients diagnosed with different
cancer types. There are several underlying reasons for these minor variations in
the frequency of reported DTCA exposure across patient groups. As suggested
from a review of the literature, differential advertising spending on treatments for
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the three cancer types or selective placement of ads in channels to target certain
demographic groups of patients may result in varying opportunities for being
exposed to DTCA in some patients. The variations in reported DTCA exposure
may also arise from disparities in gaining access to channels where DTCA are
commonly placed (e.g., lack of internet access hindering exposure to cancer
treatment advertising through web-based ad) or differences in overall media
consumption patterns across groups such that some patients tend to report higher
DTCA exposure.
•

Apart from the findings of modest differential levels of DTCA exposure in some
groups of cancer patients, this research did not identify compelling evidence to
suggest that DTCA exposure contributes to disparities in additional information
seeking across these individual patient characteristics. Contrary to hypothesized
communication disparities proposed in the Structural Influence Model, the
associations between DTCA and active information seeking behaviors (from
clinicians and non-clinician sources) were not contingent on cancer type, age,
educational attainment, or race and ethnicity. It should be cautioned, however,
that these null results do not imply that DTCA is therefore harmless in terms of
inequalities in other communication or downstream cancer outcomes. The impact
of DTCA on these outcomes poses empirical questions that remain unanswered at
this juncture and would require further investigation. Despite this caveat, the
present study concludes that there is minimal cause for concern that DTCA
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exposures may propagate divergent patterns of seeking about cancer-related
information across groups in this study population.
An additional contribution from this dissertation project to studying DTCA effects
includes the methodological approaches described here. First, the assessment of the
reliability and validity of various measurement options for the DTCA exposure variable
using a battery of criteria may be adapted in future research to design and test candidate
measures that are appropriate for assessing exposure to other forms of subspecialty
DTCA in various health domains. Second, this research explored theoretical mechanisms
of DTCA effects on information seeking behaviors based on the Integrative Model
constructs using structural equation modeling. This theoretically grounded approach has
the potential to assist future research in explicating meaningful psychosocial pathways of
DTCA’s effects on patient communication behaviors, patient-provider relationships, and
ultimately health outcomes.
Strengths and Limitations
The study is strengthened by a few design features. First, the present research
emphasizes an assessment of the quality of the DTCA exposure measure across different
reliability and validity criteria as a prerequisite for subsequent analyses on the impact of
DTCA on communication outcomes. The validation study compared the performance of
existing survey items of DTCA with alternative versions that were more elaborate (with
text explanations or ad exemplars) and replicated the validation based on data collected
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from two different samples of cancer patients (a probability-based sample of patients
from a single state versus a national sample from an opt-in survey panel). This provides
increased confidence that the DTCA exposure measure is reasonably reliable and
performs consistently in different cancer patient populations before proceeding to utilize
this measure in the various analyses in Studies 2 to 4.
Second, the principal measures for DTCA exposure and information seeking
behaviors are conceptualized more broadly compared to previous research. In the case of
DTCA exposure, the measure incorporates exposure to ads about alternative cancer
treatments, dealing with treatment side-effects, and healthcare providers; this contrasted
with the majority of past research that focuses almost exclusively on exposure to DTCA
of prescription drugs alone. The broader DTCA exposure may be viewed as a better
reflection of the growing presence of non-drug related ads in cancer treatment and other
subspecialty DTCA. Also, the information seeking measures integrate multiple cancerrelated topics that are most salient for cancer patients; this allows for analyses of the
impact of DTCA exposure on broader information seeking compared with earlier studies
that focused primarily on patients’ inquiry about an advertised medication alone.
Another crucial feature in this research study includes the ability to measure
patient communication behaviors and DTCA exposure in a large and representative
sample of cancer patients over time. First, in terms of the sampling strategy, the
probability-based sample of cancer patients from the Pennsylvania Cancer Registry is an
improvement from past surveys that tended to involve convenience samples of cancer
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patients attending a single clinic or cancer center at one time point. While not
generalizable to cancer patients across the United States, the results here could be viewed
as representative of Pennsylvanian cancer patients with the most commonly occurring
cancers (i.e., colorectal, breast, and prostate). Second, the longitudinal design in this
research enables testing for both short and longer term communication disparities in
association with DTCA that is not possible within a cross-sectional survey. The panel
design further affords the capacity to clarify the temporal order between patients’ DTCA
exposures at an earlier time point and subsequent information seeking behaviors. In
addition, the lagged analyses control for underlying seeking habits or motivation by
adjusting for previously reported seeking behaviors.
However, a few limitations in this research deserve mention and these may be
addressed in future studies. The first limitation concerns the fact that all the principal
variables are based on self-reported survey items. Inherent to survey research, selfreported measures may be subject to recall biases arising from unreliable memory of
actual exposures or seeking behaviors or social desirability for instance. While this
research includes a validation of the DTCA exposure measure with alternative survey
items, further research may be necessary to externally validate this self-reported measure.
For instance, future studies may compare patients’ self-reported DTCA exposure over
time with aggregate-level data sources of ad expenditures by manufacturers of cancerrelated medications or cancer centers.
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Likewise, the information seeking measures rely on patients’ recall of active
seeking about various topics. These measures may suffer from imprecision because much
information exchange occurs between patients and their clinicians in the course of
patients’ treatment and follow-up. As reviewed earlier, cancer patients also seek from a
wide number of information sources apart from their clinicians. Patients may not be
expected to recall these exchanges or seeking of topics from multiple sources with great
accuracy over a long period of time (e.g., over 12 months). The established literature on
patient-doctor communication provides ample means of capturing dyadic interactions
accurately in small settings (e.g., direct observation, audio or video recording, and use of
standardized patients) but these methods are prohibitively difficult to apply on a large
scale. The limitations of self-reported measures are therefore compromises in exchange
for the ability to describe the patterns of DTCA exposure and information seeking in a
large and representative sample of patients.
Another related measurement issue is the timing of the information seeking
measures one year after DTCA exposure. It is possible that effects on additional
information seeking may occur soon after DTCA exposure and therefore, the follow-up
measure of information seeking may not detect this relationship appropriately. However,
baseline reports of DTCA exposure may serve as an estimate of continuing DTCA
exposure throughout the intervening year, coinciding with the period of recall about
information seeking behaviors. Future research may require shorter intervals of follow-up
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surveys to assess information seeking effects following DTCA exposure in a timely
manner.
A further limitation relates to generalizability of the findings. As the study
population was restricted to cancer patients with three types of cancer (i.e., breast,
prostate, and colorectal cancer) from one state, it is plausible that different patterns in
DTCA exposure and communication behaviors may occur for other cancer patients or in
other regions. In the case of DTCA exposures, promotional ads for cancer treatment may
be more prevalent in geographic regions where there is intense competition between
cancer centers and hospitals (e.g., in the mid-Atlantic region) compared with regions
where there is less competition. Access to information sources may also differ between
patients across the U.S. (e.g., rural versus urban areas) and this may pose barriers for
patients to actively conduct information seeking from their clinicians or other sources
following exposure to DTCA. These issues merit further study to assess if the observed
findings in this research would differ in other cancer patient populations.
Although the panel design of the study among cancer patients from the
Pennsylvania Cancer Registry is helpful in clarifying the temporal order of DTCA
exposure and information seeking behaviors, there is may be unmeasured confounders
that explain the observed associations. For instance, patients’ underlying need for
information may influence their attentiveness to DTCA as well as their active information
seeking about their condition from different sources. While several covariates including
past seeking behaviors are included in these analyses to account for patients’ interest and
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motivation to seek information, the threat that a causal inference from the association
between DTCA and active information seeking may be spurious remains due to the
observational study design. One suggestion is for future studies to consider examining the
hypothesized relationship between DTCA exposure and patient information seeking
behaviors by analyzing the associations between naturally occurring variations in DTCA
expenditures across different regions and these communication behaviors.
Future Research Directions
This dissertation research provides the starting point for developing a program of
research to address additional questions surrounding the impact of DTCA as a form of
public health communication. One continuing concern is to build a theoretically driven
understanding of DTCA effects on communication behaviors, drawing from this research
and previous literature based on relevant constructs described in the Social Cognitive
Theory, Integrative Model, and other frameworks. Study 3 indicates that attitudes and
perceived normative pressure to engage in information seeking from sources other than
one’s physician may mediate DTCA effects on cancer patients’ seeking from such
sources. Perceived behavioral control, however, did not mediate this relationship. One
future research direction is to explore the roles of other theoretical constructs suggested
by earlier research (e.g., shared decision making preferences (Deshpande et al., 2004)) in
mediating DTCA effects on patient information seeking behaviors. This will enrich the
understanding of underlying mechanisms of DTCA’s impact on these important
communication behaviors.
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Another future research direction is aimed at investigating the impact of DTCA
during the first few months following patients’ cancer diagnoses. The study population in
this research participated in the first survey about 9 to 21 months following the initial
cancer diagnosis. In an earlier cross-sectional study within one institution, Abel and
colleagues (2009) surveyed cancer patients (diagnosed with breast cancer and
hematologic malignancies) who were already undergoing active treatment about their
opinions of DTCA of cancer-related prescription medications. In both instances, the
studies are limited by the timing of the surveys—data collection began after treatment
decisions have been made. In other words, for the surveys described in this dissertation,
most of the patients had already completed or were undergoing active treatment for their
cancer by the time they completed the first survey. Accordingly, while the analyses
indicate that DTCA exposure is associated with subsequent information seeking
behaviors, it is not possible to assess whether DTCA exposure influences cancer patients’
treatment decision process because of the timing of the survey in relation to their receipt
of treatment. Similarly for the study by Abel et al. (2009), participants were already
receiving treatment at the point of the survey data collection. Therefore, the temporal
order of events (DTCA exposure and treatment decision making) could not be
distinguished. Research is lacking in assessing if cancer-related DTCA is associated with
patients’ treatment decision processes as they weigh the risks and benefits of treatment
options. One suggestion to explore this relationship may involve interviewing a
representative sample of newly diagnosed cancer patients (within 3 months of diagnosis;
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because most patients make treatment decisions in the first few weeks following
diagnosis and complete treatment within 6 months) to assess their exposure to DTCA
exposure during this period in relation to their subsequent decision making and receipt of
various treatment options. The proposed study would involve longitudinal surveys among
newly diagnosed cancer patients within 3 months of diagnosis and followed up over one
year. Survey items on DTCA exposure may be adapted from previously validated scales
and published questionnaires (from the Pennsylvania Cancer Patient Survey described
here and others including Weissman et al. (2003) and Abel et al. (2009)) while survey
items on treatment decision making processes would derive from established scales (e.g.,
patient involvement scale (Katz et al., 2005), patient decisional conflict scale, or patient
satisfaction with decision making subscale (O’Connor, 1995)). Additionally, receipt of
treatment may be obtained from patient self-reports or extracted from medical records at
follow-up.
Conclusion
DTCA is an established and growing source of novel information about treatment
for patients with complex medical conditions including cancer. The findings from this
research provide the first steps to uncovering the impact of DTCA as a unique form of
public health communication on cancer patients’ information seeking from their
clinicians and other sources. Stakeholders involved in the ongoing debate about the
societal implications of DTCA may need to consider the potential role for DTCA in
influencing additional information seeking behaviors among patients and balancing this
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with concerns about disparities in communication or cancer outcomes that may arise due
to DTCA exposure. More research is advised to fully understand the consequences and
harness the benefits of DTCA appropriately in the context of a rapidly evolving
healthcare environment.
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Appendix A Survey Questionnaire for Study 1B
[Programming instruction: These are the screening questions for the survey]
Variable name
How old are you? ______ years old.

Age

[Programming instruction: If 21 years and older, proceed to the next question. If 20 years
and younger, screen out as ineligible]
Variable name
When were you diagnosed with cancer?

Yeardx

1

2012

2

2011

3

2010

4

Others: Specify
____________________
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[Programming instruction: If either 2012, 2011, or 2010, proceed to the next question. If
diagnosed earlier than 2010, screen out as ineligible]
Variable
name
During this survey, you may be requested to view short video clips. In

setup

order to view the clips, you should have Adobe Flash Player installed on
your computer and the speakers should be turned on during the survey.
Please note that some mobile devices might not be able to play Flash
videos.

Please click on the button below to test if you are able to hear the
following audio clip.

Were you able to hear the audio clip clearly?

No

0

Yes 1

[Programming instruction: Route to end of survey, consider ineligible]
[Programming instruction: Proceed to next item]
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[Instructions for participants: Please answer each of the following questions by selecting
the number that best describes your experience. Some of the questions may appear to be
similar, but they do address somewhat different topics. Please read each question
carefully.]
PART I ITEMS (3 QUESTIONS – ASK ALL PARTICIPANTS)

[Programming instruction: Randomize half of participants to get PART I items first
followed by PART IA, then PART II or III; Randomize the other half of participants to
get PART II or III items first, then PART IA, followed by PART I items]

[Programming instruction: All questions are required; participants will not be able to
proceed if they do not answer all the items. If participants leave out answers for an item
on the screen, display the following message: “Please answer all the items before
proceeding.”]
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Since your diagnosis, how often have you seen or heard advertisements concerning each
of the following? Check all that apply:

Never

Variable
name

Less

About

About

Almost

than

twice a

once a

every

every

month

week

day

month
cps_treatalt

Treatment

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

alternatives for your
cancer
cps_sideeff

Dealing with side
effects of treatment

cps_hospdoc

Hospitals or doctors
offering services for
cancer
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PART IA ITEMS (ASK ALL PARTICIPANTS)

The questions in the next pages explore different situations.



Sometimes you might have been actively looking for information about a specific
cancer topic (e.g., treatment).



Other times you might not have been looking for cancer information at all, but
just came across it.

Please note what each question asks about.

Variable
name
Did you actively look for information about your cancer
(about treatments but also about other topics) from any
sources since your diagnosis?
Noseek



I did not actively look for information about my cancer since
my diagnosis.
I did actively look for information about my cancer since my
diagnosis from the following sources (Check all that apply):

Seektreatdoc



My treating doctors
177

Seekothdoc



Other doctors or health professionals

Seekfam



Family members, friends, coworkers

Seekpat



Other cancer patients

Seekfacegp



Face-to-face support groups

Seekonlinegp 

On-line support groups

Seektvrad



Telephone hotlines (e.g. from the American Cancer Society)

Seekhotline



Television or radio

Seekbook



Books, brochures or pamphlets

Seeknews



Newspapers or magazines

Seekinternet



Internet (other than personal email and on-line support groups)

Seekoth



Other

Variable name
Sometimes people get information from other sources and
discuss it with their treating doctors. Where have you gotten
information that you discussed with your treating doctors
since your diagnosis?

Nodiscuss



I have not discussed information from another source with my
treating doctors since my diagnosis.
I have discussed information with my treating doctors that I got
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from the following sources (Check all that apply):
discussothdoc



Other doctors or health professionals

discussfam



Family members, friends, coworkers

discusspat



Other cancer patients

discussfacegp



Face-to-face support groups

discussonlinegp 

On-line support groups

discusstvrad



Telephone hotlines (e.g. from the American Cancer Society)

discusshotline



Television or radio

discussbook



Books, brochures or pamphlets

discussnews



Newspapers or magazines

discussinternet



Internet (other than personal email and on-line support groups)

discussoth



Other

Variable
name
Sometimes doctors suggest that their patients go to other sources
to find out more information. Where have your treating doctors
suggested you go since your diagnosis?

Nosend



My doctors have not suggested I get information from other
sources since my diagnosis.
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My doctors have suggested I get information from the following
sources since my diagnosis (Check all that apply):
sendothdoc



Other doctors or health professionals

sendfam



Family members, friends, coworkers

sendspat



Other cancer patients

sendfacegp



Face-to-face support groups

sendonlinegp 

On-line support groups

sendtvrad



Telephone hotlines (e.g. from the American Cancer Society)

sendhotline



Television or radio

sendbook



Books, brochures or pamphlets

sendnews



Newspapers or magazines

sendinternet



Internet (other than personal email and on-line support groups)

sendoth



Other

Variable
name
Where have you actively looked for information about quality of
life issues since your diagnosis? Check all that apply:

Noqual



I did not actively look for information about quality of life after
cancer since my diagnosis
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I have actively looked for this quality of life information since
my diagnosis from the following sources (Check all that apply):
Qualtreatdoc



My treating doctors

Qualothdoc



Other doctors or health professionals

Qualfam



Family members, friends, coworkers

Qualpat



Other cancer patients

Qualfacegp



Face-to-face support groups

Qualonlinegp 

On-line support groups

Qualtvrad



Telephone hotlines (e.g. from the American Cancer Society)

Qualhotline



Television or radio

Qualbook



Books, brochures or pamphlets

Qualnews



Newspapers or magazines

Qualinternet



Internet (other than personal email and on-line support groups)

Qualoth



Other

Variable name
Sometimes people find out things about their disease or
its treatment even though they are not looking for
information about their cancer at all. This might happen
because they were having a conversation or watching
television or using the Internet and just happened to
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come across it. What information have you come across
about your cancer from media sources (television, radio,
newspapers, magazines, Internet) when you were not
looking for it since your diagnosis?

Noscanmedia



I have not come across anything from media sources except
when I was looking for it since my diagnosis.
I have come across information from media sources about
the following topics since my diagnosis (Check all that
apply):

Scanmediatreat



Scanmediadochosp 

What treatments were the best for my cancer
Which doctors or hospitals would be the best for me

Scanmediasideeff



How to manage side effects of treatments

Scanmediaoth



Other: Specify _______________________________
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PART II ITEMS (4 QUESTIONS - FOR RANDOM HALF OF PARTICIPANTS
ONLY)
[Instructions for participants: The following questions ask about advertisements that you
may or may not have come across in the mass media (e.g. television, radio, newspapers,
magazines, billboards, or the internet.]

[Programming instruction: Randomize the order of presenting each set of questions
within PART II.]

[Instructions for participants: Sometimes hospitals or doctors advertise their services
(radiation therapy, chemotherapy, or comprehensive treatment) for treating patients with
cancer. These advertisements may appear in the mass media (e.g., television, radio,
newspapers, magazines, billboards, or the internet).
Please view the following two examples of advertisements concerning hospitals or
doctors offering services for cancer.]

[Programming instruction: Show two randomly selected ads (one print ad and one video)
of hospitals or doctors offering services for cancer from Pool A of ads]
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Variable name
viewad_hospdoc Were you able to view the two advertisements?

No

0

Yes 1

[Programming instruction: Route to end of survey, consider incomplete]
[Programming instruction: Proceed to next item]

Variable
name
ad_hospdoc

Since your diagnosis, how often have you seen or heard advertisements
concerning hospitals or doctors offering services for cancer?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4
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[Instructions for participants: Sometimes advertisements about dealing with side effects
of cancer treatment appear in the mass media (e.g., television, radio, newspapers,
magazines, billboards, or the internet). Please view the following two examples of
advertisements concerning dealing with side effects of treatment.]

[Programming instruction: Show two randomly selected ads (one print ad and one video)
about dealing with side effects of treatment from Pool B of ads]

Variable
name
viewad_sideeff Were you able to view the two advertisements?

No

0

Yes 1

[Programming instruction: Route to end of survey, consider incomplete]
[Programming instruction: Proceed to next item]
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Variable
name
ad_sideeff

Since your diagnosis, how often have you seen or heard advertisements
concerning dealing with treatment side effects?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4

[Instructions for participants: Sometimes advertisements about treatment alternatives for
your cancer appear in the mass media (e.g., television, radio, newspapers, magazines,
billboards, or the internet).
Please view the following two examples of advertisements concerning treatment
alternatives for your cancer.]

[Programming instruction: Show two randomly selected ads (one print ad and one video)
of advanced technology or alternatives for cancer treatment from Pool C of ads]
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Variable name
viewad_treatalt Were you able to view the two advertisements?

No

0

Yes 1

[Programming instruction: Route to end of survey, consider incomplete]
[Programming instruction: Proceed to next item]

Variable
name
ad_treatalt

Since your diagnosis, how often have you seen or heard advertisements
concerning treatment alternatives for your cancer?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4

[Instructions for participants: Sometimes advertisements about treatment for chronic
diseases that are not related to cancer appear in the mass media (e.g., television, radio,
newspapers, magazines, billboards, or the internet). Please view the following two
examples of advertisements concerning treatment for chronic diseases.]
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[Programming instruction: Show two randomly selected ads (one print ad and one video)
for the treatment of non-cancer related conditions from Pool D of ads]

Variable name
viewad_chronicdis Were you able to view the two advertisements?

No

0

Yes 1

[Programming instruction: Route to end of survey, consider incomplete]
[Programming instruction: Proceed to next item]

Variable
name
ad_chronicdis Since your diagnosis, how often have you seen or heard advertisements
concerning treatment for chronic diseases?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4
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PART III ITEMS (4 QUESTIONS - FOR RANDOM HALF OF PARTICIPANTS
ONLY)

[Programming instructions: Randomize the order of presenting each set of questions
within PART III.]

Variable
name
noad_hospdoc Sometimes hospitals or doctors advertise their services (radiation
therapy, chemotherapy, or comprehensive treatment) for treating
patients with cancer. These advertisements may appear in the mass
media (e.g., television, radio, newspapers, magazines, billboards, or the
internet).

Since your diagnosis, how often have you seen or heard advertisements
concerning hospitals or doctors offering services for cancer?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4
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Variable
name
noad_sideeff

Sometimes advertisements about dealing with side effects of cancer
treatment appear in the mass media (e.g., television, radio, newspapers,
magazines, billboards, or the internet).

Since your diagnosis, how often have you seen or heard advertisements
concerning dealing with treatment side effects?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4

Variable
name
noad_treatalt

Sometimes advertisements about treatment alternatives for your cancer
appear in the mass media (e.g., television, radio, newspapers,
magazines, billboards, or the internet).
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Since your diagnosis, how often have you seen or heard advertisements
concerning treatment alternatives for your cancer?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4

Variable name
noad_chronicdis Sometimes advertisements about treatment for chronic diseases that
are not related to cancer appear in the mass media (e.g., television,
radio, newspapers, magazines, billboards, or the internet).

Since your diagnosis, how often have you seen or heard
advertisements concerning treatment for chronic diseases?

Never

0

Less than every

About twice a

About once a

Almost every

month

month

week

day

1

2

3

4
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PART IV ITEMS [Programming instructions: Ask the following questions to ALL
participants]

This series of questions asks about how often you use several media channels.

Variable

In the past seven days, on how many days

Days (0 to 7

name

did you…

days)

Newspaper

Read a newspaper?

___

Magazine

Read a magazine?

___

Natnewstv

Watch the national news on television?

___

Localnewstv

Watch the local news on television?

___

TVprograms

Watch television programs other than news?

___

Radio

Listen to radio talk shows or news?

___

Email

Use the Internet for email?

___

Internet

Use the Internet, other than for email?

___
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People find out about health and medical issues from a variety of sources. Please indicate
how often you have done each of the following in the past 30 days:
Variable name

Not at

Less

Once

Two

all

than

per

or

once per

week

more

week

times
per
week

Gennewsmag

Read about health issues

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

in newspapers or general
magazines
Hlthnewsmag

Read special health or
medical magazines or
newsletters

Hlthtvnews

Watched special health
segments of television
newscasts

Hlthtvprogs

Watched television
programs (other than
news) which address
health issues or focus on
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doctors or hospitals
Hlthinternet

Read health information

1

2

3

4

1

2

3

4

on the internet
Hlthfamfriend

Talked with family or
friends about health
issues

The next series of statements ask about what you know now, rather than what you knew
when your original treatment choices were made. Indicate whether you agree or disagree.

Variable

Strongly

name

disagree

Disagree

Neither

Agree

agree

Strongly
agree

nor
disagree
Knowtreat

I know about

1

2

3

4

5

1

2

3

4

5

possible
future
treatments
for my
cancer.
Knowriskrec

I know about
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the long term
risk of my
cancer
coming back.
Knowprob

I know about

1

2

3

4

5

future health
problems I
might face
because of
my cancer.

This series of statements asks about whether you are confident or not about dealing with
anything that might happen in the future. I am confident in my ability to…

Variable name

Strongly

Disagree

disagree

Neither

Agree

agree

Strongly
Agree

nor
disagree
Effdecide

Actively

1

2

participate
in decisions
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3

4

5

related to
my cancer.
Effgethelp

Get help if I

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

don’t
understand
something
about my
cancer.
Effaskquestion

Ask my
doctors or
nurses
questions
about my
cancer.

Effunexp

Manage any
unexpected
problems
related to
my cancer.

Effemotprob

Deal with
any
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emotional
problems
related to
my cancer.

Variable name
Which of the following cancer types were you

Cancertype

diagnosed with?

1

Colon

2

Lung

3

Prostate

4

Breast

5

Others: Specify ____________________

Variable
name
Gender

Please indicate your gender.

1

Male

2

Female
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Variable name
Do you consider yourself to be Hispanic or

Hisp

Latino?

0

Yes

1

No

Variable name
Race

What is your race? Check all that apply:



White

1. 

Black
Asian



American Indian or Alaska Native



Native Hawaiian or other Pacific Islander



Other



198

Variable name
What is the highest grade or level of school

Educ

you completed?

1

8th grade or less

2

Some high school, but did not graduate

3

High school graduate or GED

4

Some college or 2-year degree

5

4-year college graduate

6

More than 4-year college degree

[Instructions for participants: Thank you for your participation.]
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Appendix B Panel of Video and Print Ads Displayed for Measure II Items (Study
1B)
1. Print ads for hospitals or doctors offering services
Print ad 1

Print ad 2

Print ad 3

Print ad 4

Note. All four print ads are from U Miami Sylvester Comprehensive Cancer Center

2. Video ads for hospitals or doctors offering services
Video ad 1

Video ad 2

Video ad 3

Video ad 4

UNC Cancer Care

Carle Cancer Center

Hudson Valley

Terrebonne General

Hospital Center

Medical Center –
Mary Bird Perkins
Cancer Center
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3. Print ads for treatment side effects
Print ad 1

Print ad 2

Print ad 3

Print ad 4

Zuplenz (anti-

Aloxi (anti-nausea)

Zuplenz (anti-

Zometa (prevent

nausea)

skeletal

nausea)

complications)

4. Video ads for treatment side effects
Video ad 1

Video ad 2

Video ad 3

Video ad 4

Neulasta (increase

Procrit (increase red

Procrit

Procrit

immune cell count)

blood cells)
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5. Print ads for treatment alternatives
Print ad 1

Print ad 2

Altoona Regional

Altoona Regional

Print ad 3

Print ad 4

Las Vegas
Radiosurgery

St. Peter’s

Radiosurgery
Cyberknife at

University Hospital
Summerlin
Cyberknife

6. Video ads for treatment alternatives
Video ad 1

Video ad 2

Video ad 3

Video ad 4

Memorial Cancer

Fox Chase Cancer

Novalis TX at St

Phoenix Cyberknife

Institute Cyberknife

Center Minimally

Vincent’s Medical

Invasive Surgery

Center
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Appendix C Key Survey Measures for Study 3
1.

Active information seeking behaviors

The questions in the next pages explore different situations.


Sometimes you might have been actively looking for information about a specific
cancer topic (e.g., treatment).



Other times you might not have been looking for cancer information at all, but
just came across it.

Please note what each question asks about.
When we ask what “you” did, this includes you and any family members or friends who
may have helped you look for information.

Did you actively look for information about your cancer (about treatments but
also about other topics) from any sources in the past 12 months?


I did not actively look for information about my cancer in the past 12 months.
I did actively look for information about my cancer in the past 12 months from
the following sources (Check all that apply):



My treating doctors



Other doctors or health professionals



Family members, friends, coworkers



Other cancer patients



Face-to-face support groups
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On-line support groups



Telephone hotlines (e.g. from the American Cancer Society)



Television or radio



Books, brochures or pamphlets



Newspapers or magazines



Internet (other than personal email and on-line support groups)



Other

Sometimes people get information from other sources and discuss it with their
doctors. Where have you gotten information that you discussed with your
doctors in the past 12 months?


I have not discussed information from another source with my doctors in the
past 12 months.
I have discussed information with my doctors in the past 12 months that I got
from the following sources (Check all that apply):



Other doctors or health professionals



Family members, friends, coworkers



Other cancer patients



Face-to-face support groups



On-line support groups
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Telephone hotlines (e.g. from the American Cancer Society)



Television or radio



Books, brochures or pamphlets



Newspapers or magazines



Internet (other than personal email and on-line support groups)



Other

Sometimes doctors suggest that their patients go to other sources to find out
more information. Where have your doctors suggested you go in the past 12
months?


My doctors have not suggested I get information from other sources in the past
12 months.
My doctors have suggested I get information from the following sources in the
past 12 months (Check all that apply):



Other doctors or health professionals



Family members, friends, coworkers



Other cancer patients



Face-to-face support groups



On-line support groups



Telephone hotlines (e.g. from the American Cancer Society)
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Television or radio



Books, brochures or pamphlets



Newspapers or magazines



Internet (other than personal email and on-line support groups)



Other

Where have you actively looked for information about quality of life issues like
those mentioned in questions 21 and 22 in the past 12 months? Check all that
apply:



I did not actively look for information about quality of life after cancer in the
past 12 months.
I have actively looked for this quality of life in the past 12 months from (Check
all that apply):



My treating doctors



Other doctors or health professionals



Family members, friends, coworkers



Other cancer patients



Face-to-face support groups



On-line support groups
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Telephone hotlines (e.g. from the American Cancer Society)



Television or radio



Books, brochures or pamphlets



Newspapers or magazines



Internet (other than personal email and on-line support groups)



Other

2.

Integrative Model of Behavioral Prediction measures

How likely is it that you will actively seek information about issues related to your
cancer from a source other than your doctor in the next 12 months. Please circle the
number that best reflects your response.
UNLIKELY

1

2

3

4

5

6

7

LIKELY

My actively seek information about issues related to my cancer from a source other than
your doctor in the next 12 months would be. Circle one number in each row.
USELESS

1

2

3

4

5

6

7

USEFUL

UNENJOYABLE

1

2

3

4

5

6

7

ENJOYABLE

FOOLISH

1

2

3

4

5

6

7

WISE

NOT UP TO ME

1

2

3

4

5

6

7

UP TO ME
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Most people who are important to me think I should actively seek information about
issues related to my cancer from a source other than your doctor in the next 12 months.
DISAGREE

1

2

3

4

5

6

7

AGREE

Most people like me (e.g., other cancer patients) actively seek information about issues
related to their cancer from a source other than their doctors.
DISAGREE

1

2

3

4

5

6

7

AGREE

If I really wanted to, I could actively seek information about issues related to my cancer
from a source other than your doctor in the next 12 months.
DISAGREE

1

2

3

4
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5

6

7

AGREE
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